id	sid	tid	token	lemma	pos
ajlm-2916	1	1	abstract	abstract	ADJ
ajlm-2916	1	2	introduction	introduction	NOUN
ajlm-2916	1	3	methods	method	NOUN
ajlm-2916	1	4	results	result	VERB
ajlm-2916	1	5	discussion	discussion	NOUN
ajlm-2916	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2916	1	7	references	reference	NOUN
ajlm-2916	1	8	about	about	ADP
ajlm-2916	1	9	the	the	DET
ajlm-2916	1	10	author(s	author(s	NOUN
ajlm-2916	1	11	)	)	PUNCT
ajlm-2916	1	12	nora	nora	PROPN
ajlm-2916	1	13	m.	m.	PROPN
ajlm-2916	1	14	said	say	VERB
ajlm-2916	1	15	department	department	NOUN
ajlm-2916	1	16	of	of	ADP
ajlm-2916	1	17	clinical	clinical	ADJ
ajlm-2916	1	18	pathology	pathology	NOUN
ajlm-2916	1	19	,	,	PUNCT
ajlm-2916	1	20	faculty	faculty	NOUN
ajlm-2916	1	21	of	of	ADP
ajlm-2916	1	22	medicine	medicine	NOUN
ajlm-2916	1	23	,	,	PUNCT
ajlm-2916	1	24	zagazig	zagazig	PROPN
ajlm-2916	1	25	university	university	PROPN
ajlm-2916	1	26	,	,	PUNCT
ajlm-2916	1	27	zagazig	zagazig	PROPN
ajlm-2916	1	28	,	,	PUNCT
ajlm-2916	1	29	egypt	egypt	PROPN
ajlm-2916	1	30	enas	enas	PROPN
ajlm-2916	1	31	m.	m.	PROPN
ajlm-2916	1	32	mekkawy	mekkawy	PROPN
ajlm-2916	1	33	department	department	PROPN
ajlm-2916	1	34	of	of	ADP
ajlm-2916	1	35	rheumatology	rheumatology	NOUN
ajlm-2916	1	36	and	and	CCONJ
ajlm-2916	1	37	rehabilitation	rehabilitation	NOUN
ajlm-2916	1	38	,	,	PUNCT
ajlm-2916	1	39	faculty	faculty	NOUN
ajlm-2916	1	40	of	of	ADP
ajlm-2916	1	41	medicine	medicine	NOUN
ajlm-2916	1	42	,	,	PUNCT
ajlm-2916	1	43	zagazig	zagazig	PROPN
ajlm-2916	1	44	university	university	PROPN
ajlm-2916	1	45	,	,	PUNCT
ajlm-2916	1	46	zagazig	zagazig	PROPN
ajlm-2916	1	47	,	,	PUNCT
ajlm-2916	1	48	egypt	egypt	PROPN
ajlm-2916	1	49	dina	dina	PROPN
ajlm-2916	1	50	said	say	VERB
ajlm-2916	1	51	department	department	PROPN
ajlm-2916	1	52	of	of	ADP
ajlm-2916	1	53	rheumatology	rheumatology	NOUN
ajlm-2916	1	54	and	and	CCONJ
ajlm-2916	1	55	rehabilitation	rehabilitation	NOUN
ajlm-2916	1	56	,	,	PUNCT
ajlm-2916	1	57	faculty	faculty	NOUN
ajlm-2916	1	58	of	of	ADP
ajlm-2916	1	59	medicine	medicine	NOUN
ajlm-2916	1	60	,	,	PUNCT
ajlm-2916	1	61	zagazig	zagazig	PROPN
ajlm-2916	1	62	university	university	PROPN
ajlm-2916	1	63	,	,	PUNCT
ajlm-2916	1	64	zagazig	zagazig	PROPN
ajlm-2916	1	65	,	,	PUNCT
ajlm-2916	1	66	egypt	egypt	PROPN
ajlm-2916	1	67	dina	dina	PROPN
ajlm-2916	1	68	g.	g.	PROPN
ajlm-2916	1	69	abdelhamed	abdelhamed	PROPN
ajlm-2916	1	70	department	department	PROPN
ajlm-2916	1	71	of	of	ADP
ajlm-2916	1	72	clinical	clinical	ADJ
ajlm-2916	1	73	pathology	pathology	NOUN
ajlm-2916	1	74	,	,	PUNCT
ajlm-2916	1	75	faculty	faculty	NOUN
ajlm-2916	1	76	of	of	ADP
ajlm-2916	1	77	medicine	medicine	NOUN
ajlm-2916	1	78	,	,	PUNCT
ajlm-2916	1	79	zagazig	zagazig	PROPN
ajlm-2916	1	80	university	university	PROPN
ajlm-2916	1	81	,	,	PUNCT
ajlm-2916	1	82	zagazig	zagazig	PROPN
ajlm-2916	1	83	,	,	PUNCT
ajlm-2916	1	84	egypt	egypt	PROPN
ajlm-2916	1	85	alia	alia	PROPN
ajlm-2916	1	86	a.	a.	PROPN
ajlm-2916	1	87	el	el	PROPN
ajlm-2916	1	88	shahawy	shahawy	PROPN
ajlm-2916	1	89	department	department	PROPN
ajlm-2916	1	90	of	of	ADP
ajlm-2916	1	91	medical	medical	ADJ
ajlm-2916	1	92	microbiology	microbiology	NOUN
ajlm-2916	1	93	and	and	CCONJ
ajlm-2916	1	94	immunology	immunology	NOUN
ajlm-2916	1	95	,	,	PUNCT
ajlm-2916	1	96	faculty	faculty	NOUN
ajlm-2916	1	97	of	of	ADP
ajlm-2916	1	98	medicine	medicine	NOUN
ajlm-2916	1	99	,	,	PUNCT
ajlm-2916	1	100	zagazig	zagazig	PROPN
ajlm-2916	1	101	university	university	PROPN
ajlm-2916	1	102	,	,	PUNCT
ajlm-2916	1	103	zagazig	zagazig	PROPN
ajlm-2916	1	104	,	,	PUNCT
ajlm-2916	1	105	egypt	egypt	PROPN
ajlm-2916	1	106	eman	eman	PROPN
ajlm-2916	1	107	a.	a.	PROPN
ajlm-2916	1	108	abdelaziz	abdelaziz	PROPN
ajlm-2916	1	109	department	department	PROPN
ajlm-2916	1	110	of	of	ADP
ajlm-2916	1	111	medical	medical	ADJ
ajlm-2916	1	112	biochemistry	biochemistry	NOUN
ajlm-2916	1	113	,	,	PUNCT
ajlm-2916	1	114	faculty	faculty	NOUN
ajlm-2916	1	115	of	of	ADP
ajlm-2916	1	116	medicine	medicine	NOUN
ajlm-2916	1	117	,	,	PUNCT
ajlm-2916	1	118	zagazig	zagazig	PROPN
ajlm-2916	1	119	university	university	PROPN
ajlm-2916	1	120	,	,	PUNCT
ajlm-2916	1	121	zagazig	zagazig	PROPN
ajlm-2916	1	122	,	,	PUNCT
ajlm-2916	1	123	egypt	egypt	PROPN
ajlm-2916	1	124	fatma	fatma	PROPN
ajlm-2916	1	125	z.	z.	PROPN
ajlm-2916	1	126	kamel	kamel	PROPN
ajlm-2916	1	127	department	department	PROPN
ajlm-2916	1	128	of	of	ADP
ajlm-2916	1	129	medical	medical	ADJ
ajlm-2916	1	130	microbiology	microbiology	NOUN
ajlm-2916	1	131	and	and	CCONJ
ajlm-2916	1	132	immunology	immunology	NOUN
ajlm-2916	1	133	,	,	PUNCT
ajlm-2916	1	134	faculty	faculty	NOUN
ajlm-2916	1	135	of	of	ADP
ajlm-2916	1	136	medicine	medicine	NOUN
ajlm-2916	1	137	,	,	PUNCT
ajlm-2916	1	138	zagazig	zagazig	PROPN
ajlm-2916	1	139	university	university	PROPN
ajlm-2916	1	140	,	,	PUNCT
ajlm-2916	1	141	zagazig	zagazig	PROPN
ajlm-2916	1	142	,	,	PUNCT
ajlm-2916	1	143	egypt	egypt	PROPN
ajlm-2916	1	144	alshymaa	alshymaa	PROPN
ajlm-2916	1	145	a.	a.	PROPN
ajlm-2916	1	146	ahmed	ahmed	PROPN
ajlm-2916	1	147	department	department	PROPN
ajlm-2916	1	148	of	of	ADP
ajlm-2916	1	149	clinical	clinical	ADJ
ajlm-2916	1	150	pathology	pathology	NOUN
ajlm-2916	1	151	,	,	PUNCT
ajlm-2916	1	152	faculty	faculty	NOUN
ajlm-2916	1	153	of	of	ADP
ajlm-2916	1	154	medicine	medicine	NOUN
ajlm-2916	1	155	,	,	PUNCT
ajlm-2916	1	156	zagazig	zagazig	PROPN
ajlm-2916	1	157	university	university	PROPN
ajlm-2916	1	158	,	,	PUNCT
ajlm-2916	1	159	zagazig	zagazig	PROPN
ajlm-2916	1	160	,	,	PUNCT
ajlm-2916	1	161	egypt	egypt	PROPN
ajlm-2916	1	162	citation	citation	PROPN
ajlm-2916	1	163	said	say	VERB
ajlm-2916	1	164	nm	nm	ADP
ajlm-2916	1	165	,	,	PUNCT
ajlm-2916	1	166	mekkawy	mekkawy	PROPN
ajlm-2916	1	167	em	em	PRON
ajlm-2916	1	168	,	,	PUNCT
ajlm-2916	1	169	said	say	VERB
ajlm-2916	1	170	d	d	X
ajlm-2916	1	171	,	,	PUNCT
ajlm-2916	1	172	et	et	PROPN
ajlm-2916	1	173	al	al	PROPN
ajlm-2916	1	174	.	.	PUNCT
ajlm-2916	2	1	genetic	genetic	ADJ
ajlm-2916	2	2	copy	copy	NOUN
ajlm-2916	2	3	number	number	NOUN
ajlm-2916	2	4	variation	variation	NOUN
ajlm-2916	2	5	of	of	ADP
ajlm-2916	2	6	tlr7	tlr7	PROPN
ajlm-2916	2	7	,	,	PUNCT
ajlm-2916	2	8	t	t	PROPN
ajlm-2916	2	9	-	-	PUNCT
ajlm-2916	2	10	bet	bet	NOUN
ajlm-2916	2	11	,	,	PUNCT
ajlm-2916	2	12	il12b	il12b	ADV
ajlm-2916	2	13	,	,	PUNCT
ajlm-2916	2	14	and	and	CCONJ
ajlm-2916	2	15	fcγriiib	fcγriiib	ADV
ajlm-2916	2	16	in	in	ADP
ajlm-2916	2	17	egyptian	egyptian	ADJ
ajlm-2916	2	18	ankylosing	ankylose	VERB
ajlm-2916	2	19	spondylitis	spondylitis	NOUN
ajlm-2916	2	20	patients	patient	NOUN
ajlm-2916	2	21	.	.	PUNCT
ajlm-2916	3	1	afr	afr	PROPN
ajlm-2916	3	2	j	j	PROPN
ajlm-2916	3	3	lab	lab	PROPN
ajlm-2916	3	4	med	med	PROPN
ajlm-2916	3	5	.	.	PUNCT
ajlm-2916	4	1	2025;14(1	2025;14(1	NUM
ajlm-2916	4	2	)	)	PUNCT
ajlm-2916	4	3	,	,	PUNCT
ajlm-2916	4	4	a2916	a2916	PROPN
ajlm-2916	4	5	.	.	PUNCT
ajlm-2916	5	1	https://doi.org/10.4102/ajlm.v14i1.2916	https://doi.org/10.4102/ajlm.v14i1.2916	VERB
ajlm-2916	5	2	original	original	ADJ
ajlm-2916	5	3	research	research	NOUN
ajlm-2916	5	4	genetic	genetic	ADJ
ajlm-2916	5	5	copy	copy	NOUN
ajlm-2916	5	6	number	number	NOUN
ajlm-2916	5	7	variation	variation	NOUN
ajlm-2916	5	8	of	of	ADP
ajlm-2916	5	9	tlr7	tlr7	PROPN
ajlm-2916	5	10	,	,	PUNCT
ajlm-2916	5	11	t	t	PROPN
ajlm-2916	5	12	-	-	PUNCT
ajlm-2916	5	13	bet	bet	NOUN
ajlm-2916	5	14	,	,	PUNCT
ajlm-2916	5	15	il12b	il12b	ADV
ajlm-2916	5	16	,	,	PUNCT
ajlm-2916	5	17	and	and	CCONJ
ajlm-2916	5	18	fcγriiib	fcγriiib	ADV
ajlm-2916	5	19	in	in	ADP
ajlm-2916	5	20	egyptian	egyptian	ADJ
ajlm-2916	5	21	ankylosing	ankylose	VERB
ajlm-2916	5	22	spondylitis	spondylitis	NOUN
ajlm-2916	5	23	patients	patient	NOUN
ajlm-2916	5	24	nora	nora	PROPN
ajlm-2916	5	25	m.	m.	PROPN
ajlm-2916	5	26	said	say	VERB
ajlm-2916	5	27	,	,	PUNCT
ajlm-2916	5	28	enas	enas	PROPN
ajlm-2916	5	29	m.	m.	NOUN
ajlm-2916	5	30	mekkawy	mekkawy	PROPN
ajlm-2916	5	31	,	,	PUNCT
ajlm-2916	5	32	dina	dina	PROPN
ajlm-2916	5	33	said	say	VERB
ajlm-2916	5	34	,	,	PUNCT
ajlm-2916	5	35	dina	dina	PROPN
ajlm-2916	5	36	g.	g.	PROPN
ajlm-2916	5	37	abdelhamed	abdelhamed	PROPN
ajlm-2916	5	38	,	,	PUNCT
ajlm-2916	6	1	alia	alia	ADV
ajlm-2916	6	2	a.	a.	PROPN
ajlm-2916	6	3	el	el	PROPN
ajlm-2916	6	4	shahawy	shahawy	PROPN
ajlm-2916	6	5	,	,	PUNCT
ajlm-2916	6	6	eman	eman	PROPN
ajlm-2916	6	7	a.	a.	PROPN
ajlm-2916	6	8	abdelaziz	abdelaziz	PROPN
ajlm-2916	6	9	,	,	PUNCT
ajlm-2916	6	10	fatma	fatma	PROPN
ajlm-2916	6	11	z.	z.	PROPN
ajlm-2916	6	12	kamel	kamel	PROPN
ajlm-2916	6	13	,	,	PUNCT
ajlm-2916	6	14	alshymaa	alshymaa	PROPN
ajlm-2916	6	15	a.	a.	PROPN
ajlm-2916	6	16	ahmed	ahmed	PROPN
ajlm-2916	6	17	received	receive	VERB
ajlm-2916	6	18	:	:	PUNCT
ajlm-2916	6	19	20	20	NUM
ajlm-2916	6	20	june	june	PROPN
ajlm-2916	6	21	2025	2025	NUM
ajlm-2916	6	22	;	;	PUNCT
ajlm-2916	6	23	accepted	accept	VERB
ajlm-2916	6	24	:	:	PUNCT
ajlm-2916	6	25	11	11	NUM
ajlm-2916	6	26	oct	oct	PROPN
ajlm-2916	6	27	.	.	PROPN
ajlm-2916	6	28	2025	2025	NUM
ajlm-2916	6	29	;	;	PUNCT
ajlm-2916	6	30	published	publish	VERB
ajlm-2916	6	31	:	:	PUNCT
ajlm-2916	6	32	29	29	NUM
ajlm-2916	6	33	nov	nov	NOUN
ajlm-2916	6	34	.	.	PROPN
ajlm-2916	6	35	2025	2025	NUM
ajlm-2916	6	36	copyright	copyright	NOUN
ajlm-2916	6	37	:	:	PUNCT
ajlm-2916	6	38	©	©	PROPN
ajlm-2916	6	39	2025	2025	NUM
ajlm-2916	6	40	.	.	PUNCT
ajlm-2916	7	1	the	the	DET
ajlm-2916	7	2	authors	author	NOUN
ajlm-2916	7	3	.	.	PUNCT
ajlm-2916	8	1	licensee	licensee	NOUN
ajlm-2916	8	2	:	:	PUNCT
ajlm-2916	8	3	aosis	aosis	NOUN
ajlm-2916	8	4	.	.	PUNCT
ajlm-2916	9	1	this	this	DET
ajlm-2916	9	2	work	work	NOUN
ajlm-2916	9	3	is	be	AUX
ajlm-2916	9	4	licensed	license	VERB
ajlm-2916	9	5	under	under	ADP
ajlm-2916	9	6	the	the	DET
ajlm-2916	9	7	creative	creative	ADJ
ajlm-2916	9	8	commons	common	NOUN
ajlm-2916	9	9	attribution	attribution	NOUN
ajlm-2916	9	10	4.0	4.0	NUM
ajlm-2916	9	11	international	international	NOUN
ajlm-2916	9	12	(	(	PUNCT
ajlm-2916	9	13	cc	cc	NOUN
ajlm-2916	9	14	by	by	ADP
ajlm-2916	9	15	4.0	4.0	NUM
ajlm-2916	9	16	)	)	PUNCT
ajlm-2916	9	17	license	license	NOUN
ajlm-2916	9	18	(	(	PUNCT
ajlm-2916	9	19	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
ajlm-2916	9	20	)	)	PUNCT
ajlm-2916	9	21	.	.	PUNCT
ajlm-2916	10	1	abstract	abstract	ADJ
ajlm-2916	10	2	background	background	NOUN
ajlm-2916	10	3	:	:	PUNCT
ajlm-2916	10	4	ankylosing	ankylose	VERB
ajlm-2916	10	5	spondylitis	spondylitis	NOUN
ajlm-2916	10	6	(	(	PUNCT
ajlm-2916	10	7	as	as	ADP
ajlm-2916	10	8	)	)	PUNCT
ajlm-2916	10	9	is	be	AUX
ajlm-2916	10	10	a	a	DET
ajlm-2916	10	11	polygenic	polygenic	ADJ
ajlm-2916	10	12	disorder	disorder	NOUN
ajlm-2916	10	13	.	.	PUNCT
ajlm-2916	11	1	copy	copy	NOUN
ajlm-2916	11	2	number	number	NOUN
ajlm-2916	11	3	variations	variation	NOUN
ajlm-2916	11	4	(	(	PUNCT
ajlm-2916	11	5	cnvs	cnvs	NOUN
ajlm-2916	11	6	)	)	PUNCT
ajlm-2916	11	7	alter	alter	VERB
ajlm-2916	11	8	the	the	DET
ajlm-2916	11	9	expression	expression	NOUN
ajlm-2916	11	10	of	of	ADP
ajlm-2916	11	11	tlr7	tlr7	PROPN
ajlm-2916	11	12	,	,	PUNCT
ajlm-2916	11	13	t	t	PROPN
ajlm-2916	11	14	-	-	PUNCT
ajlm-2916	11	15	bet	bet	NOUN
ajlm-2916	11	16	,	,	PUNCT
ajlm-2916	11	17	il-12b	il-12b	NOUN
ajlm-2916	11	18	,	,	PUNCT
ajlm-2916	11	19	and	and	CCONJ
ajlm-2916	11	20	fcγriiib	fcγriiib	ADJ
ajlm-2916	11	21	genes	gene	NOUN
ajlm-2916	11	22	,	,	PUNCT
ajlm-2916	11	23	contributing	contribute	VERB
ajlm-2916	11	24	to	to	ADP
ajlm-2916	11	25	as	as	ADP
ajlm-2916	11	26	development	development	NOUN
ajlm-2916	11	27	via	via	ADP
ajlm-2916	11	28	their	their	PRON
ajlm-2916	11	29	immune	immune	ADJ
ajlm-2916	11	30	system	system	NOUN
ajlm-2916	11	31	roles	role	NOUN
ajlm-2916	11	32	.	.	PUNCT
ajlm-2916	12	1	objective	objective	NOUN
ajlm-2916	12	2	:	:	PUNCT
ajlm-2916	12	3	the	the	DET
ajlm-2916	12	4	current	current	ADJ
ajlm-2916	12	5	study	study	NOUN
ajlm-2916	12	6	aimed	aim	VERB
ajlm-2916	12	7	to	to	PART
ajlm-2916	12	8	assess	assess	VERB
ajlm-2916	12	9	the	the	DET
ajlm-2916	12	10	correlation	correlation	NOUN
ajlm-2916	12	11	between	between	ADP
ajlm-2916	12	12	as	as	ADP
ajlm-2916	12	13	susceptibility	susceptibility	NOUN
ajlm-2916	12	14	and	and	CCONJ
ajlm-2916	12	15	cnvs	cnvs	NOUN
ajlm-2916	12	16	of	of	ADP
ajlm-2916	12	17	tlr7	tlr7	PROPN
ajlm-2916	12	18	,	,	PUNCT
ajlm-2916	12	19	t	t	PROPN
ajlm-2916	12	20	-	-	PUNCT
ajlm-2916	12	21	bet	bet	NOUN
ajlm-2916	12	22	,	,	PUNCT
ajlm-2916	12	23	il12b	il12b	ADV
ajlm-2916	12	24	,	,	PUNCT
ajlm-2916	12	25	and	and	CCONJ
ajlm-2916	12	26	fcγriiib	fcγriiib	ADJ
ajlm-2916	12	27	,	,	PUNCT
ajlm-2916	12	28	as	as	ADV
ajlm-2916	12	29	well	well	ADV
ajlm-2916	12	30	as	as	ADP
ajlm-2916	12	31	their	their	PRON
ajlm-2916	12	32	influence	influence	NOUN
ajlm-2916	12	33	on	on	ADP
ajlm-2916	12	34	disease	disease	NOUN
ajlm-2916	12	35	activity	activity	NOUN
ajlm-2916	12	36	.	.	PUNCT
ajlm-2916	13	1	methods	method	NOUN
ajlm-2916	13	2	:	:	PUNCT
ajlm-2916	13	3	the	the	DET
ajlm-2916	13	4	study	study	NOUN
ajlm-2916	13	5	involved	involve	VERB
ajlm-2916	13	6	42	42	NUM
ajlm-2916	13	7	healthy	healthy	ADJ
ajlm-2916	13	8	controls	control	NOUN
ajlm-2916	13	9	and	and	CCONJ
ajlm-2916	13	10	72	72	NUM
ajlm-2916	13	11	patients	patient	NOUN
ajlm-2916	13	12	with	with	ADP
ajlm-2916	13	13	as	as	ADP
ajlm-2916	13	14	,	,	PUNCT
ajlm-2916	13	15	recruited	recruit	VERB
ajlm-2916	13	16	from	from	ADP
ajlm-2916	13	17	the	the	DET
ajlm-2916	13	18	rheumatology	rheumatology	NOUN
ajlm-2916	13	19	and	and	CCONJ
ajlm-2916	13	20	rehabilitation	rehabilitation	NOUN
ajlm-2916	13	21	clinic	clinic	NOUN
ajlm-2916	13	22	of	of	ADP
ajlm-2916	13	23	zagazig	zagazig	PROPN
ajlm-2916	13	24	university	university	PROPN
ajlm-2916	13	25	hospitals	hospital	NOUN
ajlm-2916	13	26	,	,	PUNCT
ajlm-2916	13	27	zagazig	zagazig	PROPN
ajlm-2916	13	28	,	,	PUNCT
ajlm-2916	13	29	egypt	egypt	PROPN
ajlm-2916	13	30	,	,	PUNCT
ajlm-2916	13	31	from	from	ADP
ajlm-2916	13	32	01	01	NUM
ajlm-2916	13	33	november	november	PROPN
ajlm-2916	13	34	2023	2023	NUM
ajlm-2916	13	35	to	to	ADP
ajlm-2916	13	36	30	30	NUM
ajlm-2916	13	37	october	october	PROPN
ajlm-2916	13	38	2024	2024	NUM
ajlm-2916	13	39	.	.	PUNCT
ajlm-2916	14	1	sociodemographic	sociodemographic	ADJ
ajlm-2916	14	2	,	,	PUNCT
ajlm-2916	14	3	clinical	clinical	ADJ
ajlm-2916	14	4	data	datum	NOUN
ajlm-2916	14	5	and	and	CCONJ
ajlm-2916	14	6	blood	blood	NOUN
ajlm-2916	14	7	samples	sample	NOUN
ajlm-2916	14	8	were	be	AUX
ajlm-2916	14	9	collected	collect	VERB
ajlm-2916	14	10	from	from	ADP
ajlm-2916	14	11	all	all	DET
ajlm-2916	14	12	participants	participant	NOUN
ajlm-2916	14	13	.	.	PUNCT
ajlm-2916	15	1	copy	copy	VERB
ajlm-2916	15	2	number	number	NOUN
ajlm-2916	15	3	estimations	estimation	NOUN
ajlm-2916	15	4	for	for	ADP
ajlm-2916	15	5	tlr7	tlr7	NOUN
ajlm-2916	15	6	,	,	PUNCT
ajlm-2916	15	7	t	t	PROPN
ajlm-2916	15	8	-	-	PUNCT
ajlm-2916	15	9	bet	bet	NOUN
ajlm-2916	15	10	,	,	PUNCT
ajlm-2916	15	11	il12b	il12b	ADV
ajlm-2916	15	12	,	,	PUNCT
ajlm-2916	15	13	and	and	CCONJ
ajlm-2916	15	14	fcγriiib	fcγriiib	ADJ
ajlm-2916	15	15	genes	gene	NOUN
ajlm-2916	15	16	were	be	AUX
ajlm-2916	15	17	performed	perform	VERB
ajlm-2916	15	18	using	use	VERB
ajlm-2916	15	19	sybr	sybr	ADP
ajlm-2916	15	20	green	green	ADJ
ajlm-2916	15	21	real	real	ADJ
ajlm-2916	15	22	-	-	PUNCT
ajlm-2916	15	23	time	time	NOUN
ajlm-2916	15	24	polymerase	polymerase	NOUN
ajlm-2916	15	25	chain	chain	NOUN
ajlm-2916	15	26	reaction	reaction	NOUN
ajlm-2916	15	27	.	.	PUNCT
ajlm-2916	16	1	results	result	NOUN
ajlm-2916	16	2	:	:	PUNCT
ajlm-2916	16	3	of	of	ADP
ajlm-2916	16	4	72	72	NUM
ajlm-2916	16	5	cases	case	NOUN
ajlm-2916	16	6	aged	age	VERB
ajlm-2916	16	7	19	19	NUM
ajlm-2916	16	8	to	to	PART
ajlm-2916	16	9	52	52	NUM
ajlm-2916	16	10	years	year	NOUN
ajlm-2916	16	11	,	,	PUNCT
ajlm-2916	16	12	47	47	NUM
ajlm-2916	16	13	(	(	PUNCT
ajlm-2916	16	14	65.2	65.2	NUM
ajlm-2916	16	15	%	%	NOUN
ajlm-2916	16	16	)	)	PUNCT
ajlm-2916	16	17	were	be	AUX
ajlm-2916	16	18	men	man	NOUN
ajlm-2916	16	19	and	and	CCONJ
ajlm-2916	16	20	25	25	NUM
ajlm-2916	16	21	(	(	PUNCT
ajlm-2916	16	22	34.8	34.8	NUM
ajlm-2916	16	23	%	%	NOUN
ajlm-2916	16	24	)	)	PUNCT
ajlm-2916	16	25	were	be	AUX
ajlm-2916	16	26	women	woman	NOUN
ajlm-2916	16	27	.	.	PUNCT
ajlm-2916	17	1	controls	control	NOUN
ajlm-2916	17	2	included	include	VERB
ajlm-2916	17	3	42	42	NUM
ajlm-2916	17	4	participants	participant	NOUN
ajlm-2916	17	5	aged	age	VERB
ajlm-2916	17	6	27	27	NUM
ajlm-2916	17	7	to	to	PART
ajlm-2916	17	8	55	55	NUM
ajlm-2916	17	9	years	year	NOUN
ajlm-2916	17	10	,	,	PUNCT
ajlm-2916	17	11	22	22	NUM
ajlm-2916	17	12	(	(	PUNCT
ajlm-2916	17	13	52.4	52.4	NUM
ajlm-2916	17	14	%	%	NOUN
ajlm-2916	17	15	)	)	PUNCT
ajlm-2916	17	16	men	man	NOUN
ajlm-2916	17	17	and	and	CCONJ
ajlm-2916	17	18	20	20	NUM
ajlm-2916	17	19	(	(	PUNCT
ajlm-2916	17	20	47.6	47.6	NUM
ajlm-2916	17	21	%	%	NOUN
ajlm-2916	17	22	)	)	PUNCT
ajlm-2916	17	23	women	woman	NOUN
ajlm-2916	17	24	.	.	PUNCT
ajlm-2916	18	1	higher	high	ADJ
ajlm-2916	18	2	il12b	il12b	NOUN
ajlm-2916	18	3	and	and	CCONJ
ajlm-2916	18	4	fcγriiib	fcγriiib	ADJ
ajlm-2916	18	5	gene	gene	NOUN
ajlm-2916	18	6	copy	copy	NOUN
ajlm-2916	18	7	numbers	number	NOUN
ajlm-2916	18	8	were	be	AUX
ajlm-2916	18	9	significantly	significantly	ADV
ajlm-2916	18	10	associated	associate	VERB
ajlm-2916	18	11	with	with	ADP
ajlm-2916	18	12	a	a	DET
ajlm-2916	18	13	higher	high	ADJ
ajlm-2916	18	14	risk	risk	NOUN
ajlm-2916	18	15	of	of	ADP
ajlm-2916	18	16	as	as	ADP
ajlm-2916	18	17	(	(	PUNCT
ajlm-2916	18	18	p	p	X
ajlm-2916	18	19	=	=	NOUN
ajlm-2916	18	20	0.001	0.001	NUM
ajlm-2916	18	21	,	,	PUNCT
ajlm-2916	18	22	odds	odd	VERB
ajlm-2916	18	23	ratio	ratio	NOUN
ajlm-2916	18	24	[	[	X
ajlm-2916	18	25	or	or	CCONJ
ajlm-2916	18	26	]	]	X
ajlm-2916	18	27	:	:	PUNCT
ajlm-2916	18	28	3.8	3.8	NUM
ajlm-2916	18	29	,	,	PUNCT
ajlm-2916	18	30	95	95	NUM
ajlm-2916	18	31	%	%	NOUN
ajlm-2916	18	32	confidence	confidence	NOUN
ajlm-2916	18	33	interval	interval	NOUN
ajlm-2916	19	1	[	[	X
ajlm-2916	19	2	ci	ci	X
ajlm-2916	19	3	]	]	X
ajlm-2916	19	4	:	:	PUNCT
ajlm-2916	19	5	1.7–8.07	1.7–8.07	NUM
ajlm-2916	19	6	,	,	PUNCT
ajlm-2916	19	7	and	and	CCONJ
ajlm-2916	19	8	p	p	X
ajlm-2916	19	9	<	<	X
ajlm-2916	19	10	0.001	0.001	NUM
ajlm-2916	19	11	,	,	PUNCT
ajlm-2916	19	12	or	or	CCONJ
ajlm-2916	19	13	:	:	PUNCT
ajlm-2916	19	14	5.5	5.5	NUM
ajlm-2916	19	15	,	,	PUNCT
ajlm-2916	19	16	95	95	NUM
ajlm-2916	19	17	%	%	NOUN
ajlm-2916	19	18	ci	ci	NOUN
ajlm-2916	19	19	:	:	PUNCT
ajlm-2916	19	20	2.31–13.08	2.31–13.08	NUM
ajlm-2916	19	21	,	,	PUNCT
ajlm-2916	19	22	respectively	respectively	ADV
ajlm-2916	19	23	)	)	PUNCT
ajlm-2916	19	24	.	.	PUNCT
ajlm-2916	20	1	while	while	SCONJ
ajlm-2916	20	2	t	t	NOUN
ajlm-2916	20	3	-	-	PUNCT
ajlm-2916	20	4	bet	bet	NOUN
ajlm-2916	20	5	and	and	CCONJ
ajlm-2916	20	6	tlr7	tlr7	NOUN
ajlm-2916	20	7	gene	gene	NOUN
ajlm-2916	20	8	cnvs	cnvs	NOUN
ajlm-2916	20	9	showed	show	VERB
ajlm-2916	20	10	no	no	DET
ajlm-2916	20	11	significant	significant	ADJ
ajlm-2916	20	12	association	association	NOUN
ajlm-2916	20	13	with	with	ADP
ajlm-2916	20	14	as	as	ADP
ajlm-2916	20	15	risk	risk	NOUN
ajlm-2916	20	16	.	.	PUNCT
ajlm-2916	21	1	no	no	DET
ajlm-2916	21	2	significant	significant	ADJ
ajlm-2916	21	3	association	association	NOUN
ajlm-2916	21	4	was	be	AUX
ajlm-2916	21	5	observed	observe	VERB
ajlm-2916	21	6	between	between	ADP
ajlm-2916	21	7	the	the	DET
ajlm-2916	21	8	studied	studied	ADJ
ajlm-2916	21	9	cnvs	cnvs	NOUN
ajlm-2916	21	10	and	and	CCONJ
ajlm-2916	21	11	as	as	ADP
ajlm-2916	21	12	activity	activity	NOUN
ajlm-2916	21	13	.	.	PUNCT
ajlm-2916	22	1	conclusion	conclusion	NOUN
ajlm-2916	22	2	:	:	PUNCT
ajlm-2916	22	3	high	high	ADJ
ajlm-2916	22	4	copy	copy	NOUN
ajlm-2916	22	5	numbers	number	NOUN
ajlm-2916	22	6	of	of	ADP
ajlm-2916	22	7	il12b	il12b	NOUN
ajlm-2916	22	8	and	and	CCONJ
ajlm-2916	22	9	fcγriiib	fcγriiib	ADJ
ajlm-2916	22	10	genes	gene	NOUN
ajlm-2916	22	11	may	may	AUX
ajlm-2916	22	12	be	be	AUX
ajlm-2916	22	13	associated	associate	VERB
ajlm-2916	22	14	with	with	ADP
ajlm-2916	22	15	increased	increase	VERB
ajlm-2916	22	16	as	as	ADP
ajlm-2916	22	17	risk	risk	NOUN
ajlm-2916	22	18	.	.	PUNCT
ajlm-2916	23	1	however	however	ADV
ajlm-2916	23	2	,	,	PUNCT
ajlm-2916	23	3	no	no	DET
ajlm-2916	23	4	significant	significant	ADJ
ajlm-2916	23	5	correlation	correlation	NOUN
ajlm-2916	23	6	was	be	AUX
ajlm-2916	23	7	found	find	VERB
ajlm-2916	23	8	between	between	ADP
ajlm-2916	23	9	as	as	ADP
ajlm-2916	23	10	risk	risk	NOUN
ajlm-2916	23	11	and	and	CCONJ
ajlm-2916	23	12	tlr7	tlr7	NOUN
ajlm-2916	23	13	or	or	CCONJ
ajlm-2916	23	14	t	t	PROPN
ajlm-2916	23	15	-	-	PUNCT
ajlm-2916	23	16	bet	bet	NOUN
ajlm-2916	23	17	cnvs	cnvs	NOUN
ajlm-2916	23	18	.	.	PUNCT
ajlm-2916	24	1	what	what	PRON
ajlm-2916	24	2	this	this	DET
ajlm-2916	24	3	study	study	NOUN
ajlm-2916	24	4	adds	add	VERB
ajlm-2916	24	5	:	:	PUNCT
ajlm-2916	24	6	the	the	DET
ajlm-2916	24	7	findings	finding	NOUN
ajlm-2916	24	8	of	of	ADP
ajlm-2916	24	9	this	this	DET
ajlm-2916	24	10	study	study	NOUN
ajlm-2916	24	11	revealed	reveal	VERB
ajlm-2916	24	12	that	that	SCONJ
ajlm-2916	24	13	genetic	genetic	ADJ
ajlm-2916	24	14	copy	copy	NOUN
ajlm-2916	24	15	number	number	NOUN
ajlm-2916	24	16	variations	variation	NOUN
ajlm-2916	24	17	may	may	AUX
ajlm-2916	24	18	contribute	contribute	VERB
ajlm-2916	24	19	to	to	ADP
ajlm-2916	24	20	the	the	DET
ajlm-2916	24	21	risk	risk	NOUN
ajlm-2916	24	22	of	of	ADP
ajlm-2916	24	23	as	as	ADP
ajlm-2916	24	24	.	.	PUNCT
ajlm-2916	25	1	keywords	keyword	NOUN
ajlm-2916	25	2	:	:	PUNCT
ajlm-2916	25	3	ankylosing	ankylose	VERB
ajlm-2916	25	4	spondylitis	spondylitis	NOUN
ajlm-2916	25	5	;	;	PUNCT
ajlm-2916	25	6	copy	copy	VERB
ajlm-2916	25	7	number	number	NOUN
ajlm-2916	25	8	variations	variation	NOUN
ajlm-2916	25	9	;	;	PUNCT
ajlm-2916	25	10	tlr7	tlr7	NOUN
ajlm-2916	25	11	;	;	PUNCT
ajlm-2916	25	12	t	t	PROPN
ajlm-2916	25	13	-	-	PUNCT
ajlm-2916	25	14	bet	bet	NOUN
ajlm-2916	25	15	;	;	PUNCT
ajlm-2916	26	1	il12b	il12b	X
ajlm-2916	26	2	;	;	PUNCT
ajlm-2916	26	3	fcγriiib	fcγriiib	ADJ
ajlm-2916	26	4	.	.	PUNCT
ajlm-2916	26	5	introduction	introduction	NOUN
ajlm-2916	26	6	ankylosing	ankylose	VERB
ajlm-2916	26	7	spondylitis	spondylitis	NOUN
ajlm-2916	26	8	(	(	PUNCT
ajlm-2916	26	9	as	as	ADP
ajlm-2916	26	10	)	)	PUNCT
ajlm-2916	26	11	is	be	AUX
ajlm-2916	26	12	a	a	DET
ajlm-2916	26	13	common	common	ADJ
ajlm-2916	26	14	seronegative	seronegative	ADJ
ajlm-2916	26	15	autoimmune	autoimmune	ADJ
ajlm-2916	26	16	arthropathy	arthropathy	ADJ
ajlm-2916	26	17	,	,	PUNCT
ajlm-2916	26	18	primarily	primarily	ADV
ajlm-2916	26	19	characterised	characterise	VERB
ajlm-2916	26	20	by	by	ADP
ajlm-2916	26	21	axial	axial	ADJ
ajlm-2916	26	22	skeleton	skeleton	NOUN
ajlm-2916	26	23	and	and	CCONJ
ajlm-2916	26	24	sacroiliac	sacroiliac	NOUN
ajlm-2916	26	25	joint	joint	ADJ
ajlm-2916	26	26	inflammation	inflammation	NOUN
ajlm-2916	26	27	.	.	PUNCT
ajlm-2916	27	1	in	in	ADP
ajlm-2916	27	2	severe	severe	ADJ
ajlm-2916	27	3	cases	case	NOUN
ajlm-2916	27	4	,	,	PUNCT
ajlm-2916	27	5	inflammation	inflammation	NOUN
ajlm-2916	27	6	may	may	AUX
ajlm-2916	27	7	progress	progress	VERB
ajlm-2916	27	8	to	to	ADP
ajlm-2916	27	9	fibrosis	fibrosis	NOUN
ajlm-2916	27	10	and	and	CCONJ
ajlm-2916	27	11	calcification	calcification	NOUN
ajlm-2916	27	12	,	,	PUNCT
ajlm-2916	27	13	reducing	reduce	VERB
ajlm-2916	27	14	spinal	spinal	ADJ
ajlm-2916	27	15	flexibility	flexibility	NOUN
ajlm-2916	27	16	and	and	CCONJ
ajlm-2916	27	17	resulting	result	VERB
ajlm-2916	27	18	in	in	ADP
ajlm-2916	27	19	fusion	fusion	NOUN
ajlm-2916	27	20	and	and	CCONJ
ajlm-2916	27	21	restricted	restrict	VERB
ajlm-2916	27	22	mobility.1	mobility.1	PROPN
ajlm-2916	27	23	the	the	DET
ajlm-2916	27	24	primary	primary	ADJ
ajlm-2916	27	25	clinical	clinical	ADJ
ajlm-2916	27	26	symptoms	symptom	NOUN
ajlm-2916	27	27	include	include	VERB
ajlm-2916	27	28	back	back	ADJ
ajlm-2916	27	29	pain	pain	NOUN
ajlm-2916	27	30	,	,	PUNCT
ajlm-2916	27	31	progressive	progressive	ADJ
ajlm-2916	27	32	stiffness	stiffness	NOUN
ajlm-2916	27	33	of	of	ADP
ajlm-2916	27	34	the	the	DET
ajlm-2916	27	35	spine	spine	NOUN
ajlm-2916	27	36	,	,	PUNCT
ajlm-2916	27	37	and	and	CCONJ
ajlm-2916	27	38	joint	joint	ADJ
ajlm-2916	27	39	inflammation	inflammation	NOUN
ajlm-2916	27	40	.	.	PUNCT
ajlm-2916	28	1	furthermore	furthermore	ADV
ajlm-2916	28	2	,	,	PUNCT
ajlm-2916	28	3	extra	extra	ADJ
ajlm-2916	28	4	-	-	ADJ
ajlm-2916	28	5	articular	articular	ADJ
ajlm-2916	28	6	manifestations	manifestation	NOUN
ajlm-2916	28	7	,	,	PUNCT
ajlm-2916	28	8	particularly	particularly	ADV
ajlm-2916	28	9	acute	acute	ADJ
ajlm-2916	28	10	anterior	anterior	ADJ
ajlm-2916	28	11	uveitis	uveitis	NOUN
ajlm-2916	28	12	and	and	CCONJ
ajlm-2916	28	13	inflammatory	inflammatory	ADJ
ajlm-2916	28	14	bowel	bowel	NOUN
ajlm-2916	28	15	disease	disease	NOUN
ajlm-2916	28	16	,	,	PUNCT
ajlm-2916	28	17	may	may	AUX
ajlm-2916	28	18	further	far	ADV
ajlm-2916	28	19	complicate	complicate	VERB
ajlm-2916	28	20	the	the	DET
ajlm-2916	28	21	clinical	clinical	ADJ
ajlm-2916	28	22	course.2	course.2	PROPN
ajlm-2916	28	23	the	the	DET
ajlm-2916	28	24	aetiology	aetiology	NOUN
ajlm-2916	28	25	of	of	ADP
ajlm-2916	28	26	as	as	ADP
ajlm-2916	28	27	is	be	AUX
ajlm-2916	28	28	multifactorial	multifactorial	ADJ
ajlm-2916	28	29	,	,	PUNCT
ajlm-2916	28	30	involving	involve	VERB
ajlm-2916	28	31	numerous	numerous	ADJ
ajlm-2916	28	32	factors	factor	NOUN
ajlm-2916	28	33	,	,	PUNCT
ajlm-2916	28	34	such	such	ADJ
ajlm-2916	28	35	as	as	ADP
ajlm-2916	28	36	genetic	genetic	ADJ
ajlm-2916	28	37	factors	factor	NOUN
ajlm-2916	28	38	,	,	PUNCT
ajlm-2916	28	39	environmental	environmental	ADJ
ajlm-2916	28	40	influences	influence	NOUN
ajlm-2916	28	41	,	,	PUNCT
ajlm-2916	28	42	prior	prior	ADJ
ajlm-2916	28	43	infections	infection	NOUN
ajlm-2916	28	44	,	,	PUNCT
ajlm-2916	28	45	and	and	CCONJ
ajlm-2916	28	46	socio	socio	NOUN
ajlm-2916	28	47	-	-	PUNCT
ajlm-2916	28	48	economic	economic	ADJ
ajlm-2916	28	49	status.3	status.3	PROPN
ajlm-2916	28	50	the	the	DET
ajlm-2916	28	51	most	most	ADV
ajlm-2916	28	52	substantial	substantial	ADJ
ajlm-2916	28	53	genetic	genetic	ADJ
ajlm-2916	28	54	correlation	correlation	NOUN
ajlm-2916	28	55	is	be	AUX
ajlm-2916	28	56	found	find	VERB
ajlm-2916	28	57	with	with	ADP
ajlm-2916	28	58	hla	hla	PROPN
ajlm-2916	28	59	-	-	PUNCT
ajlm-2916	28	60	b27	b27	PROPN
ajlm-2916	28	61	,	,	PUNCT
ajlm-2916	28	62	a	a	DET
ajlm-2916	28	63	key	key	ADJ
ajlm-2916	28	64	genetic	genetic	ADJ
ajlm-2916	28	65	factor	factor	NOUN
ajlm-2916	28	66	accounting	account	VERB
ajlm-2916	28	67	for	for	ADP
ajlm-2916	28	68	16	16	NUM
ajlm-2916	28	69	%	%	NOUN
ajlm-2916	28	70	–	–	PUNCT
ajlm-2916	28	71	50	50	NUM
ajlm-2916	28	72	%	%	NOUN
ajlm-2916	28	73	of	of	ADP
ajlm-2916	28	74	disease	disease	NOUN
ajlm-2916	28	75	genetic	genetic	ADJ
ajlm-2916	28	76	susceptibility.4,5	susceptibility.4,5	NOUN
ajlm-2916	28	77	previous	previous	ADJ
ajlm-2916	28	78	genetic	genetic	ADJ
ajlm-2916	28	79	studies	study	NOUN
ajlm-2916	28	80	on	on	ADV
ajlm-2916	28	81	as	as	SCONJ
ajlm-2916	28	82	have	have	AUX
ajlm-2916	28	83	primarily	primarily	ADV
ajlm-2916	28	84	focused	focus	VERB
ajlm-2916	28	85	on	on	ADP
ajlm-2916	28	86	disease	disease	NOUN
ajlm-2916	28	87	susceptibility	susceptibility	NOUN
ajlm-2916	28	88	.	.	PUNCT
ajlm-2916	29	1	despite	despite	SCONJ
ajlm-2916	29	2	its	its	PRON
ajlm-2916	29	3	significance	significance	NOUN
ajlm-2916	29	4	,	,	PUNCT
ajlm-2916	29	5	investigating	investigate	VERB
ajlm-2916	29	6	genetic	genetic	ADJ
ajlm-2916	29	7	factors	factor	NOUN
ajlm-2916	29	8	associated	associate	VERB
ajlm-2916	29	9	with	with	ADP
ajlm-2916	29	10	radiographic	radiographic	ADJ
ajlm-2916	29	11	damage	damage	NOUN
ajlm-2916	29	12	and	and	CCONJ
ajlm-2916	29	13	disease	disease	NOUN
ajlm-2916	29	14	activity	activity	NOUN
ajlm-2916	29	15	has	have	AUX
ajlm-2916	29	16	been	be	AUX
ajlm-2916	29	17	largely	largely	ADV
ajlm-2916	29	18	overlooked.4,6	overlooked.4,6	ADP
ajlm-2916	29	19	recent	recent	ADJ
ajlm-2916	29	20	findings	finding	NOUN
ajlm-2916	29	21	have	have	AUX
ajlm-2916	29	22	highlighted	highlight	VERB
ajlm-2916	29	23	the	the	DET
ajlm-2916	29	24	substantial	substantial	ADJ
ajlm-2916	29	25	role	role	NOUN
ajlm-2916	29	26	of	of	ADP
ajlm-2916	29	27	copy	copy	NOUN
ajlm-2916	29	28	number	number	NOUN
ajlm-2916	29	29	variations	variation	NOUN
ajlm-2916	29	30	(	(	PUNCT
ajlm-2916	29	31	cnvs	cnvs	NOUN
ajlm-2916	29	32	)	)	PUNCT
ajlm-2916	29	33	in	in	ADP
ajlm-2916	29	34	the	the	DET
ajlm-2916	29	35	progression	progression	NOUN
ajlm-2916	29	36	of	of	ADP
ajlm-2916	29	37	as.3	as.3	PROPN
ajlm-2916	29	38	copy	copy	NOUN
ajlm-2916	29	39	number	number	NOUN
ajlm-2916	29	40	variations	variation	NOUN
ajlm-2916	29	41	are	be	AUX
ajlm-2916	29	42	structural	structural	ADJ
ajlm-2916	29	43	genomic	genomic	NOUN
ajlm-2916	29	44	alterations	alteration	NOUN
ajlm-2916	29	45	involving	involve	VERB
ajlm-2916	29	46	genome	genome	NOUN
ajlm-2916	29	47	-	-	PUNCT
ajlm-2916	29	48	wide	wide	ADJ
ajlm-2916	29	49	deletions	deletion	NOUN
ajlm-2916	29	50	or	or	CCONJ
ajlm-2916	29	51	duplications	duplication	NOUN
ajlm-2916	29	52	that	that	PRON
ajlm-2916	29	53	affect	affect	VERB
ajlm-2916	29	54	one	one	NUM
ajlm-2916	29	55	kilobase	kilobase	NOUN
ajlm-2916	29	56	to	to	ADP
ajlm-2916	29	57	several	several	ADJ
ajlm-2916	29	58	megabases.7	megabases.7	NOUN
ajlm-2916	29	59	copy	copy	VERB
ajlm-2916	29	60	number	number	NOUN
ajlm-2916	29	61	variations	variation	NOUN
ajlm-2916	29	62	can	can	AUX
ajlm-2916	29	63	significantly	significantly	ADV
ajlm-2916	29	64	alter	alter	VERB
ajlm-2916	29	65	gene	gene	NOUN
ajlm-2916	29	66	expression	expression	NOUN
ajlm-2916	29	67	by	by	ADP
ajlm-2916	29	68	altering	alter	VERB
ajlm-2916	29	69	the	the	DET
ajlm-2916	29	70	copy	copy	NOUN
ajlm-2916	29	71	number	number	NOUN
ajlm-2916	29	72	(	(	PUNCT
ajlm-2916	29	73	cn	cn	NOUN
ajlm-2916	29	74	)	)	PUNCT
ajlm-2916	29	75	of	of	ADP
ajlm-2916	29	76	dosage	dosage	NOUN
ajlm-2916	29	77	-	-	PUNCT
ajlm-2916	29	78	sensitive	sensitive	ADJ
ajlm-2916	29	79	loci	loci	NOUN
ajlm-2916	29	80	,	,	PUNCT
ajlm-2916	29	81	thereby	thereby	ADV
ajlm-2916	29	82	perturbing	perturb	VERB
ajlm-2916	29	83	gene	gene	NOUN
ajlm-2916	29	84	expression.8	expression.8	PROPN
ajlm-2916	29	85	moreover	moreover	ADV
ajlm-2916	29	86	,	,	PUNCT
ajlm-2916	29	87	cnvs	cnvs	PROPN
ajlm-2916	29	88	may	may	AUX
ajlm-2916	29	89	reposition	reposition	VERB
ajlm-2916	29	90	genes	gene	NOUN
ajlm-2916	29	91	and	and	CCONJ
ajlm-2916	29	92	regulatory	regulatory	ADJ
ajlm-2916	29	93	regions	region	NOUN
ajlm-2916	29	94	,	,	PUNCT
ajlm-2916	29	95	affecting	affect	VERB
ajlm-2916	29	96	gene	gene	NOUN
ajlm-2916	29	97	expression.9	expression.9	PROPN
ajlm-2916	29	98	research	research	NOUN
ajlm-2916	29	99	increasingly	increasingly	ADV
ajlm-2916	29	100	emphasises	emphasise	VERB
ajlm-2916	29	101	the	the	DET
ajlm-2916	29	102	significance	significance	NOUN
ajlm-2916	29	103	of	of	ADP
ajlm-2916	29	104	cnvs	cnvs	NOUN
ajlm-2916	29	105	in	in	ADP
ajlm-2916	29	106	various	various	ADJ
ajlm-2916	29	107	complex	complex	ADJ
ajlm-2916	29	108	immune	immune	ADJ
ajlm-2916	29	109	and	and	CCONJ
ajlm-2916	29	110	nonimmune	nonimmune	ADJ
ajlm-2916	29	111	disorders.10,11	disorders.10,11	NOUN
ajlm-2916	29	112	gene	gene	NOUN
ajlm-2916	29	113	cnvs	cnvs	NOUN
ajlm-2916	29	114	for	for	ADP
ajlm-2916	29	115	fc	fc	PROPN
ajlm-2916	29	116	gamma	gamma	PROPN
ajlm-2916	29	117	receptor	receptor	NOUN
ajlm-2916	29	118	iiib	iiib	NOUN
ajlm-2916	29	119	(	(	PUNCT
ajlm-2916	29	120	fcγriiib	fcγriiib	NOUN
ajlm-2916	29	121	)	)	PUNCT
ajlm-2916	29	122	,	,	PUNCT
ajlm-2916	29	123	t	t	PROPN
ajlm-2916	29	124	-	-	PUNCT
ajlm-2916	29	125	box	box	NOUN
ajlm-2916	29	126	expressed	express	VERB
ajlm-2916	29	127	in	in	ADP
ajlm-2916	29	128	t	t	PROPN
ajlm-2916	29	129	-	-	PUNCT
ajlm-2916	29	130	cells	cell	NOUN
ajlm-2916	29	131	(	(	PUNCT
ajlm-2916	29	132	t	t	NOUN
ajlm-2916	29	133	-	-	PUNCT
ajlm-2916	29	134	bet	bet	NOUN
ajlm-2916	29	135	)	)	PUNCT
ajlm-2916	29	136	,	,	PUNCT
ajlm-2916	29	137	interleukin-12b	interleukin-12b	ADP
ajlm-2916	29	138	(	(	PUNCT
ajlm-2916	29	139	il12b	il12b	ADJ
ajlm-2916	29	140	)	)	PUNCT
ajlm-2916	29	141	,	,	PUNCT
ajlm-2916	29	142	and	and	CCONJ
ajlm-2916	29	143	toll	toll	NOUN
ajlm-2916	29	144	-	-	PUNCT
ajlm-2916	29	145	like	like	ADJ
ajlm-2916	29	146	receptor	receptor	NOUN
ajlm-2916	29	147	7	7	NUM
ajlm-2916	29	148	(	(	PUNCT
ajlm-2916	29	149	tlr7	tlr7	PROPN
ajlm-2916	29	150	)	)	PUNCT
ajlm-2916	29	151	have	have	AUX
ajlm-2916	29	152	been	be	AUX
ajlm-2916	29	153	identified	identify	VERB
ajlm-2916	29	154	as	as	ADP
ajlm-2916	29	155	risk	risk	NOUN
ajlm-2916	29	156	factors	factor	NOUN
ajlm-2916	29	157	for	for	ADP
ajlm-2916	29	158	the	the	DET
ajlm-2916	29	159	onset	onset	NOUN
ajlm-2916	29	160	of	of	ADP
ajlm-2916	29	161	several	several	ADJ
ajlm-2916	29	162	autoimmune	autoimmune	ADJ
ajlm-2916	29	163	disorders	disorder	NOUN
ajlm-2916	29	164	,	,	PUNCT
ajlm-2916	29	165	such	such	ADJ
ajlm-2916	29	166	as	as	ADP
ajlm-2916	29	167	rheumatoid	rheumatoid	NOUN
ajlm-2916	29	168	arthritis	arthritis	NOUN
ajlm-2916	29	169	,	,	PUNCT
ajlm-2916	29	170	as	as	ADP
ajlm-2916	29	171	,	,	PUNCT
ajlm-2916	29	172	and	and	CCONJ
ajlm-2916	29	173	systemic	systemic	ADJ
ajlm-2916	29	174	lupus	lupus	NOUN
ajlm-2916	29	175	erythematosus.12,13,14,15	erythematosus.12,13,14,15	ADJ
ajlm-2916	29	176	lower	low	ADJ
ajlm-2916	29	177	cns	cns	NOUN
ajlm-2916	29	178	of	of	ADP
ajlm-2916	29	179	fcγriiib	fcγriiib	ADJ
ajlm-2916	29	180	genes	gene	NOUN
ajlm-2916	29	181	have	have	AUX
ajlm-2916	29	182	been	be	AUX
ajlm-2916	29	183	linked	link	VERB
ajlm-2916	29	184	to	to	ADP
ajlm-2916	29	185	an	an	DET
ajlm-2916	29	186	increased	increase	VERB
ajlm-2916	29	187	risk	risk	NOUN
ajlm-2916	29	188	of	of	ADP
ajlm-2916	29	189	developing	develop	VERB
ajlm-2916	29	190	as.16	as.16	PROPN
ajlm-2916	29	191	a	a	DET
ajlm-2916	29	192	high	high	ADJ
ajlm-2916	29	193	cn	cn	PROPN
ajlm-2916	29	194	of	of	ADP
ajlm-2916	29	195	the	the	DET
ajlm-2916	29	196	t	t	PROPN
ajlm-2916	29	197	-	-	PUNCT
ajlm-2916	29	198	bet	bet	NOUN
ajlm-2916	29	199	gene	gene	NOUN
ajlm-2916	29	200	has	have	AUX
ajlm-2916	29	201	been	be	AUX
ajlm-2916	29	202	associated	associate	VERB
ajlm-2916	29	203	with	with	ADP
ajlm-2916	29	204	increased	increase	VERB
ajlm-2916	29	205	susceptibility	susceptibility	NOUN
ajlm-2916	29	206	to	to	ADP
ajlm-2916	29	207	as	as	ADP
ajlm-2916	29	208	,	,	PUNCT
ajlm-2916	29	209	along	along	ADP
ajlm-2916	29	210	with	with	ADP
ajlm-2916	29	211	acute	acute	ADJ
ajlm-2916	29	212	anterior	anterior	ADJ
ajlm-2916	29	213	uveitis	uveitis	NOUN
ajlm-2916	29	214	,	,	PUNCT
ajlm-2916	29	215	indicating	indicate	VERB
ajlm-2916	29	216	the	the	DET
ajlm-2916	29	217	potential	potential	ADJ
ajlm-2916	29	218	impact	impact	NOUN
ajlm-2916	29	219	of	of	ADP
ajlm-2916	29	220	the	the	DET
ajlm-2916	29	221	t	t	NOUN
ajlm-2916	29	222	-	-	PUNCT
ajlm-2916	29	223	bet	bet	NOUN
ajlm-2916	29	224	gene	gene	NOUN
ajlm-2916	29	225	cnv	cnv	PROPN
ajlm-2916	29	226	on	on	ADP
ajlm-2916	29	227	the	the	DET
ajlm-2916	29	228	clinical	clinical	ADJ
ajlm-2916	29	229	course	course	NOUN
ajlm-2916	29	230	of	of	ADP
ajlm-2916	29	231	the	the	DET
ajlm-2916	29	232	disease.15	disease.15	NOUN
ajlm-2916	29	233	a	a	DET
ajlm-2916	29	234	previous	previous	ADJ
ajlm-2916	29	235	study	study	NOUN
ajlm-2916	29	236	demonstrated	demonstrate	VERB
ajlm-2916	29	237	that	that	SCONJ
ajlm-2916	29	238	extra	extra	ADJ
ajlm-2916	29	239	gene	gene	NOUN
ajlm-2916	29	240	copies	copy	NOUN
ajlm-2916	29	241	are	be	AUX
ajlm-2916	29	242	associated	associate	VERB
ajlm-2916	29	243	with	with	ADP
ajlm-2916	29	244	higher	high	ADJ
ajlm-2916	29	245	messenger	messenger	NOUN
ajlm-2916	29	246	rna	rna	NOUN
ajlm-2916	29	247	levels	level	NOUN
ajlm-2916	29	248	of	of	ADP
ajlm-2916	29	249	t	t	PROPN
ajlm-2916	29	250	-	-	PUNCT
ajlm-2916	29	251	bet	bet	NOUN
ajlm-2916	29	252	and	and	CCONJ
ajlm-2916	29	253	il-12b,17	il-12b,17	VERB
ajlm-2916	29	254	increasing	increase	VERB
ajlm-2916	29	255	il-12b	il-12b	NOUN
ajlm-2916	29	256	expression	expression	NOUN
ajlm-2916	29	257	,	,	PUNCT
ajlm-2916	29	258	which	which	PRON
ajlm-2916	29	259	has	have	AUX
ajlm-2916	29	260	been	be	AUX
ajlm-2916	29	261	demonstrated	demonstrate	VERB
ajlm-2916	29	262	to	to	PART
ajlm-2916	29	263	exacerbate	exacerbate	VERB
ajlm-2916	29	264	the	the	DET
ajlm-2916	29	265	severity	severity	NOUN
ajlm-2916	29	266	of	of	ADP
ajlm-2916	29	267	as.18	as.18	PROPN
ajlm-2916	29	268	a	a	DET
ajlm-2916	29	269	chinese	chinese	ADJ
ajlm-2916	29	270	study	study	NOUN
ajlm-2916	29	271	indicated	indicate	VERB
ajlm-2916	29	272	that	that	SCONJ
ajlm-2916	29	273	cnvs	cnvs	NOUN
ajlm-2916	29	274	in	in	ADP
ajlm-2916	29	275	the	the	DET
ajlm-2916	29	276	tlr7	tlr7	NOUN
ajlm-2916	29	277	gene	gene	NOUN
ajlm-2916	29	278	are	be	AUX
ajlm-2916	29	279	linked	link	VERB
ajlm-2916	29	280	to	to	ADP
ajlm-2916	29	281	as	as	ADP
ajlm-2916	29	282	,	,	PUNCT
ajlm-2916	29	283	with	with	ADP
ajlm-2916	29	284	a	a	DET
ajlm-2916	29	285	reduced	reduced	ADJ
ajlm-2916	29	286	cn	cn	NOUN
ajlm-2916	29	287	posing	pose	VERB
ajlm-2916	29	288	a	a	DET
ajlm-2916	29	289	risk	risk	NOUN
ajlm-2916	29	290	for	for	ADP
ajlm-2916	29	291	men	man	NOUN
ajlm-2916	29	292	and	and	CCONJ
ajlm-2916	29	293	a	a	DET
ajlm-2916	29	294	protective	protective	ADJ
ajlm-2916	29	295	effect	effect	NOUN
ajlm-2916	29	296	for	for	ADP
ajlm-2916	29	297	women.19	women.19	PRON
ajlm-2916	29	298	furthermore	furthermore	ADV
ajlm-2916	29	299	,	,	PUNCT
ajlm-2916	29	300	a	a	DET
ajlm-2916	29	301	number	number	NOUN
ajlm-2916	29	302	of	of	ADP
ajlm-2916	29	303	studies	study	NOUN
ajlm-2916	29	304	have	have	AUX
ajlm-2916	29	305	connected	connect	VERB
ajlm-2916	29	306	several	several	ADJ
ajlm-2916	29	307	gene	gene	NOUN
ajlm-2916	29	308	polymorphisms	polymorphism	NOUN
ajlm-2916	29	309	to	to	ADP
ajlm-2916	29	310	the	the	DET
ajlm-2916	29	311	progression	progression	NOUN
ajlm-2916	29	312	of	of	ADP
ajlm-2916	29	313	as	as	ADP
ajlm-2916	29	314	and	and	CCONJ
ajlm-2916	29	315	the	the	DET
ajlm-2916	29	316	activity	activity	NOUN
ajlm-2916	29	317	of	of	ADP
ajlm-2916	29	318	the	the	DET
ajlm-2916	29	319	disease	disease	NOUN
ajlm-2916	29	320	.	.	PUNCT
ajlm-2916	30	1	the	the	DET
ajlm-2916	30	2	ankylosing	ankylose	VERB
ajlm-2916	30	3	spondylitis	spondylitis	NOUN
ajlm-2916	30	4	disease	disease	NOUN
ajlm-2916	30	5	activity	activity	NOUN
ajlm-2916	30	6	score	score	NOUN
ajlm-2916	30	7	based	base	VERB
ajlm-2916	30	8	on	on	ADP
ajlm-2916	30	9	c	c	NOUN
ajlm-2916	30	10	-	-	PUNCT
ajlm-2916	30	11	reactive	reactive	ADJ
ajlm-2916	30	12	protein	protein	NOUN
ajlm-2916	30	13	is	be	AUX
ajlm-2916	30	14	the	the	DET
ajlm-2916	30	15	standard	standard	ADJ
ajlm-2916	30	16	method	method	NOUN
ajlm-2916	30	17	for	for	ADP
ajlm-2916	30	18	evaluating	evaluate	VERB
ajlm-2916	30	19	as	as	ADP
ajlm-2916	30	20	disease	disease	NOUN
ajlm-2916	30	21	activity	activity	NOUN
ajlm-2916	30	22	.	.	PUNCT
ajlm-2916	31	1	this	this	DET
ajlm-2916	31	2	validated	validate	VERB
ajlm-2916	31	3	composite	composite	ADJ
ajlm-2916	31	4	index	index	NOUN
ajlm-2916	31	5	combines	combine	VERB
ajlm-2916	31	6	c	c	ADJ
ajlm-2916	31	7	-	-	ADJ
ajlm-2916	31	8	reactive	reactive	ADJ
ajlm-2916	31	9	protein	protein	NOUN
ajlm-2916	31	10	levels	level	NOUN
ajlm-2916	31	11	with	with	ADP
ajlm-2916	31	12	patient	patient	NOUN
ajlm-2916	31	13	-	-	PUNCT
ajlm-2916	31	14	reported	report	VERB
ajlm-2916	31	15	measures	measure	NOUN
ajlm-2916	31	16	(	(	PUNCT
ajlm-2916	31	17	back	back	NOUN
ajlm-2916	31	18	pain	pain	NOUN
ajlm-2916	31	19	,	,	PUNCT
ajlm-2916	31	20	morning	morning	NOUN
ajlm-2916	31	21	stiffness	stiffness	NOUN
ajlm-2916	31	22	length	length	NOUN
ajlm-2916	31	23	,	,	PUNCT
ajlm-2916	31	24	and	and	CCONJ
ajlm-2916	31	25	global	global	ADJ
ajlm-2916	31	26	disease	disease	NOUN
ajlm-2916	31	27	activity	activity	NOUN
ajlm-2916	31	28	)	)	PUNCT
ajlm-2916	31	29	,	,	PUNCT
ajlm-2916	31	30	and	and	CCONJ
ajlm-2916	31	31	categorises	categorise	VERB
ajlm-2916	31	32	disease	disease	NOUN
ajlm-2916	31	33	activity	activity	NOUN
ajlm-2916	31	34	as	as	ADP
ajlm-2916	31	35	inactive	inactive	ADJ
ajlm-2916	31	36	(	(	PUNCT
ajlm-2916	31	37	<	<	X
ajlm-2916	31	38	1.3	1.3	NUM
ajlm-2916	31	39	)	)	PUNCT
ajlm-2916	31	40	,	,	PUNCT
ajlm-2916	31	41	low	low	ADJ
ajlm-2916	31	42	(	(	PUNCT
ajlm-2916	31	43	1.3–2.1	1.3–2.1	NUM
ajlm-2916	31	44	)	)	PUNCT
ajlm-2916	31	45	,	,	PUNCT
ajlm-2916	31	46	high	high	ADJ
ajlm-2916	31	47	(	(	PUNCT
ajlm-2916	31	48	2.1–3.5	2.1–3.5	NOUN
ajlm-2916	31	49	)	)	PUNCT
ajlm-2916	31	50	,	,	PUNCT
ajlm-2916	31	51	or	or	CCONJ
ajlm-2916	31	52	extremely	extremely	ADV
ajlm-2916	31	53	high	high	ADJ
ajlm-2916	31	54	(	(	PUNCT
ajlm-2916	31	55	≥	≥	NOUN
ajlm-2916	31	56	3.5	3.5	NUM
ajlm-2916	31	57	)	)	PUNCT
ajlm-2916	31	58	,	,	PUNCT
ajlm-2916	31	59	based	base	VERB
ajlm-2916	31	60	on	on	ADP
ajlm-2916	31	61	the	the	DET
ajlm-2916	31	62	2018	2018	NUM
ajlm-2916	31	63	criteria.20	criteria.20	NOUN
ajlm-2916	31	64	the	the	DET
ajlm-2916	31	65	link	link	NOUN
ajlm-2916	31	66	between	between	ADP
ajlm-2916	31	67	cnvs	cnvs	NOUN
ajlm-2916	31	68	and	and	CCONJ
ajlm-2916	31	69	as	as	ADP
ajlm-2916	31	70	risk	risk	NOUN
ajlm-2916	31	71	has	have	AUX
ajlm-2916	31	72	been	be	AUX
ajlm-2916	31	73	the	the	DET
ajlm-2916	31	74	subject	subject	NOUN
ajlm-2916	31	75	of	of	ADP
ajlm-2916	31	76	several	several	ADJ
ajlm-2916	31	77	studies	study	NOUN
ajlm-2916	31	78	in	in	ADP
ajlm-2916	31	79	developed	develop	VERB
ajlm-2916	31	80	countries	country	NOUN
ajlm-2916	31	81	,	,	PUNCT
ajlm-2916	31	82	but	but	CCONJ
ajlm-2916	31	83	far	far	ADV
ajlm-2916	31	84	less	less	ADV
ajlm-2916	31	85	is	be	AUX
ajlm-2916	31	86	known	know	VERB
ajlm-2916	31	87	in	in	ADP
ajlm-2916	31	88	north	north	ADJ
ajlm-2916	31	89	african	african	ADJ
ajlm-2916	31	90	countries	country	NOUN
ajlm-2916	31	91	with	with	ADP
ajlm-2916	31	92	limited	limited	ADJ
ajlm-2916	31	93	resources	resource	NOUN
ajlm-2916	31	94	,	,	PUNCT
ajlm-2916	31	95	especially	especially	ADV
ajlm-2916	31	96	egypt	egypt	PROPN
ajlm-2916	31	97	.	.	PUNCT
ajlm-2916	32	1	moreover	moreover	ADV
ajlm-2916	32	2	,	,	PUNCT
ajlm-2916	32	3	to	to	ADP
ajlm-2916	32	4	our	our	PRON
ajlm-2916	32	5	knowledge	knowledge	NOUN
ajlm-2916	32	6	,	,	PUNCT
ajlm-2916	32	7	the	the	DET
ajlm-2916	32	8	influence	influence	NOUN
ajlm-2916	32	9	of	of	ADP
ajlm-2916	32	10	these	these	DET
ajlm-2916	32	11	cnvs	cnvs	NOUN
ajlm-2916	32	12	on	on	ADP
ajlm-2916	32	13	disease	disease	NOUN
ajlm-2916	32	14	activity	activity	NOUN
ajlm-2916	32	15	has	have	AUX
ajlm-2916	32	16	not	not	PART
ajlm-2916	32	17	been	be	AUX
ajlm-2916	32	18	previously	previously	ADV
ajlm-2916	32	19	examined	examine	VERB
ajlm-2916	32	20	.	.	PUNCT
ajlm-2916	33	1	thus	thus	ADV
ajlm-2916	33	2	,	,	PUNCT
ajlm-2916	33	3	the	the	DET
ajlm-2916	33	4	purpose	purpose	NOUN
ajlm-2916	33	5	of	of	ADP
ajlm-2916	33	6	this	this	DET
ajlm-2916	33	7	study	study	NOUN
ajlm-2916	33	8	was	be	AUX
ajlm-2916	33	9	to	to	PART
ajlm-2916	33	10	examine	examine	VERB
ajlm-2916	33	11	the	the	DET
ajlm-2916	33	12	relationship	relationship	NOUN
ajlm-2916	33	13	between	between	ADP
ajlm-2916	33	14	the	the	DET
ajlm-2916	33	15	risk	risk	NOUN
ajlm-2916	33	16	of	of	ADP
ajlm-2916	33	17	developing	develop	VERB
ajlm-2916	33	18	as	as	ADP
ajlm-2916	33	19	in	in	ADP
ajlm-2916	33	20	egyptian	egyptian	ADJ
ajlm-2916	33	21	patients	patient	NOUN
ajlm-2916	33	22	and	and	CCONJ
ajlm-2916	33	23	cnvs	cnvs	NOUN
ajlm-2916	33	24	in	in	ADP
ajlm-2916	33	25	the	the	DET
ajlm-2916	33	26	fcγriiib	fcγriiib	NOUN
ajlm-2916	33	27	,	,	PUNCT
ajlm-2916	33	28	t	t	PROPN
ajlm-2916	33	29	-	-	PUNCT
ajlm-2916	33	30	bet	bet	NOUN
ajlm-2916	33	31	,	,	PUNCT
ajlm-2916	33	32	il12b	il12b	ADV
ajlm-2916	33	33	,	,	PUNCT
ajlm-2916	33	34	and	and	CCONJ
ajlm-2916	33	35	tlr7	tlr7	NOUN
ajlm-2916	33	36	genes	gene	NOUN
ajlm-2916	33	37	.	.	PUNCT
ajlm-2916	34	1	we	we	PRON
ajlm-2916	34	2	also	also	ADV
ajlm-2916	34	3	aimed	aim	VERB
ajlm-2916	34	4	to	to	PART
ajlm-2916	34	5	assess	assess	VERB
ajlm-2916	34	6	the	the	DET
ajlm-2916	34	7	influence	influence	NOUN
ajlm-2916	34	8	of	of	ADP
ajlm-2916	34	9	these	these	DET
ajlm-2916	34	10	cnvs	cnvs	NOUN
ajlm-2916	34	11	on	on	ADP
ajlm-2916	34	12	as	as	ADP
ajlm-2916	34	13	activity	activity	NOUN
ajlm-2916	34	14	.	.	PUNCT
ajlm-2916	35	1	methods	method	NOUN
ajlm-2916	35	2	ethical	ethical	ADJ
ajlm-2916	35	3	considerations	consideration	NOUN
ajlm-2916	35	4	this	this	DET
ajlm-2916	35	5	study	study	NOUN
ajlm-2916	35	6	was	be	AUX
ajlm-2916	35	7	approved	approve	VERB
ajlm-2916	35	8	by	by	ADP
ajlm-2916	35	9	the	the	DET
ajlm-2916	35	10	zagazig	zagazig	PROPN
ajlm-2916	35	11	university	university	PROPN
ajlm-2916	35	12	institutional	institutional	PROPN
ajlm-2916	35	13	review	review	PROPN
ajlm-2916	35	14	board	board	NOUN
ajlm-2916	35	15	(	(	PUNCT
ajlm-2916	35	16	approval	approval	NOUN
ajlm-2916	35	17	number	number	NOUN
ajlm-2916	35	18	:	:	PUNCT
ajlm-2916	35	19	11207	11207	NUM
ajlm-2916	35	20	)	)	PUNCT
ajlm-2916	35	21	on	on	ADP
ajlm-2916	35	22	25	25	NUM
ajlm-2916	35	23	october	october	PROPN
ajlm-2916	35	24	2023	2023	NUM
ajlm-2916	35	25	.	.	PUNCT
ajlm-2916	36	1	all	all	DET
ajlm-2916	36	2	participants	participant	NOUN
ajlm-2916	36	3	provided	provide	VERB
ajlm-2916	36	4	written	write	VERB
ajlm-2916	36	5	informed	inform	VERB
ajlm-2916	36	6	consent	consent	NOUN
ajlm-2916	36	7	prior	prior	ADV
ajlm-2916	36	8	to	to	ADP
ajlm-2916	36	9	participating	participate	VERB
ajlm-2916	36	10	.	.	PUNCT
ajlm-2916	37	1	procedures	procedure	NOUN
ajlm-2916	37	2	were	be	AUX
ajlm-2916	37	3	followed	follow	VERB
ajlm-2916	37	4	in	in	ADP
ajlm-2916	37	5	accordance	accordance	NOUN
ajlm-2916	37	6	with	with	ADP
ajlm-2916	37	7	the	the	DET
ajlm-2916	37	8	helsinki	helsinki	PROPN
ajlm-2916	37	9	declaration	declaration	PROPN
ajlm-2916	37	10	.	.	PUNCT
ajlm-2916	38	1	the	the	DET
ajlm-2916	38	2	patient	patient	NOUN
ajlm-2916	38	3	’s	’s	PART
ajlm-2916	38	4	information	information	NOUN
ajlm-2916	38	5	had	have	AUX
ajlm-2916	38	6	been	be	AUX
ajlm-2916	38	7	concealed	conceal	VERB
ajlm-2916	38	8	from	from	ADP
ajlm-2916	38	9	the	the	DET
ajlm-2916	38	10	lab	lab	NOUN
ajlm-2916	38	11	staff	staff	NOUN
ajlm-2916	38	12	as	as	SCONJ
ajlm-2916	38	13	the	the	DET
ajlm-2916	38	14	data	data	NOUN
ajlm-2916	38	15	records	record	NOUN
ajlm-2916	38	16	and	and	CCONJ
ajlm-2916	38	17	sample	sample	NOUN
ajlm-2916	38	18	tubes	tube	NOUN
ajlm-2916	38	19	were	be	AUX
ajlm-2916	38	20	coded	code	VERB
ajlm-2916	38	21	.	.	PUNCT
ajlm-2916	39	1	subjects	subject	NOUN
ajlm-2916	39	2	this	this	DET
ajlm-2916	39	3	study	study	NOUN
ajlm-2916	39	4	was	be	AUX
ajlm-2916	39	5	a	a	DET
ajlm-2916	39	6	case	case	NOUN
ajlm-2916	39	7	-	-	PUNCT
ajlm-2916	39	8	control	control	NOUN
ajlm-2916	39	9	study	study	NOUN
ajlm-2916	39	10	conducted	conduct	VERB
ajlm-2916	39	11	at	at	ADP
ajlm-2916	39	12	zagazig	zagazig	PROPN
ajlm-2916	39	13	university	university	PROPN
ajlm-2916	39	14	hospital	hospital	NOUN
ajlm-2916	39	15	,	,	PUNCT
ajlm-2916	39	16	zagazig	zagazig	PROPN
ajlm-2916	39	17	,	,	PUNCT
ajlm-2916	39	18	egypt	egypt	PROPN
ajlm-2916	39	19	,	,	PUNCT
ajlm-2916	39	20	from	from	ADP
ajlm-2916	39	21	01	01	NUM
ajlm-2916	39	22	november	november	PROPN
ajlm-2916	39	23	2023	2023	NUM
ajlm-2916	39	24	to	to	ADP
ajlm-2916	39	25	30	30	NUM
ajlm-2916	39	26	october	october	PROPN
ajlm-2916	39	27	2024	2024	NUM
ajlm-2916	39	28	.	.	PUNCT
ajlm-2916	40	1	it	it	PRON
ajlm-2916	40	2	comprised	comprise	VERB
ajlm-2916	40	3	72	72	NUM
ajlm-2916	40	4	consecutive	consecutive	ADJ
ajlm-2916	40	5	patients	patient	NOUN
ajlm-2916	40	6	with	with	ADP
ajlm-2916	40	7	as	as	SCONJ
ajlm-2916	40	8	,	,	PUNCT
ajlm-2916	40	9	recruited	recruit	VERB
ajlm-2916	40	10	from	from	ADP
ajlm-2916	40	11	the	the	DET
ajlm-2916	40	12	rheumatology	rheumatology	NOUN
ajlm-2916	40	13	and	and	CCONJ
ajlm-2916	40	14	rehabilitation	rehabilitation	NOUN
ajlm-2916	40	15	clinic	clinic	NOUN
ajlm-2916	40	16	of	of	ADP
ajlm-2916	40	17	the	the	DET
ajlm-2916	40	18	zagazig	zagazig	PROPN
ajlm-2916	40	19	university	university	PROPN
ajlm-2916	40	20	hospitals	hospital	NOUN
ajlm-2916	40	21	,	,	PUNCT
ajlm-2916	40	22	zagazig	zagazig	PROPN
ajlm-2916	40	23	,	,	PUNCT
ajlm-2916	40	24	egypt	egypt	PROPN
ajlm-2916	40	25	.	.	PUNCT
ajlm-2916	41	1	the	the	DET
ajlm-2916	41	2	control	control	PROPN
ajlm-2916	41	3	group	group	NOUN
ajlm-2916	41	4	comprised	comprise	VERB
ajlm-2916	41	5	42	42	NUM
ajlm-2916	41	6	healthy	healthy	ADJ
ajlm-2916	41	7	volunteers	volunteer	NOUN
ajlm-2916	41	8	of	of	ADP
ajlm-2916	41	9	the	the	DET
ajlm-2916	41	10	same	same	ADJ
ajlm-2916	41	11	ethnicity	ethnicity	NOUN
ajlm-2916	41	12	,	,	PUNCT
ajlm-2916	41	13	matched	match	VERB
ajlm-2916	41	14	for	for	ADP
ajlm-2916	41	15	age	age	NOUN
ajlm-2916	41	16	and	and	CCONJ
ajlm-2916	41	17	gender	gender	NOUN
ajlm-2916	41	18	,	,	PUNCT
ajlm-2916	41	19	devoid	devoid	ADJ
ajlm-2916	41	20	of	of	ADP
ajlm-2916	41	21	any	any	DET
ajlm-2916	41	22	autoimmune	autoimmune	ADJ
ajlm-2916	41	23	or	or	CCONJ
ajlm-2916	41	24	malignant	malignant	ADJ
ajlm-2916	41	25	disorders	disorder	NOUN
ajlm-2916	41	26	.	.	PUNCT
ajlm-2916	42	1	sample	sample	NOUN
ajlm-2916	42	2	size	size	NOUN
ajlm-2916	42	3	of	of	ADP
ajlm-2916	42	4	this	this	DET
ajlm-2916	42	5	study	study	NOUN
ajlm-2916	42	6	was	be	AUX
ajlm-2916	42	7	calculated	calculate	VERB
ajlm-2916	42	8	using	use	VERB
ajlm-2916	42	9	epi	epi	NOUN
ajlm-2916	42	10	info	info	NOUN
ajlm-2916	42	11	version	version	NOUN
ajlm-2916	42	12	3.01	3.01	NUM
ajlm-2916	42	13	(	(	PUNCT
ajlm-2916	42	14	centers	center	NOUN
ajlm-2916	42	15	for	for	ADP
ajlm-2916	42	16	disease	disease	NOUN
ajlm-2916	42	17	control	control	NOUN
ajlm-2916	42	18	and	and	CCONJ
ajlm-2916	42	19	prevention	prevention	NOUN
ajlm-2916	43	1	[	[	X
ajlm-2916	43	2	cdc	cdc	PROPN
ajlm-2916	43	3	]	]	X
ajlm-2916	43	4	,	,	PUNCT
ajlm-2916	43	5	atlanta	atlanta	PROPN
ajlm-2916	43	6	,	,	PUNCT
ajlm-2916	43	7	georgia	georgia	PROPN
ajlm-2916	43	8	,	,	PUNCT
ajlm-2916	43	9	united	united	PROPN
ajlm-2916	43	10	states	states	PROPN
ajlm-2916	43	11	)	)	PUNCT
ajlm-2916	43	12	,	,	PUNCT
ajlm-2916	43	13	at	at	ADP
ajlm-2916	43	14	95	95	NUM
ajlm-2916	43	15	%	%	NOUN
ajlm-2916	43	16	confidence	confidence	NOUN
ajlm-2916	43	17	interval	interval	NOUN
ajlm-2916	43	18	(	(	PUNCT
ajlm-2916	43	19	ci	ci	NOUN
ajlm-2916	43	20	)	)	PUNCT
ajlm-2916	43	21	,	,	PUNCT
ajlm-2916	43	22	based	base	VERB
ajlm-2916	43	23	on	on	ADP
ajlm-2916	43	24	the	the	DET
ajlm-2916	43	25	previously	previously	ADV
ajlm-2916	43	26	published	publish	VERB
ajlm-2916	43	27	data.12,15,19	data.12,15,19	NOUN
ajlm-2916	43	28	eligibility	eligibility	NOUN
ajlm-2916	43	29	criteria	criterion	NOUN
ajlm-2916	43	30	of	of	ADP
ajlm-2916	43	31	participating	participate	VERB
ajlm-2916	43	32	patients	patient	NOUN
ajlm-2916	43	33	included	include	VERB
ajlm-2916	43	34	fulfilling	fulfil	VERB
ajlm-2916	43	35	the	the	DET
ajlm-2916	43	36	modified	modify	VERB
ajlm-2916	43	37	new	new	PROPN
ajlm-2916	43	38	york	york	PROPN
ajlm-2916	43	39	criteria	criterion	NOUN
ajlm-2916	43	40	for	for	ADP
ajlm-2916	43	41	as	as	SCONJ
ajlm-2916	43	42	diagnosis.21	diagnosis.21	PROPN
ajlm-2916	43	43	patients	patient	NOUN
ajlm-2916	43	44	with	with	ADP
ajlm-2916	43	45	other	other	ADJ
ajlm-2916	43	46	coexisting	coexist	VERB
ajlm-2916	43	47	immunological	immunological	ADJ
ajlm-2916	43	48	or	or	CCONJ
ajlm-2916	43	49	malignant	malignant	ADJ
ajlm-2916	43	50	conditions	condition	NOUN
ajlm-2916	43	51	were	be	AUX
ajlm-2916	43	52	excluded	exclude	VERB
ajlm-2916	43	53	from	from	ADP
ajlm-2916	43	54	the	the	DET
ajlm-2916	43	55	study	study	NOUN
ajlm-2916	43	56	.	.	PUNCT
ajlm-2916	44	1	the	the	DET
ajlm-2916	44	2	diagnosis	diagnosis	NOUN
ajlm-2916	44	3	of	of	ADP
ajlm-2916	44	4	as	as	ADP
ajlm-2916	44	5	and	and	CCONJ
ajlm-2916	44	6	the	the	DET
ajlm-2916	44	7	evaluation	evaluation	NOUN
ajlm-2916	44	8	of	of	ADP
ajlm-2916	44	9	disease	disease	NOUN
ajlm-2916	44	10	activity	activity	NOUN
ajlm-2916	44	11	have	have	AUX
ajlm-2916	44	12	been	be	AUX
ajlm-2916	44	13	conducted	conduct	VERB
ajlm-2916	44	14	by	by	ADP
ajlm-2916	44	15	two	two	NUM
ajlm-2916	44	16	expert	expert	ADJ
ajlm-2916	44	17	rheumatologists	rheumatologist	NOUN
ajlm-2916	44	18	based	base	VERB
ajlm-2916	44	19	on	on	ADP
ajlm-2916	44	20	clinical	clinical	ADJ
ajlm-2916	44	21	examination	examination	NOUN
ajlm-2916	44	22	,	,	PUNCT
ajlm-2916	44	23	radiographic	radiographic	ADJ
ajlm-2916	44	24	evidence	evidence	NOUN
ajlm-2916	44	25	,	,	PUNCT
ajlm-2916	44	26	and	and	CCONJ
ajlm-2916	44	27	laboratory	laboratory	NOUN
ajlm-2916	44	28	investigations	investigation	NOUN
ajlm-2916	44	29	.	.	PUNCT
ajlm-2916	45	1	a	a	DET
ajlm-2916	45	2	verbal	verbal	ADJ
ajlm-2916	45	3	questionnaire	questionnaire	NOUN
ajlm-2916	45	4	was	be	AUX
ajlm-2916	45	5	given	give	VERB
ajlm-2916	45	6	to	to	ADP
ajlm-2916	45	7	the	the	DET
ajlm-2916	45	8	participants	participant	NOUN
ajlm-2916	45	9	in	in	ADP
ajlm-2916	45	10	order	order	NOUN
ajlm-2916	45	11	to	to	PART
ajlm-2916	45	12	gather	gather	VERB
ajlm-2916	45	13	sociodemographic	sociodemographic	ADJ
ajlm-2916	45	14	data	datum	NOUN
ajlm-2916	45	15	,	,	PUNCT
ajlm-2916	45	16	including	include	VERB
ajlm-2916	45	17	age	age	NOUN
ajlm-2916	45	18	,	,	PUNCT
ajlm-2916	45	19	ethnicity	ethnicity	NOUN
ajlm-2916	45	20	,	,	PUNCT
ajlm-2916	45	21	disease	disease	NOUN
ajlm-2916	45	22	duration	duration	NOUN
ajlm-2916	45	23	and	and	CCONJ
ajlm-2916	45	24	family	family	NOUN
ajlm-2916	45	25	history	history	NOUN
ajlm-2916	45	26	.	.	PUNCT
ajlm-2916	46	1	the	the	DET
ajlm-2916	46	2	following	follow	VERB
ajlm-2916	46	3	were	be	AUX
ajlm-2916	46	4	obtained	obtain	VERB
ajlm-2916	46	5	from	from	ADP
ajlm-2916	46	6	patients	patient	NOUN
ajlm-2916	46	7	’	'	PUNCT
ajlm-2916	46	8	records	record	NOUN
ajlm-2916	46	9	:	:	PUNCT
ajlm-2916	46	10	hla	hla	ADJ
ajlm-2916	46	11	-	-	PUNCT
ajlm-2916	46	12	b27	b27	PROPN
ajlm-2916	46	13	status	status	NOUN
ajlm-2916	46	14	,	,	PUNCT
ajlm-2916	46	15	c	c	NOUN
ajlm-2916	46	16	-	-	PUNCT
ajlm-2916	46	17	reactive	reactive	ADJ
ajlm-2916	46	18	protein	protein	NOUN
ajlm-2916	46	19	,	,	PUNCT
ajlm-2916	46	20	and	and	CCONJ
ajlm-2916	46	21	erythrocyte	erythrocyte	NOUN
ajlm-2916	46	22	sedimentation	sedimentation	NOUN
ajlm-2916	46	23	rate	rate	NOUN
ajlm-2916	46	24	levels	level	NOUN
ajlm-2916	46	25	.	.	PUNCT
ajlm-2916	47	1	disease	disease	NOUN
ajlm-2916	47	2	activity	activity	NOUN
ajlm-2916	47	3	was	be	AUX
ajlm-2916	47	4	assessed	assess	VERB
ajlm-2916	47	5	using	use	VERB
ajlm-2916	47	6	asdas.20	asdas.20	NOUN
ajlm-2916	47	7	extraction	extraction	NOUN
ajlm-2916	47	8	of	of	ADP
ajlm-2916	47	9	genomic	genomic	ADJ
ajlm-2916	47	10	dna	dna	NOUN
ajlm-2916	47	11	venous	venous	ADJ
ajlm-2916	47	12	blood	blood	NOUN
ajlm-2916	47	13	samples	sample	NOUN
ajlm-2916	47	14	were	be	AUX
ajlm-2916	47	15	collected	collect	VERB
ajlm-2916	47	16	in	in	ADP
ajlm-2916	47	17	tubes	tube	NOUN
ajlm-2916	47	18	containing	contain	VERB
ajlm-2916	47	19	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-2916	47	20	acid	acid	NOUN
ajlm-2916	47	21	.	.	PUNCT
ajlm-2916	48	1	total	total	ADJ
ajlm-2916	48	2	dna	dna	PROPN
ajlm-2916	48	3	was	be	AUX
ajlm-2916	48	4	extracted	extract	VERB
ajlm-2916	48	5	according	accord	VERB
ajlm-2916	48	6	to	to	ADP
ajlm-2916	48	7	the	the	DET
ajlm-2916	48	8	manufacturer	manufacturer	NOUN
ajlm-2916	48	9	’s	’s	PART
ajlm-2916	48	10	instructions	instruction	NOUN
ajlm-2916	48	11	using	use	VERB
ajlm-2916	48	12	dna	dna	PROPN
ajlm-2916	48	13	isolation	isolation	NOUN
ajlm-2916	48	14	kits	kit	NOUN
ajlm-2916	48	15	(	(	PUNCT
ajlm-2916	48	16	qiaamp	qiaamp	PROPN
ajlm-2916	48	17	dna	dna	PROPN
ajlm-2916	48	18	minikit	minikit	NOUN
ajlm-2916	48	19	;	;	PUNCT
ajlm-2916	48	20	qiagen	qiagen	NOUN
ajlm-2916	48	21	gmbh	gmbh	PROPN
ajlm-2916	48	22	,	,	PUNCT
ajlm-2916	48	23	hilden	hilden	PROPN
ajlm-2916	48	24	,	,	PUNCT
ajlm-2916	48	25	germany	germany	PROPN
ajlm-2916	48	26	)	)	PUNCT
ajlm-2916	48	27	and	and	CCONJ
ajlm-2916	48	28	stored	store	VERB
ajlm-2916	48	29	at	at	ADP
ajlm-2916	48	30	−20	−20	PROPN
ajlm-2916	48	31	°	°	ADP
ajlm-2916	48	32	c	c	NOUN
ajlm-2916	48	33	.	.	PUNCT
ajlm-2916	49	1	agarose	agarose	NOUN
ajlm-2916	49	2	gel	gel	NOUN
ajlm-2916	49	3	electrophoresis	electrophoresis	NOUN
ajlm-2916	49	4	was	be	AUX
ajlm-2916	49	5	used	use	VERB
ajlm-2916	49	6	to	to	PART
ajlm-2916	49	7	roughly	roughly	ADV
ajlm-2916	49	8	assess	assess	VERB
ajlm-2916	49	9	the	the	DET
ajlm-2916	49	10	extracted	extract	VERB
ajlm-2916	49	11	dna	dna	PROPN
ajlm-2916	49	12	concentration	concentration	NOUN
ajlm-2916	49	13	before	before	SCONJ
ajlm-2916	49	14	storage.22	storage.22	PROPN
ajlm-2916	49	15	copy	copy	VERB
ajlm-2916	49	16	number	number	NOUN
ajlm-2916	49	17	estimation	estimation	NOUN
ajlm-2916	49	18	real	real	ADJ
ajlm-2916	49	19	-	-	PUNCT
ajlm-2916	49	20	time	time	NOUN
ajlm-2916	49	21	quantitative	quantitative	ADJ
ajlm-2916	49	22	polymerase	polymerase	NOUN
ajlm-2916	49	23	chain	chain	NOUN
ajlm-2916	49	24	reaction	reaction	NOUN
ajlm-2916	49	25	(	(	PUNCT
ajlm-2916	49	26	pcr	pcr	PROPN
ajlm-2916	49	27	)	)	PUNCT
ajlm-2916	49	28	(	(	PUNCT
ajlm-2916	49	29	rtqpcr	rtqpcr	ADJ
ajlm-2916	49	30	,	,	PUNCT
ajlm-2916	49	31	sybr	sybr	ADV
ajlm-2916	49	32	green	green	ADJ
ajlm-2916	49	33	;	;	PUNCT
ajlm-2916	49	34	enzynomics	enzynomic	NOUN
ajlm-2916	49	35	,	,	PUNCT
ajlm-2916	49	36	life	life	NOUN
ajlm-2916	49	37	technologies	technology	NOUN
ajlm-2916	49	38	,	,	PUNCT
ajlm-2916	49	39	delhi	delhi	PROPN
ajlm-2916	49	40	,	,	PUNCT
ajlm-2916	49	41	india	india	PROPN
ajlm-2916	49	42	)	)	PUNCT
ajlm-2916	49	43	was	be	AUX
ajlm-2916	49	44	utilised	utilise	VERB
ajlm-2916	49	45	to	to	PART
ajlm-2916	49	46	assess	assess	VERB
ajlm-2916	49	47	the	the	DET
ajlm-2916	49	48	cnvs	cnvs	NOUN
ajlm-2916	49	49	of	of	ADP
ajlm-2916	49	50	fcγriiib	fcγriiib	ADJ
ajlm-2916	49	51	,	,	PUNCT
ajlm-2916	49	52	t	t	PROPN
ajlm-2916	49	53	-	-	PUNCT
ajlm-2916	49	54	bet	bet	NOUN
ajlm-2916	49	55	,	,	PUNCT
ajlm-2916	49	56	il12b	il12b	ADV
ajlm-2916	49	57	,	,	PUNCT
ajlm-2916	49	58	and	and	CCONJ
ajlm-2916	49	59	tlr7	tlr7	PROPN
ajlm-2916	49	60	,	,	PUNCT
ajlm-2916	49	61	following	follow	VERB
ajlm-2916	49	62	the	the	DET
ajlm-2916	49	63	previously	previously	ADV
ajlm-2916	49	64	described	describe	VERB
ajlm-2916	49	65	procedure.23	procedure.23	ADP
ajlm-2916	49	66	the	the	DET
ajlm-2916	49	67	concentration	concentration	NOUN
ajlm-2916	49	68	of	of	ADP
ajlm-2916	49	69	the	the	DET
ajlm-2916	49	70	extracted	extract	VERB
ajlm-2916	49	71	dna	dna	NOUN
ajlm-2916	49	72	was	be	AUX
ajlm-2916	49	73	accurately	accurately	ADV
ajlm-2916	49	74	measured	measure	VERB
ajlm-2916	49	75	using	use	VERB
ajlm-2916	49	76	a	a	DET
ajlm-2916	49	77	qubit	qubit	NOUN
ajlm-2916	49	78	fluorometer	fluorometer	NOUN
ajlm-2916	49	79	immediately	immediately	ADV
ajlm-2916	49	80	prior	prior	ADV
ajlm-2916	49	81	to	to	ADP
ajlm-2916	49	82	the	the	DET
ajlm-2916	49	83	real	real	ADJ
ajlm-2916	49	84	-	-	PUNCT
ajlm-2916	49	85	time	time	NOUN
ajlm-2916	49	86	pcr	pcr	NOUN
ajlm-2916	49	87	run	run	NOUN
ajlm-2916	49	88	for	for	ADP
ajlm-2916	49	89	mixture	mixture	NOUN
ajlm-2916	49	90	preparation.24	preparation.24	NOUN
ajlm-2916	49	91	the	the	DET
ajlm-2916	49	92	pcr	pcr	ADJ
ajlm-2916	49	93	reactions	reaction	NOUN
ajlm-2916	49	94	were	be	AUX
ajlm-2916	49	95	conducted	conduct	VERB
ajlm-2916	49	96	using	use	VERB
ajlm-2916	49	97	an	an	DET
ajlm-2916	49	98	applied	apply	VERB
ajlm-2916	49	99	biosystems	biosystem	NOUN
ajlm-2916	49	100	7500	7500	NUM
ajlm-2916	49	101	real	real	ADJ
ajlm-2916	49	102	-	-	PUNCT
ajlm-2916	49	103	time	time	NOUN
ajlm-2916	49	104	pcr	pcr	ADJ
ajlm-2916	49	105	machine	machine	NOUN
ajlm-2916	49	106	,	,	PUNCT
ajlm-2916	49	107	following	follow	VERB
ajlm-2916	49	108	the	the	DET
ajlm-2916	49	109	manufacturer	manufacturer	NOUN
ajlm-2916	49	110	’s	’s	PART
ajlm-2916	49	111	instructions	instruction	NOUN
ajlm-2916	49	112	for	for	ADP
ajlm-2916	49	113	the	the	DET
ajlm-2916	49	114	pcr	pcr	ADJ
ajlm-2916	49	115	mixture	mixture	NOUN
ajlm-2916	49	116	and	and	CCONJ
ajlm-2916	49	117	cycling	cycling	NOUN
ajlm-2916	49	118	conditions	condition	NOUN
ajlm-2916	49	119	.	.	PUNCT
ajlm-2916	50	1	forkhead	forkhead	AUX
ajlm-2916	50	2	box	box	NOUN
ajlm-2916	50	3	protein	protein	NOUN
ajlm-2916	50	4	p2	p2	NOUN
ajlm-2916	50	5	(	(	PUNCT
ajlm-2916	50	6	foxp2	foxp2	NOUN
ajlm-2916	50	7	)	)	PUNCT
ajlm-2916	50	8	gene	gene	NOUN
ajlm-2916	50	9	(	(	PUNCT
ajlm-2916	50	10	a	a	DET
ajlm-2916	50	11	non	non	ADJ
ajlm-2916	50	12	-	-	ADJ
ajlm-2916	50	13	cnv	cnv	ADJ
ajlm-2916	50	14	gene	gene	NOUN
ajlm-2916	50	15	)	)	PUNCT
ajlm-2916	50	16	served	serve	VERB
ajlm-2916	50	17	as	as	ADP
ajlm-2916	50	18	the	the	DET
ajlm-2916	50	19	reference	reference	NOUN
ajlm-2916	50	20	for	for	ADP
ajlm-2916	50	21	normalisation	normalisation	NOUN
ajlm-2916	50	22	.	.	PUNCT
ajlm-2916	51	1	table	table	NOUN
ajlm-2916	51	2	1	1	NUM
ajlm-2916	51	3	lists	list	VERB
ajlm-2916	51	4	the	the	DET
ajlm-2916	51	5	primer	primer	NOUN
ajlm-2916	51	6	sequences	sequence	NOUN
ajlm-2916	51	7	used	use	VERB
ajlm-2916	51	8	to	to	PART
ajlm-2916	51	9	estimate	estimate	VERB
ajlm-2916	51	10	cnvs	cnvs	NOUN
ajlm-2916	51	11	for	for	ADP
ajlm-2916	51	12	the	the	DET
ajlm-2916	51	13	genes	gene	NOUN
ajlm-2916	51	14	under	under	ADP
ajlm-2916	51	15	study	study	NOUN
ajlm-2916	51	16	and	and	CCONJ
ajlm-2916	51	17	the	the	DET
ajlm-2916	51	18	reference	reference	NOUN
ajlm-2916	51	19	gene	gene	NOUN
ajlm-2916	51	20	foxp2	foxp2	NOUN
ajlm-2916	51	21	.	.	PUNCT
ajlm-2916	51	22	table	table	NOUN
ajlm-2916	51	23	1	1	NUM
ajlm-2916	51	24	:	:	PUNCT
ajlm-2916	51	25	 	 	SPACE
ajlm-2916	51	26	primer	primer	NOUN
ajlm-2916	51	27	sequences	sequence	NOUN
ajlm-2916	51	28	for	for	ADP
ajlm-2916	51	29	estimating	estimate	VERB
ajlm-2916	51	30	copy	copy	NOUN
ajlm-2916	51	31	number	number	NOUN
ajlm-2916	51	32	variations	variation	NOUN
ajlm-2916	51	33	for	for	ADP
ajlm-2916	51	34	the	the	DET
ajlm-2916	51	35	reference	reference	NOUN
ajlm-2916	51	36	gene	gene	NOUN
ajlm-2916	51	37	foxp2	foxp2	NOUN
ajlm-2916	51	38	and	and	CCONJ
ajlm-2916	51	39	the	the	DET
ajlm-2916	51	40	genes	gene	NOUN
ajlm-2916	51	41	under	under	ADP
ajlm-2916	51	42	study	study	NOUN
ajlm-2916	51	43	,	,	PUNCT
ajlm-2916	51	44	zagazig	zagazig	PROPN
ajlm-2916	51	45	university	university	PROPN
ajlm-2916	51	46	hospitals	hospital	NOUN
ajlm-2916	51	47	,	,	PUNCT
ajlm-2916	51	48	zagazig	zagazig	PROPN
ajlm-2916	51	49	,	,	PUNCT
ajlm-2916	51	50	egypt	egypt	PROPN
ajlm-2916	51	51	,	,	PUNCT
ajlm-2916	51	52	november	november	PROPN
ajlm-2916	51	53	2023	2023	NUM
ajlm-2916	51	54	–	–	PUNCT
ajlm-2916	51	55	october	october	PROPN
ajlm-2916	51	56	2024	2024	NUM
ajlm-2916	51	57	.	.	PUNCT
ajlm-2916	52	1	copy	copy	NOUN
ajlm-2916	52	2	numbers	number	NOUN
ajlm-2916	52	3	(	(	PUNCT
ajlm-2916	52	4	cns	cns	NOUN
ajlm-2916	52	5	)	)	PUNCT
ajlm-2916	52	6	were	be	AUX
ajlm-2916	52	7	calculated	calculate	VERB
ajlm-2916	52	8	using	use	VERB
ajlm-2916	52	9	the	the	DET
ajlm-2916	52	10	comparative	comparative	ADJ
ajlm-2916	52	11	cycle	cycle	NOUN
ajlm-2916	52	12	threshold	threshold	NOUN
ajlm-2916	52	13	(	(	PUNCT
ajlm-2916	52	14	2-^^ct	2-^^ct	NUM
ajlm-2916	52	15	)	)	PUNCT
ajlm-2916	52	16	method.23	method.23	PROPN
ajlm-2916	52	17	copy	copy	VERB
ajlm-2916	52	18	numbers	number	NOUN
ajlm-2916	52	19	for	for	ADP
ajlm-2916	52	20	fcγriiib	fcγriiib	ADJ
ajlm-2916	52	21	,	,	PUNCT
ajlm-2916	52	22	t	t	PROPN
ajlm-2916	52	23	-	-	PUNCT
ajlm-2916	52	24	bet	bet	NOUN
ajlm-2916	52	25	,	,	PUNCT
ajlm-2916	52	26	il12b	il12b	ADV
ajlm-2916	52	27	,	,	PUNCT
ajlm-2916	52	28	and	and	CCONJ
ajlm-2916	52	29	tlr7	tlr7	NOUN
ajlm-2916	52	30	were	be	AUX
ajlm-2916	52	31	categorised	categorise	VERB
ajlm-2916	52	32	as	as	ADP
ajlm-2916	52	33	low	low	ADJ
ajlm-2916	52	34	cn	cn	PROPN
ajlm-2916	52	35	(	(	PUNCT
ajlm-2916	52	36	<	<	X
ajlm-2916	52	37	2	2	NUM
ajlm-2916	52	38	)	)	PUNCT
ajlm-2916	52	39	,	,	PUNCT
ajlm-2916	52	40	normal	normal	ADJ
ajlm-2916	52	41	cn	cn	INTJ
ajlm-2916	52	42	(=	(=	PROPN
ajlm-2916	52	43	2	2	NUM
ajlm-2916	52	44	)	)	PUNCT
ajlm-2916	52	45	,	,	PUNCT
ajlm-2916	52	46	and	and	CCONJ
ajlm-2916	52	47	high	high	ADJ
ajlm-2916	52	48	cn	cn	PROPN
ajlm-2916	52	49	(	(	PUNCT
ajlm-2916	52	50	>	>	X
ajlm-2916	52	51	2	2	NUM
ajlm-2916	52	52	)	)	PUNCT
ajlm-2916	52	53	.	.	PUNCT
ajlm-2916	53	1	data	datum	NOUN
ajlm-2916	53	2	analysis	analysis	NOUN
ajlm-2916	53	3	data	datum	NOUN
ajlm-2916	53	4	were	be	AUX
ajlm-2916	53	5	tabulated	tabulate	VERB
ajlm-2916	53	6	and	and	CCONJ
ajlm-2916	53	7	analysed	analyse	VERB
ajlm-2916	53	8	using	use	VERB
ajlm-2916	53	9	spss-22	spss-22	PROPN
ajlm-2916	53	10	(	(	PUNCT
ajlm-2916	53	11	ibm	ibm	PROPN
ajlm-2916	53	12	corporation	corporation	PROPN
ajlm-2916	53	13	,	,	PUNCT
ajlm-2916	53	14	armonk	armonk	PROPN
ajlm-2916	53	15	,	,	PUNCT
ajlm-2916	53	16	new	new	PROPN
ajlm-2916	53	17	york	york	PROPN
ajlm-2916	53	18	,	,	PUNCT
ajlm-2916	53	19	united	united	PROPN
ajlm-2916	53	20	states	states	PROPN
ajlm-2916	53	21	)	)	PUNCT
ajlm-2916	53	22	.	.	PUNCT
ajlm-2916	54	1	student	student	NOUN
ajlm-2916	54	2	’s	’s	PART
ajlm-2916	54	3	t	t	PROPN
ajlm-2916	54	4	-	-	PUNCT
ajlm-2916	54	5	test	test	NOUN
ajlm-2916	54	6	and	and	CCONJ
ajlm-2916	54	7	one	one	NUM
ajlm-2916	54	8	-	-	PUNCT
ajlm-2916	54	9	way	way	NOUN
ajlm-2916	54	10	analysis	analysis	NOUN
ajlm-2916	54	11	of	of	ADP
ajlm-2916	54	12	variation	variation	NOUN
ajlm-2916	54	13	with	with	ADP
ajlm-2916	54	14	least	least	ADJ
ajlm-2916	54	15	significant	significant	ADJ
ajlm-2916	54	16	difference	difference	NOUN
ajlm-2916	54	17	post	post	ADJ
ajlm-2916	54	18	-	-	ADJ
ajlm-2916	54	19	hoc	hoc	ADJ
ajlm-2916	54	20	test	test	NOUN
ajlm-2916	54	21	were	be	AUX
ajlm-2916	54	22	used	use	VERB
ajlm-2916	54	23	to	to	PART
ajlm-2916	54	24	compare	compare	VERB
ajlm-2916	54	25	means	mean	NOUN
ajlm-2916	54	26	,	,	PUNCT
ajlm-2916	54	27	and	and	CCONJ
ajlm-2916	54	28	the	the	DET
ajlm-2916	54	29	kruskal	kruskal	PROPN
ajlm-2916	54	30	-	-	PUNCT
ajlm-2916	54	31	wallis	wallis	PROPN
ajlm-2916	54	32	test	test	NOUN
ajlm-2916	54	33	was	be	AUX
ajlm-2916	54	34	used	use	VERB
ajlm-2916	54	35	to	to	PART
ajlm-2916	54	36	compare	compare	VERB
ajlm-2916	54	37	medians	median	NOUN
ajlm-2916	54	38	.	.	PUNCT
ajlm-2916	55	1	chi	chi	ADJ
ajlm-2916	55	2	-	-	PUNCT
ajlm-2916	55	3	square	square	PROPN
ajlm-2916	55	4	and	and	CCONJ
ajlm-2916	55	5	fisher	fisher	PROPN
ajlm-2916	55	6	’s	’s	PART
ajlm-2916	55	7	exact	exact	ADJ
ajlm-2916	55	8	tests	test	NOUN
ajlm-2916	55	9	were	be	AUX
ajlm-2916	55	10	used	use	VERB
ajlm-2916	55	11	to	to	PART
ajlm-2916	55	12	compare	compare	VERB
ajlm-2916	55	13	frequencies	frequency	NOUN
ajlm-2916	55	14	.	.	PUNCT
ajlm-2916	56	1	the	the	DET
ajlm-2916	56	2	level	level	NOUN
ajlm-2916	56	3	of	of	ADP
ajlm-2916	56	4	statistical	statistical	ADJ
ajlm-2916	56	5	significance	significance	NOUN
ajlm-2916	56	6	was	be	AUX
ajlm-2916	56	7	set	set	VERB
ajlm-2916	56	8	at	at	ADP
ajlm-2916	56	9	a	a	DET
ajlm-2916	56	10	p	p	NOUN
ajlm-2916	56	11	-	-	PUNCT
ajlm-2916	56	12	value	value	NOUN
ajlm-2916	56	13	of	of	ADP
ajlm-2916	56	14	<	<	X
ajlm-2916	56	15	0.05	0.05	NUM
ajlm-2916	56	16	.	.	PUNCT
ajlm-2916	57	1	results	result	NOUN
ajlm-2916	57	2	demographic	demographic	ADJ
ajlm-2916	57	3	and	and	CCONJ
ajlm-2916	57	4	clinical	clinical	ADJ
ajlm-2916	57	5	characteristics	characteristic	NOUN
ajlm-2916	57	6	the	the	DET
ajlm-2916	57	7	study	study	NOUN
ajlm-2916	57	8	included	include	VERB
ajlm-2916	57	9	114	114	NUM
ajlm-2916	57	10	participants	participant	NOUN
ajlm-2916	57	11	:	:	PUNCT
ajlm-2916	57	12	72	72	NUM
ajlm-2916	57	13	as	as	ADP
ajlm-2916	57	14	patients	patient	NOUN
ajlm-2916	57	15	and	and	CCONJ
ajlm-2916	57	16	42	42	NUM
ajlm-2916	57	17	healthy	healthy	ADJ
ajlm-2916	57	18	controls	control	NOUN
ajlm-2916	57	19	.	.	PUNCT
ajlm-2916	58	1	among	among	ADP
ajlm-2916	58	2	the	the	DET
ajlm-2916	58	3	72	72	NUM
ajlm-2916	58	4	as	as	ADP
ajlm-2916	58	5	patients	patient	NOUN
ajlm-2916	58	6	,	,	PUNCT
ajlm-2916	58	7	aged	age	VERB
ajlm-2916	58	8	19	19	NUM
ajlm-2916	58	9	to	to	PART
ajlm-2916	58	10	52	52	NUM
ajlm-2916	58	11	years	year	NOUN
ajlm-2916	58	12	,	,	PUNCT
ajlm-2916	58	13	47	47	NUM
ajlm-2916	58	14	(	(	PUNCT
ajlm-2916	58	15	65.2	65.2	NUM
ajlm-2916	58	16	%	%	NOUN
ajlm-2916	58	17	)	)	PUNCT
ajlm-2916	58	18	were	be	AUX
ajlm-2916	58	19	men	man	NOUN
ajlm-2916	58	20	and	and	CCONJ
ajlm-2916	58	21	25	25	NUM
ajlm-2916	58	22	(	(	PUNCT
ajlm-2916	58	23	34.8	34.8	NUM
ajlm-2916	58	24	%	%	NOUN
ajlm-2916	58	25	)	)	PUNCT
ajlm-2916	58	26	were	be	AUX
ajlm-2916	58	27	women	woman	NOUN
ajlm-2916	58	28	.	.	PUNCT
ajlm-2916	59	1	the	the	DET
ajlm-2916	59	2	control	control	PROPN
ajlm-2916	59	3	group	group	NOUN
ajlm-2916	59	4	consisted	consist	VERB
ajlm-2916	59	5	of	of	ADP
ajlm-2916	59	6	42	42	NUM
ajlm-2916	59	7	individuals	individual	NOUN
ajlm-2916	59	8	aged	age	VERB
ajlm-2916	59	9	27	27	NUM
ajlm-2916	59	10	to	to	PART
ajlm-2916	59	11	55	55	NUM
ajlm-2916	59	12	years	year	NOUN
ajlm-2916	59	13	,	,	PUNCT
ajlm-2916	59	14	with	with	ADP
ajlm-2916	59	15	22	22	NUM
ajlm-2916	59	16	(	(	PUNCT
ajlm-2916	59	17	52.4	52.4	NUM
ajlm-2916	59	18	%	%	NOUN
ajlm-2916	59	19	)	)	PUNCT
ajlm-2916	59	20	men	man	NOUN
ajlm-2916	59	21	and	and	CCONJ
ajlm-2916	59	22	20	20	NUM
ajlm-2916	59	23	(	(	PUNCT
ajlm-2916	59	24	47.6	47.6	NUM
ajlm-2916	59	25	%	%	NOUN
ajlm-2916	59	26	)	)	PUNCT
ajlm-2916	59	27	women	woman	NOUN
ajlm-2916	59	28	.	.	PUNCT
ajlm-2916	60	1	among	among	ADP
ajlm-2916	60	2	patients	patient	NOUN
ajlm-2916	60	3	with	with	ADP
ajlm-2916	60	4	as	as	ADP
ajlm-2916	60	5	,	,	PUNCT
ajlm-2916	60	6	11.1	11.1	NUM
ajlm-2916	60	7	%	%	NOUN
ajlm-2916	60	8	exhibited	exhibit	VERB
ajlm-2916	60	9	low	low	ADJ
ajlm-2916	60	10	disease	disease	NOUN
ajlm-2916	60	11	activity	activity	NOUN
ajlm-2916	60	12	,	,	PUNCT
ajlm-2916	60	13	58.3	58.3	NUM
ajlm-2916	60	14	%	%	NOUN
ajlm-2916	60	15	demonstrated	demonstrate	VERB
ajlm-2916	60	16	high	high	ADJ
ajlm-2916	60	17	activity	activity	NOUN
ajlm-2916	60	18	,	,	PUNCT
ajlm-2916	60	19	and	and	CCONJ
ajlm-2916	60	20	30.6	30.6	NUM
ajlm-2916	60	21	%	%	NOUN
ajlm-2916	60	22	presented	present	VERB
ajlm-2916	60	23	with	with	ADP
ajlm-2916	60	24	very	very	ADV
ajlm-2916	60	25	high	high	ADJ
ajlm-2916	60	26	activity	activity	NOUN
ajlm-2916	60	27	.	.	PUNCT
ajlm-2916	61	1	table	table	NOUN
ajlm-2916	61	2	2	2	NUM
ajlm-2916	61	3	and	and	CCONJ
ajlm-2916	61	4	table	table	NOUN
ajlm-2916	61	5	3	3	NUM
ajlm-2916	61	6	summarise	summarise	VERB
ajlm-2916	61	7	the	the	DET
ajlm-2916	61	8	demographics	demographic	NOUN
ajlm-2916	61	9	and	and	CCONJ
ajlm-2916	61	10	clinical	clinical	ADJ
ajlm-2916	61	11	characteristics	characteristic	NOUN
ajlm-2916	61	12	of	of	ADP
ajlm-2916	61	13	the	the	DET
ajlm-2916	61	14	study	study	NOUN
ajlm-2916	61	15	participants	participant	NOUN
ajlm-2916	61	16	.	.	PUNCT
ajlm-2916	62	1	table	table	NOUN
ajlm-2916	62	2	2	2	NUM
ajlm-2916	62	3	:	:	PUNCT
ajlm-2916	62	4	 	 	SPACE
ajlm-2916	62	5	demographic	demographic	ADJ
ajlm-2916	62	6	characteristics	characteristic	NOUN
ajlm-2916	62	7	of	of	ADP
ajlm-2916	62	8	the	the	DET
ajlm-2916	62	9	study	study	NOUN
ajlm-2916	62	10	participants	participant	NOUN
ajlm-2916	62	11	,	,	PUNCT
ajlm-2916	62	12	zagazig	zagazig	PROPN
ajlm-2916	62	13	university	university	NOUN
ajlm-2916	62	14	hospitals	hospital	NOUN
ajlm-2916	62	15	,	,	PUNCT
ajlm-2916	62	16	zagazig	zagazig	PROPN
ajlm-2916	62	17	,	,	PUNCT
ajlm-2916	62	18	egypt	egypt	PROPN
ajlm-2916	62	19	,	,	PUNCT
ajlm-2916	62	20	november	november	PROPN
ajlm-2916	62	21	2023	2023	NUM
ajlm-2916	62	22	–	–	PUNCT
ajlm-2916	62	23	october	october	PROPN
ajlm-2916	62	24	2024	2024	NUM
ajlm-2916	62	25	.	.	PUNCT
ajlm-2916	63	1	table	table	NOUN
ajlm-2916	63	2	3	3	NUM
ajlm-2916	63	3	:	:	PUNCT
ajlm-2916	63	4	 	 	SPACE
ajlm-2916	63	5	clinical	clinical	ADJ
ajlm-2916	63	6	characteristics	characteristic	NOUN
ajlm-2916	63	7	of	of	ADP
ajlm-2916	63	8	the	the	DET
ajlm-2916	63	9	study	study	NOUN
ajlm-2916	63	10	participants	participant	NOUN
ajlm-2916	63	11	,	,	PUNCT
ajlm-2916	63	12	zagazig	zagazig	PROPN
ajlm-2916	63	13	university	university	NOUN
ajlm-2916	63	14	hospitals	hospital	NOUN
ajlm-2916	63	15	,	,	PUNCT
ajlm-2916	63	16	zagazig	zagazig	PROPN
ajlm-2916	63	17	,	,	PUNCT
ajlm-2916	63	18	egypt	egypt	PROPN
ajlm-2916	63	19	,	,	PUNCT
ajlm-2916	63	20	november	november	PROPN
ajlm-2916	63	21	2023	2023	NUM
ajlm-2916	63	22	–	–	PUNCT
ajlm-2916	63	23	october	october	PROPN
ajlm-2916	63	24	2024	2024	NUM
ajlm-2916	63	25	.	.	PUNCT
ajlm-2916	64	1	frequency	frequency	NOUN
ajlm-2916	64	2	distribution	distribution	NOUN
ajlm-2916	64	3	of	of	ADP
ajlm-2916	64	4	fcγriiib	fcγriiib	ADJ
ajlm-2916	64	5	,	,	PUNCT
ajlm-2916	64	6	t	t	PROPN
ajlm-2916	64	7	-	-	PUNCT
ajlm-2916	64	8	bet	bet	NOUN
ajlm-2916	64	9	,	,	PUNCT
ajlm-2916	64	10	il12b	il12b	ADV
ajlm-2916	64	11	,	,	PUNCT
ajlm-2916	64	12	and	and	CCONJ
ajlm-2916	64	13	tlr7	tlr7	NOUN
ajlm-2916	64	14	genes	gene	NOUN
ajlm-2916	64	15	copy	copy	VERB
ajlm-2916	64	16	number	number	NOUN
ajlm-2916	64	17	variations	variation	NOUN
ajlm-2916	64	18	patients	patient	NOUN
ajlm-2916	64	19	and	and	CCONJ
ajlm-2916	64	20	healthy	healthy	ADJ
ajlm-2916	64	21	controls	control	NOUN
ajlm-2916	64	22	were	be	AUX
ajlm-2916	64	23	compared	compare	VERB
ajlm-2916	64	24	regarding	regard	VERB
ajlm-2916	64	25	the	the	DET
ajlm-2916	64	26	frequency	frequency	NOUN
ajlm-2916	64	27	of	of	ADP
ajlm-2916	64	28	cnv	cnv	PROPN
ajlm-2916	64	29	in	in	ADP
ajlm-2916	64	30	the	the	DET
ajlm-2916	64	31	genes	gene	NOUN
ajlm-2916	64	32	under	under	ADP
ajlm-2916	64	33	investigation	investigation	NOUN
ajlm-2916	64	34	(	(	PUNCT
ajlm-2916	64	35	table	table	NOUN
ajlm-2916	64	36	4	4	NUM
ajlm-2916	64	37	)	)	PUNCT
ajlm-2916	64	38	.	.	PUNCT
ajlm-2916	65	1	table	table	NOUN
ajlm-2916	65	2	4	4	NUM
ajlm-2916	65	3	:	:	PUNCT
ajlm-2916	65	4	 	 	SPACE
ajlm-2916	65	5	fcγriiib	fcγriiib	ADJ
ajlm-2916	65	6	,	,	PUNCT
ajlm-2916	65	7	t	t	PROPN
ajlm-2916	65	8	-	-	PUNCT
ajlm-2916	65	9	bet	bet	NOUN
ajlm-2916	65	10	,	,	PUNCT
ajlm-2916	65	11	il12b	il12b	ADV
ajlm-2916	65	12	,	,	PUNCT
ajlm-2916	65	13	and	and	CCONJ
ajlm-2916	65	14	tlr7	tlr7	NOUN
ajlm-2916	65	15	gene	gene	NOUN
ajlm-2916	65	16	copy	copy	NOUN
ajlm-2916	65	17	number	number	NOUN
ajlm-2916	65	18	variation	variation	NOUN
ajlm-2916	65	19	distribution	distribution	NOUN
ajlm-2916	65	20	in	in	ADP
ajlm-2916	65	21	ankylosing	ankylose	VERB
ajlm-2916	65	22	spondylitis	spondylitis	ADJ
ajlm-2916	65	23	patients	patient	NOUN
ajlm-2916	65	24	and	and	CCONJ
ajlm-2916	65	25	healthy	healthy	ADJ
ajlm-2916	65	26	controls	control	NOUN
ajlm-2916	65	27	,	,	PUNCT
ajlm-2916	65	28	zagazig	zagazig	PROPN
ajlm-2916	65	29	university	university	NOUN
ajlm-2916	65	30	hospitals	hospital	NOUN
ajlm-2916	65	31	,	,	PUNCT
ajlm-2916	65	32	zagazig	zagazig	PROPN
ajlm-2916	65	33	,	,	PUNCT
ajlm-2916	65	34	egypt	egypt	PROPN
ajlm-2916	65	35	,	,	PUNCT
ajlm-2916	65	36	november	november	PROPN
ajlm-2916	65	37	2023	2023	NUM
ajlm-2916	65	38	–	–	PUNCT
ajlm-2916	65	39	october	october	PROPN
ajlm-2916	65	40	2024	2024	NUM
ajlm-2916	65	41	.	.	PUNCT
ajlm-2916	66	1	elevated	elevate	VERB
ajlm-2916	66	2	cns	cns	NOUN
ajlm-2916	66	3	of	of	ADP
ajlm-2916	66	4	the	the	DET
ajlm-2916	66	5	il12b	il12b	ADJ
ajlm-2916	66	6	and	and	CCONJ
ajlm-2916	66	7	fcγriiib	fcγriiib	ADJ
ajlm-2916	66	8	genes	gene	NOUN
ajlm-2916	66	9	(	(	PUNCT
ajlm-2916	66	10	>	>	X
ajlm-2916	66	11	2	2	NUM
ajlm-2916	66	12	)	)	PUNCT
ajlm-2916	66	13	were	be	AUX
ajlm-2916	66	14	associated	associate	VERB
ajlm-2916	66	15	with	with	ADP
ajlm-2916	66	16	an	an	DET
ajlm-2916	66	17	increased	increase	VERB
ajlm-2916	66	18	risk	risk	NOUN
ajlm-2916	66	19	of	of	ADP
ajlm-2916	66	20	as	as	ADP
ajlm-2916	66	21	(	(	PUNCT
ajlm-2916	66	22	>	>	X
ajlm-2916	66	23	2	2	NUM
ajlm-2916	66	24	)	)	PUNCT
ajlm-2916	66	25	(	(	PUNCT
ajlm-2916	66	26	il12b	il12b	ADV
ajlm-2916	66	27	:	:	PUNCT
ajlm-2916	66	28	p	p	X
ajlm-2916	66	29	=	=	NOUN
ajlm-2916	66	30	0.001	0.001	NUM
ajlm-2916	66	31	,	,	PUNCT
ajlm-2916	66	32	odds	odd	VERB
ajlm-2916	66	33	ratio	ratio	NOUN
ajlm-2916	66	34	[	[	X
ajlm-2916	66	35	or	or	CCONJ
ajlm-2916	66	36	]	]	X
ajlm-2916	66	37	:	:	PUNCT
ajlm-2916	66	38	3.8	3.8	NUM
ajlm-2916	66	39	,	,	PUNCT
ajlm-2916	66	40	95	95	NUM
ajlm-2916	66	41	%	%	NOUN
ajlm-2916	66	42	ci	ci	NOUN
ajlm-2916	66	43	:	:	PUNCT
ajlm-2916	66	44	1.7–8.07	1.7–8.07	NUM
ajlm-2916	66	45	;	;	PUNCT
ajlm-2916	66	46	fcγriiib	fcγriiib	ADJ
ajlm-2916	66	47	:	:	PUNCT
ajlm-2916	66	48	p	p	X
ajlm-2916	66	49	<	<	X
ajlm-2916	66	50	0.001	0.001	NUM
ajlm-2916	66	51	,	,	PUNCT
ajlm-2916	66	52	or	or	CCONJ
ajlm-2916	66	53	:	:	PUNCT
ajlm-2916	66	54	5.5	5.5	NUM
ajlm-2916	66	55	,	,	PUNCT
ajlm-2916	66	56	95	95	NUM
ajlm-2916	66	57	%	%	NOUN
ajlm-2916	66	58	ci	ci	NOUN
ajlm-2916	66	59	:	:	PUNCT
ajlm-2916	66	60	2.31–13.08	2.31–13.08	NUM
ajlm-2916	66	61	)	)	PUNCT
ajlm-2916	66	62	.	.	PUNCT
ajlm-2916	67	1	while	while	SCONJ
ajlm-2916	67	2	low	low	ADJ
ajlm-2916	67	3	cns	cns	NOUN
ajlm-2916	67	4	of	of	ADP
ajlm-2916	67	5	il12b	il12b	NOUN
ajlm-2916	67	6	and	and	CCONJ
ajlm-2916	67	7	fcγriiib	fcγriiib	ADJ
ajlm-2916	67	8	genes	gene	NOUN
ajlm-2916	67	9	(	(	PUNCT
ajlm-2916	67	10	<	<	X
ajlm-2916	67	11	2	2	NUM
ajlm-2916	67	12	)	)	PUNCT
ajlm-2916	67	13	were	be	AUX
ajlm-2916	67	14	found	find	VERB
ajlm-2916	67	15	to	to	PART
ajlm-2916	67	16	be	be	AUX
ajlm-2916	67	17	associated	associate	VERB
ajlm-2916	67	18	with	with	ADP
ajlm-2916	67	19	reduced	reduced	ADJ
ajlm-2916	67	20	risk	risk	NOUN
ajlm-2916	67	21	of	of	ADP
ajlm-2916	67	22	as	as	ADP
ajlm-2916	67	23	(	(	PUNCT
ajlm-2916	67	24	il12b	il12b	ADV
ajlm-2916	67	25	:	:	PUNCT
ajlm-2916	67	26	p	p	X
ajlm-2916	67	27	=	=	NOUN
ajlm-2916	67	28	0.02	0.02	NUM
ajlm-2916	67	29	,	,	PUNCT
ajlm-2916	67	30	or	or	CCONJ
ajlm-2916	67	31	:	:	PUNCT
ajlm-2916	67	32	0.38	0.38	NUM
ajlm-2916	67	33	,	,	PUNCT
ajlm-2916	67	34	95	95	NUM
ajlm-2916	67	35	%	%	NOUN
ajlm-2916	67	36	ci	ci	NOUN
ajlm-2916	67	37	:	:	PUNCT
ajlm-2916	67	38	0.16–0.87	0.16–0.87	NUM
ajlm-2916	67	39	;	;	PUNCT
ajlm-2916	67	40	fcγriiib	fcγriiib	ADJ
ajlm-2916	67	41	:	:	PUNCT
ajlm-2916	67	42	p	p	X
ajlm-2916	67	43	=	=	NOUN
ajlm-2916	67	44	0.001	0.001	NUM
ajlm-2916	67	45	,	,	PUNCT
ajlm-2916	67	46	or	or	CCONJ
ajlm-2916	67	47	:	:	PUNCT
ajlm-2916	67	48	0.22	0.22	NUM
ajlm-2916	67	49	,	,	PUNCT
ajlm-2916	67	50	95	95	NUM
ajlm-2916	67	51	%	%	NOUN
ajlm-2916	67	52	ci	ci	NOUN
ajlm-2916	67	53	:	:	PUNCT
ajlm-2916	67	54	0.09–0.54	0.09–0.54	NUM
ajlm-2916	67	55	)	)	PUNCT
ajlm-2916	67	56	.	.	PUNCT
ajlm-2916	68	1	however	however	ADV
ajlm-2916	68	2	,	,	PUNCT
ajlm-2916	68	3	neither	neither	CCONJ
ajlm-2916	68	4	t	t	NOUN
ajlm-2916	68	5	-	-	PUNCT
ajlm-2916	68	6	bet	bet	NOUN
ajlm-2916	68	7	nor	nor	CCONJ
ajlm-2916	68	8	tlr7	tlr7	NOUN
ajlm-2916	68	9	gene	gene	NOUN
ajlm-2916	68	10	cnvs	cnvs	NOUN
ajlm-2916	68	11	were	be	AUX
ajlm-2916	68	12	significantly	significantly	ADV
ajlm-2916	68	13	associated	associate	VERB
ajlm-2916	68	14	with	with	ADP
ajlm-2916	68	15	the	the	DET
ajlm-2916	68	16	risk	risk	NOUN
ajlm-2916	68	17	of	of	ADP
ajlm-2916	68	18	as	as	ADP
ajlm-2916	68	19	.	.	PROPN
ajlm-2916	68	20	association	association	NOUN
ajlm-2916	68	21	between	between	ADP
ajlm-2916	68	22	ankylosing	ankylose	VERB
ajlm-2916	68	23	spondylitis	spondylitis	ADJ
ajlm-2916	68	24	activity	activity	NOUN
ajlm-2916	68	25	and	and	CCONJ
ajlm-2916	68	26	copy	copy	VERB
ajlm-2916	68	27	number	number	NOUN
ajlm-2916	68	28	variations	variation	NOUN
ajlm-2916	68	29	in	in	ADP
ajlm-2916	68	30	fcγriiib	fcγriiib	ADJ
ajlm-2916	68	31	,	,	PUNCT
ajlm-2916	68	32	t	t	PROPN
ajlm-2916	68	33	-	-	PUNCT
ajlm-2916	68	34	bet	bet	NOUN
ajlm-2916	68	35	,	,	PUNCT
ajlm-2916	68	36	il12b	il12b	ADV
ajlm-2916	68	37	,	,	PUNCT
ajlm-2916	68	38	and	and	CCONJ
ajlm-2916	68	39	tlr7	tlr7	NOUN
ajlm-2916	68	40	genes	gene	NOUN
ajlm-2916	68	41	to	to	PART
ajlm-2916	68	42	determine	determine	VERB
ajlm-2916	68	43	the	the	DET
ajlm-2916	68	44	association	association	NOUN
ajlm-2916	68	45	between	between	ADP
ajlm-2916	68	46	cnvs	cnvs	NOUN
ajlm-2916	68	47	of	of	ADP
ajlm-2916	68	48	the	the	DET
ajlm-2916	68	49	examined	examine	VERB
ajlm-2916	68	50	genes	gene	NOUN
ajlm-2916	68	51	and	and	CCONJ
ajlm-2916	68	52	as	as	ADP
ajlm-2916	68	53	activity	activity	NOUN
ajlm-2916	68	54	,	,	PUNCT
ajlm-2916	68	55	we	we	PRON
ajlm-2916	68	56	analysed	analyse	VERB
ajlm-2916	68	57	the	the	DET
ajlm-2916	68	58	differences	difference	NOUN
ajlm-2916	68	59	in	in	ADP
ajlm-2916	68	60	cases	case	NOUN
ajlm-2916	68	61	concerning	concern	VERB
ajlm-2916	68	62	cnvs	cnvs	NOUN
ajlm-2916	68	63	and	and	CCONJ
ajlm-2916	68	64	the	the	DET
ajlm-2916	68	65	erythrocyte	erythrocyte	PROPN
ajlm-2916	68	66	sedimentation	sedimentation	NOUN
ajlm-2916	68	67	rate	rate	NOUN
ajlm-2916	68	68	,	,	PUNCT
ajlm-2916	68	69	c	c	NOUN
ajlm-2916	68	70	-	-	PUNCT
ajlm-2916	68	71	reactive	reactive	ADJ
ajlm-2916	68	72	protein	protein	NOUN
ajlm-2916	68	73	,	,	PUNCT
ajlm-2916	68	74	hla	hla	PROPN
ajlm-2916	68	75	-	-	PUNCT
ajlm-2916	68	76	b27	b27	PROPN
ajlm-2916	68	77	,	,	PUNCT
ajlm-2916	68	78	and	and	CCONJ
ajlm-2916	68	79	ankylosing	ankylose	VERB
ajlm-2916	68	80	spondylitis	spondylitis	NOUN
ajlm-2916	68	81	disease	disease	NOUN
ajlm-2916	68	82	activity	activity	NOUN
ajlm-2916	68	83	score	score	NOUN
ajlm-2916	68	84	–	–	PUNCT
ajlm-2916	68	85	c	c	NOUN
ajlm-2916	68	86	-	-	ADJ
ajlm-2916	68	87	reactive	reactive	ADJ
ajlm-2916	68	88	protein	protein	NOUN
ajlm-2916	68	89	grade	grade	NOUN
ajlm-2916	68	90	(	(	PUNCT
ajlm-2916	68	91	table	table	NOUN
ajlm-2916	68	92	5	5	NUM
ajlm-2916	68	93	)	)	PUNCT
ajlm-2916	68	94	.	.	PUNCT
ajlm-2916	69	1	however	however	ADV
ajlm-2916	69	2	,	,	PUNCT
ajlm-2916	69	3	we	we	PRON
ajlm-2916	69	4	could	could	AUX
ajlm-2916	69	5	not	not	PART
ajlm-2916	69	6	identify	identify	VERB
ajlm-2916	69	7	any	any	DET
ajlm-2916	69	8	correlation	correlation	NOUN
ajlm-2916	69	9	between	between	ADP
ajlm-2916	69	10	the	the	DET
ajlm-2916	69	11	clinical	clinical	ADJ
ajlm-2916	69	12	manifestations	manifestation	NOUN
ajlm-2916	69	13	of	of	ADP
ajlm-2916	69	14	as	as	ADP
ajlm-2916	69	15	and	and	CCONJ
ajlm-2916	69	16	fcγriiib	fcγriiib	ADJ
ajlm-2916	69	17	,	,	PUNCT
ajlm-2916	69	18	t	t	PROPN
ajlm-2916	69	19	-	-	PUNCT
ajlm-2916	69	20	bet	bet	NOUN
ajlm-2916	69	21	,	,	PUNCT
ajlm-2916	69	22	il12b	il12b	ADV
ajlm-2916	69	23	,	,	PUNCT
ajlm-2916	69	24	and	and	CCONJ
ajlm-2916	69	25	tlr7	tlr7	NOUN
ajlm-2916	69	26	cnvs	cnvs	NOUN
ajlm-2916	69	27	.	.	PUNCT
ajlm-2916	70	1	table	table	NOUN
ajlm-2916	70	2	5	5	NUM
ajlm-2916	70	3	:	:	PUNCT
ajlm-2916	70	4	 	 	SPACE
ajlm-2916	70	5	ankylosing	ankylose	VERB
ajlm-2916	70	6	spondylitis	spondylitis	NOUN
ajlm-2916	70	7	disease	disease	NOUN
ajlm-2916	70	8	activity	activity	NOUN
ajlm-2916	70	9	score	score	NOUN
ajlm-2916	70	10	–	–	PUNCT
ajlm-2916	70	11	c	c	NOUN
ajlm-2916	70	12	-	-	ADJ
ajlm-2916	70	13	reactive	reactive	ADJ
ajlm-2916	70	14	protein	protein	NOUN
ajlm-2916	70	15	grade	grade	NOUN
ajlm-2916	70	16	and	and	CCONJ
ajlm-2916	70	17	copy	copy	VERB
ajlm-2916	70	18	number	number	NOUN
ajlm-2916	70	19	variation	variation	NOUN
ajlm-2916	70	20	frequencies	frequency	NOUN
ajlm-2916	70	21	of	of	ADP
ajlm-2916	70	22	fcγriiib	fcγriiib	ADJ
ajlm-2916	70	23	,	,	PUNCT
ajlm-2916	70	24	t	t	PROPN
ajlm-2916	70	25	-	-	PUNCT
ajlm-2916	70	26	bet	bet	NOUN
ajlm-2916	70	27	,	,	PUNCT
ajlm-2916	70	28	il12b	il12b	ADV
ajlm-2916	70	29	,	,	PUNCT
ajlm-2916	70	30	and	and	CCONJ
ajlm-2916	70	31	tlr7	tlr7	PROPN
ajlm-2916	70	32	,	,	PUNCT
ajlm-2916	70	33	zagazig	zagazig	PROPN
ajlm-2916	70	34	university	university	PROPN
ajlm-2916	70	35	hospitals	hospital	NOUN
ajlm-2916	70	36	,	,	PUNCT
ajlm-2916	70	37	zagazig	zagazig	PROPN
ajlm-2916	70	38	,	,	PUNCT
ajlm-2916	70	39	egypt	egypt	PROPN
ajlm-2916	70	40	,	,	PUNCT
ajlm-2916	70	41	november	november	PROPN
ajlm-2916	70	42	2023	2023	NUM
ajlm-2916	70	43	–	–	PUNCT
ajlm-2916	70	44	october	october	PROPN
ajlm-2916	70	45	2024	2024	NUM
ajlm-2916	70	46	.	.	PUNCT
ajlm-2916	71	1	discussion	discussion	NOUN
ajlm-2916	71	2	the	the	DET
ajlm-2916	71	3	study	study	NOUN
ajlm-2916	71	4	examined	examine	VERB
ajlm-2916	71	5	the	the	DET
ajlm-2916	71	6	association	association	NOUN
ajlm-2916	71	7	between	between	ADP
ajlm-2916	71	8	the	the	DET
ajlm-2916	71	9	risk	risk	NOUN
ajlm-2916	71	10	of	of	ADP
ajlm-2916	71	11	as	as	ADP
ajlm-2916	71	12	and	and	CCONJ
ajlm-2916	71	13	cnvs	cnvs	NOUN
ajlm-2916	71	14	in	in	ADP
ajlm-2916	71	15	the	the	DET
ajlm-2916	71	16	fcγriiib	fcγriiib	NOUN
ajlm-2916	71	17	,	,	PUNCT
ajlm-2916	71	18	t	t	PROPN
ajlm-2916	71	19	-	-	PUNCT
ajlm-2916	71	20	bet	bet	NOUN
ajlm-2916	71	21	,	,	PUNCT
ajlm-2916	71	22	il12b	il12b	ADV
ajlm-2916	71	23	,	,	PUNCT
ajlm-2916	71	24	and	and	CCONJ
ajlm-2916	71	25	tlr7	tlr7	NOUN
ajlm-2916	71	26	genes	gene	NOUN
ajlm-2916	71	27	among	among	ADP
ajlm-2916	71	28	egyptian	egyptian	ADJ
ajlm-2916	71	29	patients	patient	NOUN
ajlm-2916	71	30	,	,	PUNCT
ajlm-2916	71	31	as	as	ADV
ajlm-2916	71	32	well	well	ADV
ajlm-2916	71	33	as	as	ADP
ajlm-2916	71	34	their	their	PRON
ajlm-2916	71	35	impact	impact	NOUN
ajlm-2916	71	36	on	on	ADP
ajlm-2916	71	37	disease	disease	NOUN
ajlm-2916	71	38	activity	activity	NOUN
ajlm-2916	71	39	.	.	PUNCT
ajlm-2916	72	1	the	the	DET
ajlm-2916	72	2	results	result	NOUN
ajlm-2916	72	3	of	of	ADP
ajlm-2916	72	4	the	the	DET
ajlm-2916	72	5	current	current	ADJ
ajlm-2916	72	6	investigation	investigation	NOUN
ajlm-2916	72	7	showed	show	VERB
ajlm-2916	72	8	a	a	DET
ajlm-2916	72	9	strong	strong	ADJ
ajlm-2916	72	10	correlation	correlation	NOUN
ajlm-2916	72	11	between	between	ADP
ajlm-2916	72	12	elevated	elevate	VERB
ajlm-2916	72	13	fcγriiib	fcγriiib	ADJ
ajlm-2916	72	14	and	and	CCONJ
ajlm-2916	72	15	il12b	il12b	ADV
ajlm-2916	72	16	copy	copy	VERB
ajlm-2916	72	17	numbers	number	NOUN
ajlm-2916	72	18	(	(	PUNCT
ajlm-2916	72	19	>	>	X
ajlm-2916	72	20	2	2	NUM
ajlm-2916	72	21	copies	copy	NOUN
ajlm-2916	72	22	)	)	PUNCT
ajlm-2916	72	23	and	and	CCONJ
ajlm-2916	72	24	a	a	DET
ajlm-2916	72	25	higher	high	ADJ
ajlm-2916	72	26	risk	risk	NOUN
ajlm-2916	72	27	of	of	ADP
ajlm-2916	72	28	as	as	ADP
ajlm-2916	72	29	,	,	PUNCT
ajlm-2916	72	30	with	with	ADP
ajlm-2916	72	31	3.8	3.8	NUM
ajlm-2916	72	32	-	-	NUM
ajlm-2916	72	33	fold	fold	ADJ
ajlm-2916	72	34	and	and	CCONJ
ajlm-2916	72	35	5.5	5.5	NUM
ajlm-2916	72	36	-	-	ADJ
ajlm-2916	72	37	fold	fold	ADJ
ajlm-2916	72	38	increases	increase	NOUN
ajlm-2916	72	39	in	in	ADP
ajlm-2916	72	40	risk	risk	NOUN
ajlm-2916	72	41	associated	associate	VERB
ajlm-2916	72	42	with	with	ADP
ajlm-2916	72	43	each	each	PRON
ajlm-2916	72	44	.	.	PUNCT
ajlm-2916	73	1	as	as	ADP
ajlm-2916	73	2	for	for	ADP
ajlm-2916	73	3	the	the	DET
ajlm-2916	73	4	t	t	NOUN
ajlm-2916	73	5	-	-	PUNCT
ajlm-2916	73	6	bet	bet	NOUN
ajlm-2916	73	7	gene	gene	NOUN
ajlm-2916	73	8	cnv	cnv	PROPN
ajlm-2916	73	9	,	,	PUNCT
ajlm-2916	73	10	there	there	PRON
ajlm-2916	73	11	was	be	VERB
ajlm-2916	73	12	no	no	DET
ajlm-2916	73	13	significant	significant	ADJ
ajlm-2916	73	14	distinction	distinction	NOUN
ajlm-2916	73	15	between	between	ADP
ajlm-2916	73	16	as	as	ADP
ajlm-2916	73	17	patients	patient	NOUN
ajlm-2916	73	18	and	and	CCONJ
ajlm-2916	73	19	healthy	healthy	ADJ
ajlm-2916	73	20	controls	control	NOUN
ajlm-2916	73	21	,	,	PUNCT
ajlm-2916	73	22	even	even	ADV
ajlm-2916	73	23	though	though	SCONJ
ajlm-2916	73	24	as	as	SCONJ
ajlm-2916	73	25	patients	patient	NOUN
ajlm-2916	73	26	had	have	VERB
ajlm-2916	73	27	a	a	DET
ajlm-2916	73	28	higher	high	ADJ
ajlm-2916	73	29	frequency	frequency	NOUN
ajlm-2916	73	30	(	(	PUNCT
ajlm-2916	73	31	51.4	51.4	NUM
ajlm-2916	73	32	%	%	NOUN
ajlm-2916	73	33	)	)	PUNCT
ajlm-2916	73	34	of	of	ADP
ajlm-2916	73	35	increased	increase	VERB
ajlm-2916	73	36	cns	cns	NOUN
ajlm-2916	73	37	(	(	PUNCT
ajlm-2916	73	38	>	>	X
ajlm-2916	73	39	2	2	NUM
ajlm-2916	73	40	copies	copy	NOUN
ajlm-2916	73	41	)	)	PUNCT
ajlm-2916	73	42	.	.	PUNCT
ajlm-2916	74	1	furthermore	furthermore	ADV
ajlm-2916	74	2	,	,	PUNCT
ajlm-2916	74	3	as	as	SCONJ
ajlm-2916	74	4	patients	patient	NOUN
ajlm-2916	74	5	had	have	VERB
ajlm-2916	74	6	a	a	DET
ajlm-2916	74	7	higher	high	ADJ
ajlm-2916	74	8	frequency	frequency	NOUN
ajlm-2916	74	9	of	of	ADP
ajlm-2916	74	10	low	low	ADJ
ajlm-2916	74	11	tlr7	tlr7	NOUN
ajlm-2916	74	12	cn	cn	PROPN
ajlm-2916	74	13	(	(	PUNCT
ajlm-2916	74	14	59.7	59.7	NUM
ajlm-2916	74	15	%	%	NOUN
ajlm-2916	74	16	)	)	PUNCT
ajlm-2916	74	17	.	.	PUNCT
ajlm-2916	75	1	nevertheless	nevertheless	ADV
ajlm-2916	75	2	,	,	PUNCT
ajlm-2916	75	3	no	no	DET
ajlm-2916	75	4	significant	significant	ADJ
ajlm-2916	75	5	link	link	NOUN
ajlm-2916	75	6	between	between	ADP
ajlm-2916	75	7	as	as	SCONJ
ajlm-2916	75	8	risk	risk	NOUN
ajlm-2916	75	9	and	and	CCONJ
ajlm-2916	75	10	tlr7	tlr7	NOUN
ajlm-2916	75	11	cnvs	cnvs	NOUN
ajlm-2916	75	12	was	be	AUX
ajlm-2916	75	13	found	find	VERB
ajlm-2916	75	14	.	.	PUNCT
ajlm-2916	76	1	meanwhile	meanwhile	ADV
ajlm-2916	76	2	,	,	PUNCT
ajlm-2916	76	3	we	we	PRON
ajlm-2916	76	4	found	find	VERB
ajlm-2916	76	5	no	no	DET
ajlm-2916	76	6	association	association	NOUN
ajlm-2916	76	7	between	between	ADP
ajlm-2916	76	8	as	as	ADP
ajlm-2916	76	9	activity	activity	NOUN
ajlm-2916	76	10	and	and	CCONJ
ajlm-2916	76	11	cnvs	cnvs	NOUN
ajlm-2916	76	12	of	of	ADP
ajlm-2916	76	13	tlr7	tlr7	PROPN
ajlm-2916	76	14	,	,	PUNCT
ajlm-2916	76	15	il12b	il12b	ADV
ajlm-2916	76	16	,	,	PUNCT
ajlm-2916	76	17	t	t	PROPN
ajlm-2916	76	18	-	-	PUNCT
ajlm-2916	76	19	bet	bet	NOUN
ajlm-2916	76	20	,	,	PUNCT
ajlm-2916	76	21	or	or	CCONJ
ajlm-2916	76	22	fcγriiib	fcγriiib	ADJ
ajlm-2916	76	23	.	.	PUNCT
ajlm-2916	77	1	in	in	ADP
ajlm-2916	77	2	contrast	contrast	NOUN
ajlm-2916	77	3	to	to	ADP
ajlm-2916	77	4	our	our	PRON
ajlm-2916	77	5	findings	finding	NOUN
ajlm-2916	77	6	,	,	PUNCT
ajlm-2916	77	7	the	the	DET
ajlm-2916	77	8	analysis	analysis	NOUN
ajlm-2916	77	9	of	of	ADP
ajlm-2916	77	10	fcγriiib	fcγriiib	ADJ
ajlm-2916	77	11	cnv	cnv	NOUN
ajlm-2916	77	12	frequency	frequency	NOUN
ajlm-2916	77	13	distribution	distribution	NOUN
ajlm-2916	77	14	in	in	ADP
ajlm-2916	77	15	a	a	DET
ajlm-2916	77	16	study	study	NOUN
ajlm-2916	77	17	of	of	ADP
ajlm-2916	77	18	algerian	algerian	ADJ
ajlm-2916	77	19	as	as	ADP
ajlm-2916	77	20	patients	patient	NOUN
ajlm-2916	77	21	in	in	ADP
ajlm-2916	77	22	2019	2019	NUM
ajlm-2916	77	23	showed	show	VERB
ajlm-2916	77	24	no	no	DET
ajlm-2916	77	25	statistically	statistically	ADV
ajlm-2916	77	26	significant	significant	ADJ
ajlm-2916	77	27	difference	difference	NOUN
ajlm-2916	77	28	between	between	ADP
ajlm-2916	77	29	patients	patient	NOUN
ajlm-2916	77	30	and	and	CCONJ
ajlm-2916	77	31	controls.28	controls.28	NOUN
ajlm-2916	77	32	a	a	DET
ajlm-2916	77	33	chinese	chinese	ADJ
ajlm-2916	77	34	study	study	NOUN
ajlm-2916	77	35	in	in	ADP
ajlm-2916	77	36	2016	2016	NUM
ajlm-2916	77	37	indicated	indicate	VERB
ajlm-2916	77	38	that	that	SCONJ
ajlm-2916	77	39	a	a	DET
ajlm-2916	77	40	low	low	ADJ
ajlm-2916	77	41	cn	cn	PROPN
ajlm-2916	77	42	(	(	PUNCT
ajlm-2916	77	43	≤	≤	NOUN
ajlm-2916	77	44	3	3	NUM
ajlm-2916	77	45	)	)	PUNCT
ajlm-2916	77	46	of	of	ADP
ajlm-2916	77	47	the	the	DET
ajlm-2916	77	48	fcγriiib	fcγriiib	ADJ
ajlm-2916	77	49	gene	gene	NOUN
ajlm-2916	77	50	may	may	AUX
ajlm-2916	77	51	be	be	AUX
ajlm-2916	77	52	a	a	DET
ajlm-2916	77	53	risk	risk	NOUN
ajlm-2916	77	54	factor	factor	NOUN
ajlm-2916	77	55	for	for	ADP
ajlm-2916	77	56	as.12	as.12	NOUN
ajlm-2916	77	57	the	the	DET
ajlm-2916	77	58	observed	observed	ADJ
ajlm-2916	77	59	discrepancy	discrepancy	NOUN
ajlm-2916	77	60	in	in	ADP
ajlm-2916	77	61	results	result	NOUN
ajlm-2916	77	62	may	may	AUX
ajlm-2916	77	63	be	be	AUX
ajlm-2916	77	64	attributed	attribute	VERB
ajlm-2916	77	65	to	to	ADP
ajlm-2916	77	66	variations	variation	NOUN
ajlm-2916	77	67	in	in	ADP
ajlm-2916	77	68	the	the	DET
ajlm-2916	77	69	distribution	distribution	NOUN
ajlm-2916	77	70	of	of	ADP
ajlm-2916	77	71	cn	cn	PROPN
ajlm-2916	77	72	groups	group	NOUN
ajlm-2916	77	73	,	,	PUNCT
ajlm-2916	77	74	as	as	SCONJ
ajlm-2916	77	75	our	our	PRON
ajlm-2916	77	76	study	study	NOUN
ajlm-2916	77	77	defined	define	VERB
ajlm-2916	77	78	three	three	NUM
ajlm-2916	77	79	copies	copy	NOUN
ajlm-2916	77	80	as	as	ADP
ajlm-2916	77	81	a	a	DET
ajlm-2916	77	82	high	high	ADJ
ajlm-2916	77	83	cn	cn	PROPN
ajlm-2916	77	84	.	.	PROPN
ajlm-2916	77	85	to	to	ADP
ajlm-2916	77	86	the	the	DET
ajlm-2916	77	87	best	good	ADJ
ajlm-2916	77	88	of	of	ADP
ajlm-2916	77	89	our	our	PRON
ajlm-2916	77	90	knowledge	knowledge	NOUN
ajlm-2916	77	91	,	,	PUNCT
ajlm-2916	77	92	this	this	PRON
ajlm-2916	77	93	is	be	AUX
ajlm-2916	77	94	the	the	DET
ajlm-2916	77	95	first	first	ADJ
ajlm-2916	77	96	study	study	NOUN
ajlm-2916	77	97	to	to	PART
ajlm-2916	77	98	investigate	investigate	VERB
ajlm-2916	77	99	the	the	DET
ajlm-2916	77	100	association	association	NOUN
ajlm-2916	77	101	of	of	ADP
ajlm-2916	77	102	il12b	il12b	X
ajlm-2916	77	103	cnv	cnv	PROPN
ajlm-2916	77	104	and	and	CCONJ
ajlm-2916	77	105	the	the	DET
ajlm-2916	77	106	risk	risk	NOUN
ajlm-2916	77	107	of	of	ADP
ajlm-2916	77	108	as	as	ADP
ajlm-2916	77	109	.	.	PUNCT
ajlm-2916	77	110	previous	previous	ADJ
ajlm-2916	77	111	research	research	NOUN
ajlm-2916	77	112	,	,	PUNCT
ajlm-2916	77	113	however	however	ADV
ajlm-2916	77	114	,	,	PUNCT
ajlm-2916	77	115	including	include	VERB
ajlm-2916	77	116	a	a	DET
ajlm-2916	77	117	chinese	chinese	ADJ
ajlm-2916	77	118	study	study	NOUN
ajlm-2916	77	119	in	in	ADP
ajlm-2916	77	120	2024	2024	NUM
ajlm-2916	77	121	and	and	CCONJ
ajlm-2916	77	122	a	a	DET
ajlm-2916	77	123	bulgarian	bulgarian	ADJ
ajlm-2916	77	124	study	study	NOUN
ajlm-2916	77	125	in	in	ADP
ajlm-2916	77	126	2019	2019	NUM
ajlm-2916	77	127	,	,	PUNCT
ajlm-2916	77	128	found	find	VERB
ajlm-2916	77	129	a	a	DET
ajlm-2916	77	130	strong	strong	ADJ
ajlm-2916	77	131	correlation	correlation	NOUN
ajlm-2916	77	132	between	between	ADP
ajlm-2916	77	133	il12b	il12b	ADJ
ajlm-2916	77	134	snps	snps	PROPN
ajlm-2916	77	135	and	and	CCONJ
ajlm-2916	77	136	an	an	DET
ajlm-2916	77	137	increased	increase	VERB
ajlm-2916	77	138	genetic	genetic	ADJ
ajlm-2916	77	139	risk	risk	NOUN
ajlm-2916	77	140	for	for	ADP
ajlm-2916	77	141	as.29,30	as.29,30	PROPN
ajlm-2916	77	142	additionally	additionally	ADV
ajlm-2916	77	143	,	,	PUNCT
ajlm-2916	77	144	il12b	il12b	ADV
ajlm-2916	77	145	has	have	AUX
ajlm-2916	77	146	been	be	AUX
ajlm-2916	77	147	identified	identify	VERB
ajlm-2916	77	148	as	as	ADP
ajlm-2916	77	149	a	a	DET
ajlm-2916	77	150	possible	possible	ADJ
ajlm-2916	77	151	therapeutic	therapeutic	ADJ
ajlm-2916	77	152	target	target	NOUN
ajlm-2916	77	153	for	for	ADP
ajlm-2916	77	154	as	as	ADP
ajlm-2916	77	155	in	in	ADP
ajlm-2916	77	156	two	two	NUM
ajlm-2916	77	157	recent	recent	ADJ
ajlm-2916	77	158	chinese	chinese	ADJ
ajlm-2916	77	159	studies	study	NOUN
ajlm-2916	77	160	conducted	conduct	VERB
ajlm-2916	77	161	in	in	ADP
ajlm-2916	77	162	2024.30,31	2024.30,31	NUM
ajlm-2916	77	163	in	in	ADP
ajlm-2916	77	164	contrast	contrast	NOUN
ajlm-2916	77	165	to	to	ADP
ajlm-2916	77	166	our	our	PRON
ajlm-2916	77	167	findings	finding	NOUN
ajlm-2916	77	168	,	,	PUNCT
ajlm-2916	77	169	a	a	DET
ajlm-2916	77	170	study	study	NOUN
ajlm-2916	77	171	conducted	conduct	VERB
ajlm-2916	77	172	in	in	ADP
ajlm-2916	77	173	china	china	PROPN
ajlm-2916	77	174	in	in	ADP
ajlm-2916	77	175	2016	2016	NUM
ajlm-2916	77	176	identified	identify	VERB
ajlm-2916	77	177	a	a	DET
ajlm-2916	77	178	higher	high	ADJ
ajlm-2916	77	179	prevalence	prevalence	NOUN
ajlm-2916	77	180	of	of	ADP
ajlm-2916	77	181	a	a	DET
ajlm-2916	77	182	high	high	ADJ
ajlm-2916	77	183	t	t	NOUN
ajlm-2916	77	184	-	-	PUNCT
ajlm-2916	77	185	bet	bet	NOUN
ajlm-2916	77	186	cn	cn	PROPN
ajlm-2916	77	187	in	in	ADP
ajlm-2916	77	188	as	as	ADP
ajlm-2916	77	189	patients	patient	NOUN
ajlm-2916	77	190	,	,	PUNCT
ajlm-2916	77	191	which	which	PRON
ajlm-2916	77	192	was	be	AUX
ajlm-2916	77	193	significantly	significantly	ADV
ajlm-2916	77	194	correlated	correlate	VERB
ajlm-2916	77	195	with	with	ADP
ajlm-2916	77	196	disease	disease	NOUN
ajlm-2916	77	197	risk.15	risk.15	NOUN
ajlm-2916	77	198	a	a	DET
ajlm-2916	77	199	chinese	chinese	ADJ
ajlm-2916	77	200	study	study	NOUN
ajlm-2916	77	201	in	in	ADP
ajlm-2916	77	202	2018	2018	NUM
ajlm-2916	77	203	identified	identify	VERB
ajlm-2916	77	204	a	a	DET
ajlm-2916	77	205	significant	significant	ADJ
ajlm-2916	77	206	correlation	correlation	NOUN
ajlm-2916	77	207	between	between	ADP
ajlm-2916	77	208	low	low	ADJ
ajlm-2916	77	209	tlr7	tlr7	NOUN
ajlm-2916	77	210	cn	cn	PROPN
ajlm-2916	77	211	and	and	CCONJ
ajlm-2916	77	212	the	the	DET
ajlm-2916	77	213	risk	risk	NOUN
ajlm-2916	77	214	of	of	ADP
ajlm-2916	77	215	as	as	ADP
ajlm-2916	77	216	.	.	PUNCT
ajlm-2916	78	1	nevertheless	nevertheless	ADV
ajlm-2916	78	2	,	,	PUNCT
ajlm-2916	78	3	the	the	DET
ajlm-2916	78	4	cns	cns	NOUN
ajlm-2916	78	5	found	find	VERB
ajlm-2916	78	6	in	in	ADP
ajlm-2916	78	7	this	this	DET
ajlm-2916	78	8	investigation	investigation	NOUN
ajlm-2916	78	9	were	be	AUX
ajlm-2916	78	10	restricted	restrict	VERB
ajlm-2916	78	11	to	to	ADP
ajlm-2916	78	12	one	one	NUM
ajlm-2916	78	13	or	or	CCONJ
ajlm-2916	78	14	two	two	NUM
ajlm-2916	78	15	copies	copy	NOUN
ajlm-2916	78	16	,	,	PUNCT
ajlm-2916	78	17	in	in	ADP
ajlm-2916	78	18	contrast	contrast	NOUN
ajlm-2916	78	19	to	to	ADP
ajlm-2916	78	20	our	our	PRON
ajlm-2916	78	21	analysis	analysis	NOUN
ajlm-2916	78	22	,	,	PUNCT
ajlm-2916	78	23	which	which	PRON
ajlm-2916	78	24	found	find	VERB
ajlm-2916	78	25	that	that	SCONJ
ajlm-2916	78	26	more	more	ADJ
ajlm-2916	78	27	than	than	ADP
ajlm-2916	78	28	two	two	NUM
ajlm-2916	78	29	copies	copy	NOUN
ajlm-2916	78	30	of	of	ADP
ajlm-2916	78	31	the	the	DET
ajlm-2916	78	32	gene	gene	NOUN
ajlm-2916	78	33	were	be	AUX
ajlm-2916	78	34	found	find	VERB
ajlm-2916	78	35	in	in	ADP
ajlm-2916	78	36	51.4	51.4	NUM
ajlm-2916	78	37	%	%	NOUN
ajlm-2916	78	38	of	of	ADP
ajlm-2916	78	39	as	as	ADP
ajlm-2916	78	40	patients	patient	NOUN
ajlm-2916	78	41	and	and	CCONJ
ajlm-2916	78	42	42.9	42.9	NUM
ajlm-2916	78	43	%	%	NOUN
ajlm-2916	78	44	of	of	ADP
ajlm-2916	78	45	healthy	healthy	ADJ
ajlm-2916	78	46	controls.19	controls.19	NOUN
ajlm-2916	78	47	however	however	ADV
ajlm-2916	78	48	,	,	PUNCT
ajlm-2916	78	49	our	our	PRON
ajlm-2916	78	50	findings	finding	NOUN
ajlm-2916	78	51	aligned	align	VERB
ajlm-2916	78	52	with	with	ADP
ajlm-2916	78	53	those	those	PRON
ajlm-2916	78	54	of	of	ADP
ajlm-2916	78	55	the	the	DET
ajlm-2916	78	56	chinese	chinese	ADJ
ajlm-2916	78	57	2018	2018	NUM
ajlm-2916	78	58	study	study	NOUN
ajlm-2916	78	59	by	by	ADP
ajlm-2916	78	60	wang	wang	PROPN
ajlm-2916	78	61	et	et	PROPN
ajlm-2916	78	62	al	al	PROPN
ajlm-2916	78	63	.	.	PROPN
ajlm-2916	78	64	,	,	PUNCT
ajlm-2916	78	65	which	which	PRON
ajlm-2916	78	66	indicated	indicate	VERB
ajlm-2916	78	67	no	no	DET
ajlm-2916	78	68	association	association	NOUN
ajlm-2916	78	69	between	between	ADP
ajlm-2916	78	70	clinical	clinical	ADJ
ajlm-2916	78	71	manifestations	manifestation	NOUN
ajlm-2916	78	72	and	and	CCONJ
ajlm-2916	78	73	tlr7	tlr7	NOUN
ajlm-2916	78	74	cnvs.19	cnvs.19	VERB
ajlm-2916	78	75	no	no	DET
ajlm-2916	78	76	prior	prior	ADJ
ajlm-2916	78	77	research	research	NOUN
ajlm-2916	78	78	has	have	AUX
ajlm-2916	78	79	examined	examine	VERB
ajlm-2916	78	80	the	the	DET
ajlm-2916	78	81	relationship	relationship	NOUN
ajlm-2916	78	82	between	between	ADP
ajlm-2916	78	83	as	as	ADP
ajlm-2916	78	84	activity	activity	NOUN
ajlm-2916	78	85	and	and	CCONJ
ajlm-2916	78	86	fcγriiib	fcγriiib	ADJ
ajlm-2916	78	87	,	,	PUNCT
ajlm-2916	78	88	t	t	PROPN
ajlm-2916	78	89	-	-	PUNCT
ajlm-2916	78	90	bet	bet	NOUN
ajlm-2916	78	91	,	,	PUNCT
ajlm-2916	78	92	and	and	CCONJ
ajlm-2916	78	93	il12b	il12b	ADV
ajlm-2916	78	94	cnvs	cnvs	NOUN
ajlm-2916	78	95	.	.	PUNCT
ajlm-2916	79	1	limitations	limitation	NOUN
ajlm-2916	79	2	it	it	PRON
ajlm-2916	79	3	is	be	AUX
ajlm-2916	79	4	important	important	ADJ
ajlm-2916	79	5	to	to	PART
ajlm-2916	79	6	take	take	VERB
ajlm-2916	79	7	into	into	ADP
ajlm-2916	79	8	account	account	NOUN
ajlm-2916	79	9	the	the	DET
ajlm-2916	79	10	limitations	limitation	NOUN
ajlm-2916	79	11	of	of	ADP
ajlm-2916	79	12	this	this	DET
ajlm-2916	79	13	study	study	NOUN
ajlm-2916	79	14	when	when	SCONJ
ajlm-2916	79	15	evaluating	evaluate	VERB
ajlm-2916	79	16	the	the	DET
ajlm-2916	79	17	results	result	NOUN
ajlm-2916	79	18	.	.	PUNCT
ajlm-2916	80	1	first	first	ADV
ajlm-2916	80	2	,	,	PUNCT
ajlm-2916	80	3	the	the	DET
ajlm-2916	80	4	study	study	NOUN
ajlm-2916	80	5	was	be	AUX
ajlm-2916	80	6	conducted	conduct	VERB
ajlm-2916	80	7	at	at	ADP
ajlm-2916	80	8	a	a	DET
ajlm-2916	80	9	single	single	ADJ
ajlm-2916	80	10	centre	centre	NOUN
ajlm-2916	80	11	and	and	CCONJ
ajlm-2916	80	12	had	have	VERB
ajlm-2916	80	13	a	a	DET
ajlm-2916	80	14	relatively	relatively	ADV
ajlm-2916	80	15	small	small	ADJ
ajlm-2916	80	16	sample	sample	NOUN
ajlm-2916	80	17	size	size	NOUN
ajlm-2916	80	18	.	.	PUNCT
ajlm-2916	81	1	therefore	therefore	ADV
ajlm-2916	81	2	,	,	PUNCT
ajlm-2916	81	3	subsequent	subsequent	ADJ
ajlm-2916	81	4	multicentre	multicentre	NOUN
ajlm-2916	81	5	studies	study	NOUN
ajlm-2916	81	6	with	with	ADP
ajlm-2916	81	7	larger	large	ADJ
ajlm-2916	81	8	cohorts	cohort	NOUN
ajlm-2916	81	9	may	may	AUX
ajlm-2916	81	10	be	be	AUX
ajlm-2916	81	11	necessary	necessary	ADJ
ajlm-2916	81	12	to	to	PART
ajlm-2916	81	13	corroborate	corroborate	VERB
ajlm-2916	81	14	the	the	DET
ajlm-2916	81	15	results	result	NOUN
ajlm-2916	81	16	,	,	PUNCT
ajlm-2916	81	17	as	as	SCONJ
ajlm-2916	81	18	they	they	PRON
ajlm-2916	81	19	might	might	AUX
ajlm-2916	81	20	be	be	AUX
ajlm-2916	81	21	lacking	lack	VERB
ajlm-2916	81	22	sufficient	sufficient	ADJ
ajlm-2916	81	23	power	power	NOUN
ajlm-2916	81	24	.	.	PUNCT
ajlm-2916	82	1	second	second	ADJ
ajlm-2916	82	2	,	,	PUNCT
ajlm-2916	82	3	despite	despite	SCONJ
ajlm-2916	82	4	the	the	DET
ajlm-2916	82	5	established	establish	VERB
ajlm-2916	82	6	impact	impact	NOUN
ajlm-2916	82	7	of	of	ADP
ajlm-2916	82	8	genetic	genetic	ADJ
ajlm-2916	82	9	cnvs	cnvs	NOUN
ajlm-2916	82	10	on	on	ADP
ajlm-2916	82	11	the	the	DET
ajlm-2916	82	12	level	level	NOUN
ajlm-2916	82	13	of	of	ADP
ajlm-2916	82	14	gene	gene	NOUN
ajlm-2916	82	15	expression	expression	NOUN
ajlm-2916	82	16	,	,	PUNCT
ajlm-2916	82	17	which	which	PRON
ajlm-2916	82	18	may	may	AUX
ajlm-2916	82	19	influence	influence	VERB
ajlm-2916	82	20	the	the	DET
ajlm-2916	82	21	outcomes	outcome	NOUN
ajlm-2916	82	22	of	of	ADP
ajlm-2916	82	23	therapy	therapy	NOUN
ajlm-2916	82	24	,	,	PUNCT
ajlm-2916	82	25	the	the	DET
ajlm-2916	82	26	study	study	NOUN
ajlm-2916	82	27	did	do	AUX
ajlm-2916	82	28	not	not	PART
ajlm-2916	82	29	address	address	VERB
ajlm-2916	82	30	the	the	DET
ajlm-2916	82	31	effect	effect	NOUN
ajlm-2916	82	32	of	of	ADP
ajlm-2916	82	33	the	the	DET
ajlm-2916	82	34	genes	gene	NOUN
ajlm-2916	82	35	under	under	ADP
ajlm-2916	82	36	investigation	investigation	NOUN
ajlm-2916	82	37	on	on	ADP
ajlm-2916	82	38	the	the	DET
ajlm-2916	82	39	response	response	NOUN
ajlm-2916	82	40	to	to	ADP
ajlm-2916	82	41	therapy	therapy	NOUN
ajlm-2916	82	42	.	.	PUNCT
ajlm-2916	83	1	conclusion	conclusion	NOUN
ajlm-2916	83	2	the	the	DET
ajlm-2916	83	3	study	study	NOUN
ajlm-2916	83	4	’s	’s	PART
ajlm-2916	83	5	findings	finding	NOUN
ajlm-2916	83	6	indicate	indicate	VERB
ajlm-2916	83	7	that	that	SCONJ
ajlm-2916	83	8	possessing	possess	VERB
ajlm-2916	83	9	more	more	ADJ
ajlm-2916	83	10	than	than	ADP
ajlm-2916	83	11	two	two	NUM
ajlm-2916	83	12	copies	copy	NOUN
ajlm-2916	83	13	of	of	ADP
ajlm-2916	83	14	both	both	DET
ajlm-2916	83	15	il12b	il12b	NOUN
ajlm-2916	83	16	and	and	CCONJ
ajlm-2916	83	17	fcγriiib	fcγriiib	NOUN
ajlm-2916	83	18	may	may	AUX
ajlm-2916	83	19	increase	increase	VERB
ajlm-2916	83	20	the	the	DET
ajlm-2916	83	21	risk	risk	NOUN
ajlm-2916	83	22	of	of	ADP
ajlm-2916	83	23	developing	develop	VERB
ajlm-2916	83	24	as	as	ADP
ajlm-2916	83	25	.	.	PUNCT
ajlm-2916	84	1	however	however	ADV
ajlm-2916	84	2	,	,	PUNCT
ajlm-2916	84	3	as	as	SCONJ
ajlm-2916	84	4	risk	risk	NOUN
ajlm-2916	84	5	was	be	AUX
ajlm-2916	84	6	not	not	PART
ajlm-2916	84	7	significantly	significantly	ADV
ajlm-2916	84	8	correlated	correlate	VERB
ajlm-2916	84	9	with	with	ADP
ajlm-2916	84	10	tlr7	tlr7	NOUN
ajlm-2916	84	11	or	or	CCONJ
ajlm-2916	84	12	t	t	NOUN
ajlm-2916	84	13	-	-	PUNCT
ajlm-2916	84	14	bet	bet	NOUN
ajlm-2916	84	15	cnvs	cnvs	NOUN
ajlm-2916	84	16	.	.	PUNCT
ajlm-2916	85	1	acknowledgements	acknowledgement	NOUN
ajlm-2916	85	2	we	we	PRON
ajlm-2916	85	3	express	express	VERB
ajlm-2916	85	4	our	our	PRON
ajlm-2916	85	5	gratitude	gratitude	NOUN
ajlm-2916	85	6	to	to	ADP
ajlm-2916	85	7	all	all	PRON
ajlm-2916	85	8	of	of	ADP
ajlm-2916	85	9	the	the	DET
ajlm-2916	85	10	willing	willing	ADJ
ajlm-2916	85	11	participants	participant	NOUN
ajlm-2916	85	12	in	in	ADP
ajlm-2916	85	13	this	this	DET
ajlm-2916	85	14	study	study	NOUN
ajlm-2916	85	15	,	,	PUNCT
ajlm-2916	85	16	as	as	ADV
ajlm-2916	85	17	well	well	ADV
ajlm-2916	85	18	as	as	ADP
ajlm-2916	85	19	to	to	ADP
ajlm-2916	85	20	the	the	DET
ajlm-2916	85	21	staff	staff	NOUN
ajlm-2916	85	22	at	at	ADP
ajlm-2916	85	23	zagazig	zagazig	PROPN
ajlm-2916	85	24	university	university	PROPN
ajlm-2916	85	25	hospitals	hospital	NOUN
ajlm-2916	85	26	,	,	PUNCT
ajlm-2916	85	27	particularly	particularly	ADV
ajlm-2916	85	28	the	the	DET
ajlm-2916	85	29	medical	medical	PROPN
ajlm-2916	85	30	laboratory	laboratory	PROPN
ajlm-2916	85	31	department	department	PROPN
ajlm-2916	85	32	and	and	CCONJ
ajlm-2916	85	33	the	the	DET
ajlm-2916	85	34	rheumatology	rheumatology	NOUN
ajlm-2916	85	35	and	and	CCONJ
ajlm-2916	85	36	rehabilitation	rehabilitation	NOUN
ajlm-2916	85	37	clinic	clinic	NOUN
ajlm-2916	85	38	in	in	ADP
ajlm-2916	85	39	zagazig	zagazig	PROPN
ajlm-2916	85	40	,	,	PUNCT
ajlm-2916	85	41	egypt	egypt	PROPN
ajlm-2916	85	42	,	,	PUNCT
ajlm-2916	85	43	for	for	ADP
ajlm-2916	85	44	their	their	PRON
ajlm-2916	85	45	technical	technical	ADJ
ajlm-2916	85	46	assistance	assistance	NOUN
ajlm-2916	85	47	throughout	throughout	ADP
ajlm-2916	85	48	this	this	DET
ajlm-2916	85	49	study	study	NOUN
ajlm-2916	85	50	.	.	PUNCT
ajlm-2916	86	1	competing	compete	VERB
ajlm-2916	86	2	interests	interest	NOUN
ajlm-2916	86	3	the	the	DET
ajlm-2916	86	4	authors	author	NOUN
ajlm-2916	86	5	declare	declare	VERB
ajlm-2916	86	6	that	that	SCONJ
ajlm-2916	86	7	they	they	PRON
ajlm-2916	86	8	have	have	VERB
ajlm-2916	86	9	no	no	DET
ajlm-2916	86	10	financial	financial	ADJ
ajlm-2916	86	11	or	or	CCONJ
ajlm-2916	86	12	personal	personal	ADJ
ajlm-2916	86	13	relationships	relationship	NOUN
ajlm-2916	86	14	that	that	PRON
ajlm-2916	86	15	may	may	AUX
ajlm-2916	86	16	have	have	AUX
ajlm-2916	86	17	inappropriately	inappropriately	ADV
ajlm-2916	86	18	influenced	influence	VERB
ajlm-2916	86	19	them	they	PRON
ajlm-2916	86	20	in	in	ADP
ajlm-2916	86	21	writing	write	VERB
ajlm-2916	86	22	this	this	DET
ajlm-2916	86	23	article	article	NOUN
ajlm-2916	86	24	.	.	PUNCT
ajlm-2916	87	1	authors	author	NOUN
ajlm-2916	87	2	’	’	PART
ajlm-2916	87	3	contributions	contribution	NOUN
ajlm-2916	87	4	n.m.s	n.m.	NOUN
ajlm-2916	87	5	.	.	PUNCT
ajlm-2916	88	1	and	and	CCONJ
ajlm-2916	88	2	a.a.a	a.a.a	PROPN
ajlm-2916	88	3	.	.	PROPN
ajlm-2916	88	4	helped	help	VERB
ajlm-2916	88	5	to	to	PART
ajlm-2916	88	6	conceptualise	conceptualise	VERB
ajlm-2916	88	7	the	the	DET
ajlm-2916	88	8	study	study	NOUN
ajlm-2916	88	9	.	.	PUNCT
ajlm-2916	89	1	n.m.s	n.m.	NOUN
ajlm-2916	89	2	.	.	PROPN
ajlm-2916	89	3	,	,	PUNCT
ajlm-2916	89	4	e.m.m	e.m.m	PROPN
ajlm-2916	89	5	.	.	PROPN
ajlm-2916	89	6	,	,	PUNCT
ajlm-2916	89	7	d.s	d.s	PROPN
ajlm-2916	89	8	.	.	PROPN
ajlm-2916	89	9	,	,	PUNCT
ajlm-2916	89	10	and	and	CCONJ
ajlm-2916	89	11	d.g.a	d.g.a	NOUN
ajlm-2916	89	12	.	.	PUNCT
ajlm-2916	90	1	all	all	PRON
ajlm-2916	90	2	made	make	VERB
ajlm-2916	90	3	contributions	contribution	NOUN
ajlm-2916	90	4	to	to	ADP
ajlm-2916	90	5	the	the	DET
ajlm-2916	90	6	study	study	NOUN
ajlm-2916	90	7	’s	’s	PART
ajlm-2916	90	8	investigation	investigation	NOUN
ajlm-2916	90	9	.	.	PUNCT
ajlm-2916	91	1	contributions	contribution	NOUN
ajlm-2916	91	2	to	to	ADP
ajlm-2916	91	3	data	datum	NOUN
ajlm-2916	91	4	curation	curation	NOUN
ajlm-2916	91	5	came	come	VERB
ajlm-2916	91	6	from	from	ADP
ajlm-2916	91	7	e.m.m	e.m.m	PROPN
ajlm-2916	91	8	.	.	PROPN
ajlm-2916	91	9	,	,	PUNCT
ajlm-2916	91	10	d.s	d.s	PROPN
ajlm-2916	91	11	.	.	PROPN
ajlm-2916	91	12	,	,	PUNCT
ajlm-2916	91	13	d.g.a	d.g.a	PROPN
ajlm-2916	91	14	.	.	PUNCT
ajlm-2916	91	15	and	and	CCONJ
ajlm-2916	91	16	a.a.a	a.a.a	PROPN
ajlm-2916	91	17	.	.	PUNCT
ajlm-2916	92	1	d.g.a	d.g.a	PROPN
ajlm-2916	92	2	.	.	PROPN
ajlm-2916	92	3	,	,	PUNCT
ajlm-2916	92	4	a.a.a	a.a.a	PROPN
ajlm-2916	92	5	.	.	PROPN
ajlm-2916	92	6	,	,	PUNCT
ajlm-2916	93	1	a.a.e.s	a.a.e.s	PROPN
ajlm-2916	93	2	.	.	PROPN
ajlm-2916	93	3	,	,	PUNCT
ajlm-2916	93	4	e.a.a	e.a.a	PROPN
ajlm-2916	93	5	.	.	PUNCT
ajlm-2916	93	6	,	,	PUNCT
ajlm-2916	93	7	and	and	CCONJ
ajlm-2916	93	8	f.z.k	f.z.k	NOUN
ajlm-2916	93	9	.	.	PUNCT
ajlm-2916	94	1	all	all	PRON
ajlm-2916	94	2	made	make	VERB
ajlm-2916	94	3	contributions	contribution	NOUN
ajlm-2916	94	4	to	to	ADP
ajlm-2916	94	5	the	the	DET
ajlm-2916	94	6	methodology	methodology	NOUN
ajlm-2916	94	7	.	.	PUNCT
ajlm-2916	95	1	the	the	DET
ajlm-2916	95	2	project	project	NOUN
ajlm-2916	95	3	administration	administration	NOUN
ajlm-2916	95	4	and	and	CCONJ
ajlm-2916	95	5	original	original	ADJ
ajlm-2916	95	6	draft	draft	NOUN
ajlm-2916	95	7	preparation	preparation	NOUN
ajlm-2916	95	8	were	be	AUX
ajlm-2916	95	9	handled	handle	VERB
ajlm-2916	95	10	by	by	ADP
ajlm-2916	95	11	n.m.s	n.m.	NOUN
ajlm-2916	95	12	.	.	PUNCT
ajlm-2916	96	1	the	the	DET
ajlm-2916	96	2	article	article	NOUN
ajlm-2916	96	3	was	be	AUX
ajlm-2916	96	4	reviewed	review	VERB
ajlm-2916	96	5	and	and	CCONJ
ajlm-2916	96	6	edited	edit	VERB
ajlm-2916	96	7	with	with	ADP
ajlm-2916	96	8	assistance	assistance	NOUN
ajlm-2916	96	9	from	from	ADP
ajlm-2916	96	10	e.m.m	e.m.m	PROPN
ajlm-2916	96	11	.	.	PROPN
ajlm-2916	96	12	,	,	PUNCT
ajlm-2916	96	13	d.s	d.s	PROPN
ajlm-2916	96	14	.	.	PROPN
ajlm-2916	96	15	,	,	PUNCT
ajlm-2916	96	16	f.z.k	f.z.k	NOUN
ajlm-2916	96	17	.	.	PROPN
ajlm-2916	96	18	,	,	PUNCT
ajlm-2916	96	19	e.a.a	e.a.a	PROPN
ajlm-2916	96	20	.	.	PUNCT
ajlm-2916	96	21	,	,	PUNCT
ajlm-2916	97	1	a.a.e.s	a.a.e.s	PROPN
ajlm-2916	97	2	.	.	PUNCT
ajlm-2916	98	1	and	and	CCONJ
ajlm-2916	98	2	a.a.a	a.a.a	PROPN
ajlm-2916	98	3	.	.	PUNCT
ajlm-2916	99	1	f.z.k	f.z.k	PROPN
ajlm-2916	99	2	.	.	PROPN
ajlm-2916	99	3	,	,	PUNCT
ajlm-2916	99	4	e.a.a	e.a.a	PROPN
ajlm-2916	99	5	.	.	PUNCT
ajlm-2916	99	6	,	,	PUNCT
ajlm-2916	99	7	and	and	CCONJ
ajlm-2916	99	8	a.a.e.s	a.a.e.s	PROPN
ajlm-2916	99	9	.	.	PUNCT
ajlm-2916	99	10	assisted	assist	VERB
ajlm-2916	99	11	with	with	ADP
ajlm-2916	99	12	the	the	DET
ajlm-2916	99	13	study	study	NOUN
ajlm-2916	99	14	supervision	supervision	NOUN
ajlm-2916	99	15	.	.	PUNCT
ajlm-2916	100	1	all	all	PRON
ajlm-2916	100	2	of	of	ADP
ajlm-2916	100	3	the	the	DET
ajlm-2916	100	4	authors	author	NOUN
ajlm-2916	100	5	read	read	VERB
ajlm-2916	100	6	and	and	CCONJ
ajlm-2916	100	7	approved	approve	VERB
ajlm-2916	100	8	the	the	DET
ajlm-2916	100	9	article	article	NOUN
ajlm-2916	100	10	.	.	PUNCT
ajlm-2916	101	1	sources	source	NOUN
ajlm-2916	101	2	of	of	ADP
ajlm-2916	101	3	support	support	NOUN
ajlm-2916	101	4	this	this	DET
ajlm-2916	101	5	research	research	NOUN
ajlm-2916	101	6	received	receive	VERB
ajlm-2916	101	7	no	no	DET
ajlm-2916	101	8	specific	specific	ADJ
ajlm-2916	101	9	grant	grant	NOUN
ajlm-2916	101	10	from	from	ADP
ajlm-2916	101	11	any	any	DET
ajlm-2916	101	12	funding	funding	NOUN
ajlm-2916	101	13	agency	agency	NOUN
ajlm-2916	101	14	in	in	ADP
ajlm-2916	101	15	the	the	DET
ajlm-2916	101	16	public	public	ADJ
ajlm-2916	101	17	,	,	PUNCT
ajlm-2916	101	18	commercial	commercial	ADJ
ajlm-2916	101	19	,	,	PUNCT
ajlm-2916	101	20	or	or	CCONJ
ajlm-2916	101	21	not	not	PART
ajlm-2916	101	22	-	-	PUNCT
ajlm-2916	101	23	for	for	ADP
ajlm-2916	101	24	-	-	PUNCT
ajlm-2916	101	25	profit	profit	NOUN
ajlm-2916	101	26	sectors	sector	NOUN
ajlm-2916	101	27	.	.	PUNCT
ajlm-2916	102	1	data	datum	NOUN
ajlm-2916	102	2	availability	availability	NOUN
ajlm-2916	102	3	the	the	DET
ajlm-2916	102	4	data	data	NOUN
ajlm-2916	102	5	sets	set	NOUN
ajlm-2916	102	6	generated	generate	VERB
ajlm-2916	102	7	and	and	CCONJ
ajlm-2916	102	8	analysed	analyse	VERB
ajlm-2916	102	9	during	during	ADP
ajlm-2916	102	10	the	the	DET
ajlm-2916	102	11	current	current	ADJ
ajlm-2916	102	12	study	study	NOUN
ajlm-2916	102	13	are	be	AUX
ajlm-2916	102	14	available	available	ADJ
ajlm-2916	102	15	from	from	ADP
ajlm-2916	102	16	the	the	DET
ajlm-2916	102	17	corresponding	corresponding	ADJ
ajlm-2916	102	18	author	author	NOUN
ajlm-2916	102	19	,	,	PUNCT
ajlm-2916	102	20	n.m.s	n.m.s	INTJ
ajlm-2916	102	21	.	.	PROPN
ajlm-2916	102	22	,	,	PUNCT
ajlm-2916	102	23	on	on	ADP
ajlm-2916	102	24	reasonable	reasonable	ADJ
ajlm-2916	102	25	request	request	NOUN
ajlm-2916	102	26	.	.	PUNCT
ajlm-2916	103	1	disclaimer	disclaimer	VERB
ajlm-2916	103	2	the	the	DET
ajlm-2916	103	3	views	view	NOUN
ajlm-2916	103	4	and	and	CCONJ
ajlm-2916	103	5	opinions	opinion	NOUN
ajlm-2916	103	6	expressed	express	VERB
ajlm-2916	103	7	in	in	ADP
ajlm-2916	103	8	this	this	DET
ajlm-2916	103	9	article	article	NOUN
ajlm-2916	103	10	are	be	AUX
ajlm-2916	103	11	those	those	PRON
ajlm-2916	103	12	of	of	ADP
ajlm-2916	103	13	the	the	DET
ajlm-2916	103	14	authors	author	NOUN
ajlm-2916	103	15	and	and	CCONJ
ajlm-2916	103	16	are	be	AUX
ajlm-2916	103	17	the	the	DET
ajlm-2916	103	18	product	product	NOUN
ajlm-2916	103	19	of	of	ADP
ajlm-2916	103	20	professional	professional	ADJ
ajlm-2916	103	21	research	research	NOUN
ajlm-2916	103	22	.	.	PUNCT
ajlm-2916	104	1	the	the	DET
ajlm-2916	104	2	article	article	NOUN
ajlm-2916	104	3	does	do	AUX
ajlm-2916	104	4	not	not	PART
ajlm-2916	104	5	necessarily	necessarily	ADV
ajlm-2916	104	6	reflect	reflect	VERB
ajlm-2916	104	7	the	the	DET
ajlm-2916	104	8	official	official	ADJ
ajlm-2916	104	9	policy	policy	NOUN
ajlm-2916	104	10	or	or	CCONJ
ajlm-2916	104	11	position	position	NOUN
ajlm-2916	104	12	of	of	ADP
ajlm-2916	104	13	any	any	DET
ajlm-2916	104	14	affiliated	affiliated	ADJ
ajlm-2916	104	15	institution	institution	NOUN
ajlm-2916	104	16	,	,	PUNCT
ajlm-2916	104	17	funder	funder	NOUN
ajlm-2916	104	18	,	,	PUNCT
ajlm-2916	104	19	agency	agency	NOUN
ajlm-2916	104	20	,	,	PUNCT
ajlm-2916	104	21	or	or	CCONJ
ajlm-2916	104	22	that	that	PRON
ajlm-2916	104	23	of	of	ADP
ajlm-2916	104	24	the	the	DET
ajlm-2916	104	25	publisher	publisher	NOUN
ajlm-2916	104	26	.	.	PUNCT
ajlm-2916	105	1	the	the	DET
ajlm-2916	105	2	authors	author	NOUN
ajlm-2916	105	3	are	be	AUX
ajlm-2916	105	4	responsible	responsible	ADJ
ajlm-2916	105	5	for	for	ADP
ajlm-2916	105	6	this	this	DET
ajlm-2916	105	7	article	article	NOUN
ajlm-2916	105	8	’s	’s	PART
ajlm-2916	105	9	results	result	NOUN
ajlm-2916	105	10	,	,	PUNCT
ajlm-2916	105	11	findings	finding	NOUN
ajlm-2916	105	12	,	,	PUNCT
ajlm-2916	105	13	and	and	CCONJ
ajlm-2916	105	14	content	content	NOUN
ajlm-2916	105	15	.	.	PUNCT
ajlm-2916	106	1	references	reference	NOUN
ajlm-2916	106	2	thomas	thomas	PROPN
ajlm-2916	106	3	gp	gp	PROPN
ajlm-2916	106	4	,	,	PUNCT
ajlm-2916	106	5	willner	willner	NOUN
ajlm-2916	106	6	d	d	PROPN
ajlm-2916	106	7	,	,	PUNCT
ajlm-2916	106	8	robinson	robinson	PROPN
ajlm-2916	106	9	pc	pc	PROPN
ajlm-2916	106	10	,	,	PUNCT
ajlm-2916	106	11	et	et	PROPN
ajlm-2916	106	12	al	al	PROPN
ajlm-2916	106	13	.	.	PUNCT
ajlm-2916	107	1	genetic	genetic	ADJ
ajlm-2916	107	2	diagnostic	diagnostic	ADJ
ajlm-2916	107	3	profiling	profiling	NOUN
ajlm-2916	107	4	in	in	ADP
ajlm-2916	107	5	axial	axial	ADJ
ajlm-2916	107	6	spondyloarthritis	spondyloarthritis	NOUN
ajlm-2916	107	7	:	:	PUNCT
ajlm-2916	107	8	a	a	DET
ajlm-2916	107	9	real	real	ADJ
ajlm-2916	107	10	world	world	NOUN
ajlm-2916	107	11	study	study	NOUN
ajlm-2916	107	12	.	.	PUNCT
ajlm-2916	108	1	clin	clin	PROPN
ajlm-2916	108	2	exp	exp	NOUN
ajlm-2916	108	3	rheumatol	rheumatol	NOUN
ajlm-2916	109	1	[	[	X
ajlm-2916	109	2	serial	serial	ADJ
ajlm-2916	109	3	online	online	NOUN
ajlm-2916	109	4	]	]	PUNCT
ajlm-2916	109	5	.	.	PUNCT
ajlm-2916	110	1	2017	2017	NUM
ajlm-2916	111	1	[	[	X
ajlm-2916	111	2	cited	cite	VERB
ajlm-2916	111	3	2025	2025	NUM
ajlm-2916	111	4	jun	jun	PROPN
ajlm-2916	111	5	19	19	NUM
ajlm-2916	111	6	]	]	PUNCT
ajlm-2916	111	7	;	;	PUNCT
ajlm-2916	112	1	35(2):229–233	35(2):229–233	X
ajlm-2916	112	2	.	.	PUNCT
ajlm-2916	112	3	available	available	ADJ
ajlm-2916	112	4	from	from	ADP
ajlm-2916	112	5	:	:	PUNCT
ajlm-2916	112	6	https://hdl.handle.net/1887/114610	https://hdl.handle.net/1887/114610	PROPN
ajlm-2916	112	7	zhu	zhu	PROPN
ajlm-2916	112	8	w	w	PROPN
ajlm-2916	112	9	,	,	PUNCT
ajlm-2916	112	10	he	he	PRON
ajlm-2916	112	11	x	x	NOUN
ajlm-2916	112	12	,	,	PUNCT
ajlm-2916	112	13	cheng	cheng	PROPN
ajlm-2916	112	14	k	k	PROPN
ajlm-2916	112	15	,	,	PUNCT
ajlm-2916	112	16	et	et	PROPN
ajlm-2916	112	17	al	al	PROPN
ajlm-2916	112	18	.	.	PUNCT
ajlm-2916	113	1	ankylosing	ankylose	VERB
ajlm-2916	113	2	spondylitis	spondylitis	NOUN
ajlm-2916	113	3	:	:	PUNCT
ajlm-2916	113	4	etiology	etiology	NOUN
ajlm-2916	113	5	,	,	PUNCT
ajlm-2916	113	6	pathogenesis	pathogenesis	NOUN
ajlm-2916	113	7	,	,	PUNCT
ajlm-2916	113	8	and	and	CCONJ
ajlm-2916	113	9	treatments	treatment	NOUN
ajlm-2916	113	10	.	.	PUNCT
ajlm-2916	114	1	bone	bone	NOUN
ajlm-2916	114	2	res	re	NOUN
ajlm-2916	114	3	.	.	PUNCT
ajlm-2916	115	1	2019;7(1):22	2019;7(1):22	NUM
ajlm-2916	115	2	.	.	PUNCT
ajlm-2916	115	3	https://doi.org/10.1038/s41413-019-0057-8	https://doi.org/10.1038/s41413-019-0057-8	PROPN
ajlm-2916	115	4	biały	biały	PROPN
ajlm-2916	115	5	s	s	PROPN
ajlm-2916	115	6	,	,	PUNCT
ajlm-2916	115	7	iwaszko	iwaszko	NOUN
ajlm-2916	115	8	m	m	PROPN
ajlm-2916	115	9	,	,	PUNCT
ajlm-2916	115	10	świerkot	świerkot	PROPN
ajlm-2916	115	11	j	j	PROPN
ajlm-2916	115	12	,	,	PUNCT
ajlm-2916	115	13	et	et	PROPN
ajlm-2916	115	14	al	al	PROPN
ajlm-2916	115	15	.	.	PUNCT
ajlm-2916	116	1	genetic	genetic	ADJ
ajlm-2916	116	2	variability	variability	NOUN
ajlm-2916	116	3	of	of	ADP
ajlm-2916	116	4	three	three	NUM
ajlm-2916	116	5	common	common	ADJ
ajlm-2916	116	6	nk	nk	NOUN
ajlm-2916	116	7	and	and	CCONJ
ajlm-2916	116	8	γδ	γδ	ADP
ajlm-2916	116	9	t	t	NOUN
ajlm-2916	116	10	cell	cell	NOUN
ajlm-2916	116	11	receptor	receptor	NOUN
ajlm-2916	116	12	genes	gene	NOUN
ajlm-2916	116	13	(	(	PUNCT
ajlm-2916	116	14	fcγ3r	fcγ3r	PROPN
ajlm-2916	116	15	,	,	PUNCT
ajlm-2916	116	16	ncr3	ncr3	PROPN
ajlm-2916	116	17	,	,	PUNCT
ajlm-2916	116	18	and	and	CCONJ
ajlm-2916	116	19	dnam-1	dnam-1	NOUN
ajlm-2916	116	20	)	)	PUNCT
ajlm-2916	116	21	and	and	CCONJ
ajlm-2916	116	22	their	their	PRON
ajlm-2916	116	23	role	role	NOUN
ajlm-2916	116	24	in	in	ADP
ajlm-2916	116	25	polish	polish	ADJ
ajlm-2916	116	26	patients	patient	NOUN
ajlm-2916	116	27	with	with	ADP
ajlm-2916	116	28	rheumatoid	rheumatoid	NOUN
ajlm-2916	116	29	arthritis	arthritis	NOUN
ajlm-2916	116	30	and	and	CCONJ
ajlm-2916	116	31	ankylosing	ankylose	VERB
ajlm-2916	116	32	spondylitis	spondylitis	NOUN
ajlm-2916	116	33	.	.	PUNCT
ajlm-2916	117	1	immunol	immunol	NOUN
ajlm-2916	117	2	res	re	NOUN
ajlm-2916	117	3	.	.	PUNCT
ajlm-2916	118	1	2024;72(4):614–625	2024;72(4):614–625	X
ajlm-2916	118	2	.	.	PUNCT
ajlm-2916	119	1	https://doi.org/10.1007/s12026-024-09488-3	https://doi.org/10.1007/s12026-024-09488-3	PROPN
ajlm-2916	119	2	nam	nam	PROPN
ajlm-2916	119	3	b	b	PROPN
ajlm-2916	119	4	,	,	PUNCT
ajlm-2916	119	5	jo	jo	PROPN
ajlm-2916	119	6	s	s	PROPN
ajlm-2916	119	7	,	,	PUNCT
ajlm-2916	119	8	bang	bang	PROPN
ajlm-2916	119	9	sy	sy	PROPN
ajlm-2916	119	10	,	,	PUNCT
ajlm-2916	119	11	et	et	PROPN
ajlm-2916	119	12	al	al	PROPN
ajlm-2916	119	13	.	.	PROPN
ajlm-2916	120	1	clinical	clinical	ADJ
ajlm-2916	120	2	and	and	CCONJ
ajlm-2916	120	3	genetic	genetic	ADJ
ajlm-2916	120	4	factors	factor	NOUN
ajlm-2916	120	5	associated	associate	VERB
ajlm-2916	120	6	with	with	ADP
ajlm-2916	120	7	radiographic	radiographic	ADJ
ajlm-2916	120	8	damage	damage	NOUN
ajlm-2916	120	9	in	in	ADP
ajlm-2916	120	10	patients	patient	NOUN
ajlm-2916	120	11	with	with	ADP
ajlm-2916	120	12	ankylosing	ankylose	VERB
ajlm-2916	120	13	spondylitis	spondylitis	NOUN
ajlm-2916	120	14	.	.	PUNCT
ajlm-2916	121	1	ann	ann	PROPN
ajlm-2916	121	2	rheum	rheum	PROPN
ajlm-2916	121	3	dis	dis	PROPN
ajlm-2916	121	4	.	.	PUNCT
ajlm-2916	122	1	2023;82(4):527–532	2023;82(4):527–532	X
ajlm-2916	122	2	.	.	PUNCT
ajlm-2916	122	3	https://doi.org/10.1136/annrheumdis-2022-222796	https://doi.org/10.1136/annrheumdis-2022-222796	PROPN
ajlm-2916	122	4	brown	brown	PROPN
ajlm-2916	122	5	ma	ma	PROPN
ajlm-2916	122	6	,	,	PUNCT
ajlm-2916	122	7	kennedy	kennedy	PROPN
ajlm-2916	122	8	lg	lg	PROPN
ajlm-2916	122	9	,	,	PUNCT
ajlm-2916	122	10	macgregor	macgregor	PROPN
ajlm-2916	122	11	aj	aj	PROPN
ajlm-2916	122	12	,	,	PUNCT
ajlm-2916	122	13	et	et	PROPN
ajlm-2916	122	14	al	al	PROPN
ajlm-2916	122	15	.	.	PROPN
ajlm-2916	122	16	susceptibility	susceptibility	NOUN
ajlm-2916	122	17	to	to	ADP
ajlm-2916	122	18	ankylosing	ankylose	VERB
ajlm-2916	122	19	spondylitis	spondylitis	NOUN
ajlm-2916	122	20	in	in	ADP
ajlm-2916	122	21	twins	twin	NOUN
ajlm-2916	122	22	the	the	DET
ajlm-2916	122	23	role	role	NOUN
ajlm-2916	122	24	of	of	ADP
ajlm-2916	122	25	genes	gene	NOUN
ajlm-2916	122	26	,	,	PUNCT
ajlm-2916	122	27	hla	hla	PROPN
ajlm-2916	122	28	,	,	PUNCT
ajlm-2916	122	29	and	and	CCONJ
ajlm-2916	122	30	the	the	DET
ajlm-2916	122	31	environment	environment	NOUN
ajlm-2916	122	32	.	.	PUNCT
ajlm-2916	123	1	arthritis	arthritis	NOUN
ajlm-2916	123	2	rheum	rheum	NOUN
ajlm-2916	123	3	.	.	PUNCT
ajlm-2916	124	1	1997;40(10):1823–1828	1997;40(10):1823–1828	X
ajlm-2916	124	2	.	.	PUNCT
ajlm-2916	125	1	https://doi.org/10.1002/art.1780401015	https://doi.org/10.1002/art.1780401015	PROPN
ajlm-2916	125	2	díaz	díaz	NOUN
ajlm-2916	125	3	-	-	PUNCT
ajlm-2916	125	4	peña	peña	NOUN
ajlm-2916	125	5	r	r	NOUN
ajlm-2916	125	6	,	,	PUNCT
ajlm-2916	125	7	lópez	lópez	NOUN
ajlm-2916	125	8	-	-	PUNCT
ajlm-2916	125	9	vázquez	vázquez	NOUN
ajlm-2916	125	10	a	a	PRON
ajlm-2916	125	11	,	,	PUNCT
ajlm-2916	125	12	lópez	lópez	NOUN
ajlm-2916	125	13	-	-	PUNCT
ajlm-2916	125	14	larrea	larrea	PROPN
ajlm-2916	125	15	c.	c.	PROPN
ajlm-2916	125	16	old	old	ADJ
ajlm-2916	125	17	and	and	CCONJ
ajlm-2916	125	18	new	new	ADJ
ajlm-2916	125	19	hla	hla	PROPN
ajlm-2916	125	20	associations	association	NOUN
ajlm-2916	125	21	with	with	ADP
ajlm-2916	125	22	ankylosing	ankylose	VERB
ajlm-2916	125	23	spondylitis	spondylitis	NOUN
ajlm-2916	125	24	.	.	PUNCT
ajlm-2916	126	1	tissue	tissue	NOUN
ajlm-2916	126	2	antigens	antigen	NOUN
ajlm-2916	126	3	.	.	PUNCT
ajlm-2916	127	1	2012;80(3):205–213	2012;80(3):205–213	NUM
ajlm-2916	127	2	.	.	PUNCT
ajlm-2916	127	3	https://doi.org/10.1111/j.1399-0039.2012.01944.x	https://doi.org/10.1111/j.1399-0039.2012.01944.x	NOUN
ajlm-2916	127	4	stankiewicz	stankiewicz	NOUN
ajlm-2916	128	1	p	p	X
ajlm-2916	128	2	,	,	PUNCT
ajlm-2916	128	3	lupski	lupski	PROPN
ajlm-2916	128	4	jr	jr	PROPN
ajlm-2916	128	5	.	.	PROPN
ajlm-2916	128	6	structural	structural	ADJ
ajlm-2916	128	7	variation	variation	NOUN
ajlm-2916	128	8	in	in	ADP
ajlm-2916	128	9	the	the	DET
ajlm-2916	128	10	human	human	ADJ
ajlm-2916	128	11	genome	genome	NOUN
ajlm-2916	128	12	and	and	CCONJ
ajlm-2916	128	13	its	its	PRON
ajlm-2916	128	14	role	role	NOUN
ajlm-2916	128	15	in	in	ADP
ajlm-2916	128	16	disease	disease	NOUN
ajlm-2916	128	17	.	.	PUNCT
ajlm-2916	129	1	ann	ann	PROPN
ajlm-2916	129	2	rev	rev	PROPN
ajlm-2916	129	3	med	med	PROPN
ajlm-2916	129	4	.	.	PUNCT
ajlm-2916	130	1	2010;61(1):437–455	2010;61(1):437–455	X
ajlm-2916	130	2	.	.	PUNCT
ajlm-2916	130	3	https://doi.org/10.1146/annurev-med-100708-204735	https://doi.org/10.1146/annurev-med-100708-204735	PROPN
ajlm-2916	130	4	gamazon	gamazon	X
ajlm-2916	130	5	er	er	INTJ
ajlm-2916	130	6	,	,	PUNCT
ajlm-2916	130	7	stranger	strange	ADJ
ajlm-2916	130	8	be	be	AUX
ajlm-2916	130	9	.	.	PUNCT
ajlm-2916	131	1	the	the	DET
ajlm-2916	131	2	impact	impact	NOUN
ajlm-2916	131	3	of	of	ADP
ajlm-2916	131	4	human	human	ADJ
ajlm-2916	131	5	copy	copy	NOUN
ajlm-2916	131	6	number	number	NOUN
ajlm-2916	131	7	variation	variation	NOUN
ajlm-2916	131	8	on	on	ADP
ajlm-2916	131	9	gene	gene	NOUN
ajlm-2916	131	10	expression	expression	NOUN
ajlm-2916	131	11	.	.	PUNCT
ajlm-2916	132	1	brief	brief	ADJ
ajlm-2916	132	2	funct	funct	PROPN
ajlm-2916	132	3	genom	genom	PROPN
ajlm-2916	132	4	.	.	PUNCT
ajlm-2916	133	1	2015;14(5):352–357	2015;14(5):352–357	NUM
ajlm-2916	133	2	.	.	PUNCT
ajlm-2916	133	3	https://doi.org/10.1093/bfgp/elv017	https://doi.org/10.1093/bfgp/elv017	PROPN
ajlm-2916	133	4	usher	usher	PROPN
ajlm-2916	133	5	cl	cl	NOUN
ajlm-2916	133	6	,	,	PUNCT
ajlm-2916	133	7	mccarroll	mccarroll	VERB
ajlm-2916	133	8	sa	sa	PROPN
ajlm-2916	133	9	.	.	PUNCT
ajlm-2916	134	1	complex	complex	ADJ
ajlm-2916	134	2	and	and	CCONJ
ajlm-2916	134	3	multi	multi	ADJ
ajlm-2916	134	4	-	-	ADJ
ajlm-2916	134	5	allelic	allelic	ADJ
ajlm-2916	134	6	copy	copy	NOUN
ajlm-2916	134	7	number	number	NOUN
ajlm-2916	134	8	variation	variation	NOUN
ajlm-2916	134	9	in	in	ADP
ajlm-2916	134	10	human	human	ADJ
ajlm-2916	134	11	disease	disease	NOUN
ajlm-2916	134	12	.	.	PUNCT
ajlm-2916	135	1	brief	brief	ADJ
ajlm-2916	135	2	funct	funct	PROPN
ajlm-2916	135	3	genom	genom	NOUN
ajlm-2916	135	4	.	.	PUNCT
ajlm-2916	136	1	2015;14(5):329–338	2015;14(5):329–338	NUM
ajlm-2916	136	2	.	.	PUNCT
ajlm-2916	136	3	https://doi.org/10.1093/bfgp/elv028	https://doi.org/10.1093/bfgp/elv028	PROPN
ajlm-2916	136	4	bigagli	bigagli	NOUN
ajlm-2916	136	5	e	e	NOUN
ajlm-2916	136	6	,	,	PUNCT
ajlm-2916	136	7	de	de	X
ajlm-2916	136	8	filippo	filippo	PROPN
ajlm-2916	136	9	c	c	PROPN
ajlm-2916	136	10	,	,	PUNCT
ajlm-2916	136	11	castagnini	castagnini	PROPN
ajlm-2916	136	12	c	c	NOUN
ajlm-2916	136	13	,	,	PUNCT
ajlm-2916	136	14	et	et	PROPN
ajlm-2916	136	15	al	al	PROPN
ajlm-2916	136	16	.	.	PROPN
ajlm-2916	137	1	dna	dna	PROPN
ajlm-2916	137	2	copy	copy	VERB
ajlm-2916	137	3	number	number	NOUN
ajlm-2916	137	4	alterations	alteration	NOUN
ajlm-2916	137	5	,	,	PUNCT
ajlm-2916	137	6	gene	gene	NOUN
ajlm-2916	137	7	expression	expression	NOUN
ajlm-2916	137	8	changes	change	NOUN
ajlm-2916	137	9	and	and	CCONJ
ajlm-2916	137	10	disease	disease	NOUN
ajlm-2916	137	11	-	-	PUNCT
ajlm-2916	137	12	free	free	ADJ
ajlm-2916	137	13	survival	survival	NOUN
ajlm-2916	137	14	in	in	ADP
ajlm-2916	137	15	patients	patient	NOUN
ajlm-2916	137	16	with	with	ADP
ajlm-2916	137	17	colorectal	colorectal	ADJ
ajlm-2916	137	18	cancer	cancer	NOUN
ajlm-2916	137	19	:	:	PUNCT
ajlm-2916	137	20	a	a	DET
ajlm-2916	137	21	10	10	NUM
ajlm-2916	137	22	year	year	NOUN
ajlm-2916	137	23	follow	follow	NOUN
ajlm-2916	137	24	-	-	PUNCT
ajlm-2916	137	25	up	up	NOUN
ajlm-2916	137	26	.	.	PUNCT
ajlm-2916	138	1	cell	cell	NOUN
ajlm-2916	138	2	oncol	oncol	ADJ
ajlm-2916	138	3	.	.	PUNCT
ajlm-2916	139	1	2016;39(6):545–558	2016;39(6):545–558	X
ajlm-2916	139	2	.	.	X
ajlm-2916	139	3	https://doi.org/10.1007/s13402-016-0299-z	https://doi.org/10.1007/s13402-016-0299-z	PROPN
ajlm-2916	139	4	aghaei	aghaei	PROPN
ajlm-2916	139	5	h	h	PROPN
ajlm-2916	139	6	,	,	PUNCT
ajlm-2916	139	7	farhadi	farhadi	NOUN
ajlm-2916	139	8	e	e	NOUN
ajlm-2916	139	9	,	,	PUNCT
ajlm-2916	139	10	akhtari	akhtari	NOUN
ajlm-2916	139	11	m	m	PROPN
ajlm-2916	139	12	,	,	PUNCT
ajlm-2916	139	13	et	et	PROPN
ajlm-2916	139	14	al	al	PROPN
ajlm-2916	139	15	.	.	PROPN
ajlm-2916	139	16	copy	copy	NOUN
ajlm-2916	139	17	number	number	NOUN
ajlm-2916	139	18	variation	variation	NOUN
ajlm-2916	139	19	of	of	ADP
ajlm-2916	139	20	il17ra	il17ra	NOUN
ajlm-2916	139	21	gene	gene	NOUN
ajlm-2916	139	22	and	and	CCONJ
ajlm-2916	139	23	its	its	PRON
ajlm-2916	139	24	association	association	NOUN
ajlm-2916	139	25	with	with	ADP
ajlm-2916	139	26	the	the	DET
ajlm-2916	139	27	ankylosing	ankylose	VERB
ajlm-2916	139	28	spondylitis	spondylitis	ADJ
ajlm-2916	139	29	risk	risk	NOUN
ajlm-2916	139	30	in	in	ADP
ajlm-2916	139	31	iranian	iranian	ADJ
ajlm-2916	139	32	patients	patient	NOUN
ajlm-2916	139	33	:	:	PUNCT
ajlm-2916	139	34	a	a	DET
ajlm-2916	139	35	case	case	NOUN
ajlm-2916	139	36	-	-	PUNCT
ajlm-2916	139	37	control	control	NOUN
ajlm-2916	139	38	study	study	NOUN
ajlm-2916	139	39	.	.	PUNCT
ajlm-2916	140	1	bmc	bmc	PROPN
ajlm-2916	140	2	med	med	ADJ
ajlm-2916	140	3	genet	genet	NOUN
ajlm-2916	140	4	.	.	PUNCT
ajlm-2916	141	1	2020;21(1):147	2020;21(1):147	NUM
ajlm-2916	141	2	.	.	PUNCT
ajlm-2916	142	1	https://doi.org/10.1186/s12881-020-01078-y	https://doi.org/10.1186/s12881-020-01078-y	PROPN
ajlm-2916	142	2	wang	wang	PROPN
ajlm-2916	142	3	l	l	PROPN
ajlm-2916	142	4	,	,	PUNCT
ajlm-2916	142	5	yang	yang	PROPN
ajlm-2916	142	6	x	x	PROPN
ajlm-2916	142	7	,	,	PUNCT
ajlm-2916	142	8	cai	cai	PROPN
ajlm-2916	142	9	g	g	PROPN
ajlm-2916	142	10	,	,	PUNCT
ajlm-2916	142	11	et	et	PROPN
ajlm-2916	142	12	al	al	PROPN
ajlm-2916	142	13	.	.	PROPN
ajlm-2916	142	14	association	association	PROPN
ajlm-2916	142	15	study	study	NOUN
ajlm-2916	142	16	of	of	ADP
ajlm-2916	142	17	copy	copy	NOUN
ajlm-2916	142	18	number	number	NOUN
ajlm-2916	142	19	variants	variant	NOUN
ajlm-2916	142	20	in	in	ADP
ajlm-2916	142	21	fcgr3a	fcgr3a	ADJ
ajlm-2916	142	22	and	and	CCONJ
ajlm-2916	142	23	fcgr3b	fcgr3b	NOUN
ajlm-2916	142	24	gene	gene	NOUN
ajlm-2916	142	25	with	with	ADP
ajlm-2916	142	26	risk	risk	NOUN
ajlm-2916	142	27	of	of	ADP
ajlm-2916	142	28	ankylosing	ankylose	VERB
ajlm-2916	142	29	spondylitis	spondylitis	NOUN
ajlm-2916	142	30	in	in	ADP
ajlm-2916	142	31	a	a	DET
ajlm-2916	142	32	chinese	chinese	ADJ
ajlm-2916	142	33	population	population	NOUN
ajlm-2916	142	34	.	.	PUNCT
ajlm-2916	143	1	rheumatol	rheumatol	PROPN
ajlm-2916	143	2	int	int	NOUN
ajlm-2916	143	3	.	.	PUNCT
ajlm-2916	144	1	2016;36(3):437–442	2016;36(3):437–442	NUM
ajlm-2916	144	2	.	.	PUNCT
ajlm-2916	144	3	https://doi.org/10.1007/s00296-015-3384-0	https://doi.org/10.1007/s00296-015-3384-0	NUM
ajlm-2916	144	4	aslam	aslam	PROPN
ajlm-2916	144	5	mm	mm	PROPN
ajlm-2916	144	6	,	,	PUNCT
ajlm-2916	144	7	john	john	PROPN
ajlm-2916	144	8	p	p	PROPN
ajlm-2916	144	9	,	,	PUNCT
ajlm-2916	144	10	fan	fan	PROPN
ajlm-2916	144	11	kh	kh	PROPN
ajlm-2916	144	12	,	,	PUNCT
ajlm-2916	144	13	et	et	PROPN
ajlm-2916	144	14	al	al	PROPN
ajlm-2916	144	15	.	.	PROPN
ajlm-2916	144	16	association	association	PROPN
ajlm-2916	144	17	of	of	ADP
ajlm-2916	144	18	fc	fc	PROPN
ajlm-2916	144	19	gamma	gamma	PROPN
ajlm-2916	144	20	receptor	receptor	NOUN
ajlm-2916	144	21	3b	3b	NUM
ajlm-2916	144	22	gene	gene	NOUN
ajlm-2916	144	23	copy	copy	VERB
ajlm-2916	144	24	number	number	NOUN
ajlm-2916	144	25	variation	variation	NOUN
ajlm-2916	144	26	with	with	ADP
ajlm-2916	144	27	rheumatoid	rheumatoid	NOUN
ajlm-2916	144	28	arthritis	arthritis	NOUN
ajlm-2916	144	29	susceptibility	susceptibility	NOUN
ajlm-2916	144	30	.	.	PUNCT
ajlm-2916	145	1	genes	gene	NOUN
ajlm-2916	145	2	.	.	PUNCT
ajlm-2916	146	1	2022;13(12	2022;13(12	NUM
ajlm-2916	146	2	):	):	PUNCT
ajlm-2916	146	3	2238	2238	NUM
ajlm-2916	146	4	.	.	PUNCT
ajlm-2916	147	1	https://doi.org/10.3390/genes13122238	https://doi.org/10.3390/genes13122238	NOUN
ajlm-2916	147	2	garcía	garcía	NOUN
ajlm-2916	147	3	-	-	PUNCT
ajlm-2916	147	4	ortiz	ortiz	PROPN
ajlm-2916	147	5	h	h	NOUN
ajlm-2916	147	6	,	,	PUNCT
ajlm-2916	147	7	velázquez	velázquez	NOUN
ajlm-2916	147	8	-	-	PUNCT
ajlm-2916	147	9	cruz	cruz	NOUN
ajlm-2916	147	10	r	r	PROPN
ajlm-2916	147	11	,	,	PUNCT
ajlm-2916	147	12	espinosa	espinosa	NOUN
ajlm-2916	147	13	-	-	PUNCT
ajlm-2916	147	14	rosales	rosales	PROPN
ajlm-2916	148	1	f	f	NOUN
ajlm-2916	148	2	,	,	PUNCT
ajlm-2916	148	3	jiménez	jiménez	PROPN
ajlm-2916	148	4	-	-	PUNCT
ajlm-2916	148	5	morales	morales	PROPN
ajlm-2916	148	6	s	s	PROPN
ajlm-2916	148	7	,	,	PUNCT
ajlm-2916	148	8	baca	baca	PROPN
ajlm-2916	148	9	v	v	PROPN
ajlm-2916	148	10	,	,	PUNCT
ajlm-2916	148	11	orozco	orozco	PROPN
ajlm-2916	148	12	l.	l.	PROPN
ajlm-2916	148	13	association	association	PROPN
ajlm-2916	148	14	of	of	ADP
ajlm-2916	148	15	tlr7	tlr7	PROPN
ajlm-2916	148	16	copy	copy	VERB
ajlm-2916	148	17	number	number	NOUN
ajlm-2916	148	18	variation	variation	NOUN
ajlm-2916	148	19	with	with	ADP
ajlm-2916	148	20	susceptibility	susceptibility	NOUN
ajlm-2916	148	21	to	to	ADP
ajlm-2916	148	22	childhood	childhood	NOUN
ajlm-2916	148	23	-	-	PUNCT
ajlm-2916	148	24	onset	onset	VERB
ajlm-2916	148	25	systemic	systemic	ADJ
ajlm-2916	148	26	lupus	lupus	NOUN
ajlm-2916	148	27	erythematosus	erythematosus	NOUN
ajlm-2916	148	28	in	in	ADP
ajlm-2916	148	29	mexican	mexican	ADJ
ajlm-2916	148	30	population	population	NOUN
ajlm-2916	148	31	.	.	PUNCT
ajlm-2916	149	1	ann	ann	PROPN
ajlm-2916	149	2	rheum	rheum	PROPN
ajlm-2916	149	3	dis	dis	PROPN
ajlm-2916	149	4	.	.	PUNCT
ajlm-2916	150	1	2010;69(10):1861–1865	2010;69(10):1861–1865	NUM
ajlm-2916	150	2	.	.	PUNCT
ajlm-2916	150	3	https://doi.org/10.1136/ard.2009.124313	https://doi.org/10.1136/ard.2009.124313	PROPN
ajlm-2916	150	4	bai	bai	PROPN
ajlm-2916	150	5	l	l	PROPN
ajlm-2916	150	6	,	,	PUNCT
ajlm-2916	150	7	liu	liu	PROPN
ajlm-2916	150	8	y	y	PROPN
ajlm-2916	150	9	,	,	PUNCT
ajlm-2916	150	10	hou	hou	PROPN
ajlm-2916	150	11	s	s	PROPN
ajlm-2916	150	12	,	,	PUNCT
ajlm-2916	150	13	liao	liao	PROPN
ajlm-2916	150	14	d	d	PROPN
ajlm-2916	150	15	,	,	PUNCT
ajlm-2916	150	16	kijlstra	kijlstra	PROPN
ajlm-2916	150	17	a	a	X
ajlm-2916	150	18	,	,	PUNCT
ajlm-2916	150	19	yang	yang	PROPN
ajlm-2916	150	20	p.	p.	PROPN
ajlm-2916	150	21	association	association	PROPN
ajlm-2916	150	22	of	of	ADP
ajlm-2916	150	23	t	t	PROPN
ajlm-2916	150	24	-	-	PUNCT
ajlm-2916	150	25	bet	bet	NOUN
ajlm-2916	150	26	,	,	PUNCT
ajlm-2916	150	27	gata-3	gata-3	PROPN
ajlm-2916	150	28	,	,	PUNCT
ajlm-2916	150	29	rorc	rorc	NOUN
ajlm-2916	150	30	,	,	PUNCT
ajlm-2916	150	31	and	and	CCONJ
ajlm-2916	150	32	foxp3	foxp3	NOUN
ajlm-2916	150	33	copy	copy	VERB
ajlm-2916	150	34	number	number	NOUN
ajlm-2916	150	35	variations	variation	NOUN
ajlm-2916	150	36	with	with	ADP
ajlm-2916	150	37	acute	acute	ADJ
ajlm-2916	150	38	anterior	anterior	ADJ
ajlm-2916	150	39	uveitis	uveitis	NOUN
ajlm-2916	150	40	with	with	ADP
ajlm-2916	150	41	or	or	CCONJ
ajlm-2916	150	42	without	without	ADP
ajlm-2916	150	43	ankylosing	ankylose	VERB
ajlm-2916	150	44	spondylitis	spondylitis	NOUN
ajlm-2916	150	45	in	in	ADP
ajlm-2916	150	46	chinese	chinese	PROPN
ajlm-2916	150	47	han	han	PROPN
ajlm-2916	150	48	.	.	PROPN
ajlm-2916	150	49	invest	invest	VERB
ajlm-2916	150	50	ophthalmol	ophthalmol	PROPN
ajlm-2916	150	51	vis	vis	X
ajlm-2916	150	52	sci	sci	PROPN
ajlm-2916	150	53	.	.	PUNCT
ajlm-2916	151	1	2016;57(4):1847–1852	2016;57(4):1847–1852	PROPN
ajlm-2916	151	2	.	.	PUNCT
ajlm-2916	152	1	https://doi.org/10.1167/iovs.15-17960	https://doi.org/10.1167/iovs.15-17960	PROPN
ajlm-2916	152	2	qi	qi	PROPN
ajlm-2916	152	3	y	y	PROPN
ajlm-2916	152	4	,	,	PUNCT
ajlm-2916	152	5	zhou	zhou	PROPN
ajlm-2916	152	6	x	x	PROPN
ajlm-2916	152	7	,	,	PUNCT
ajlm-2916	152	8	bu	bu	PROPN
ajlm-2916	153	1	d	d	PROPN
ajlm-2916	153	2	,	,	PUNCT
ajlm-2916	153	3	hou	hou	PROPN
ajlm-2916	153	4	p	p	PROPN
ajlm-2916	153	5	,	,	PUNCT
ajlm-2916	153	6	lv	lv	PROPN
ajlm-2916	153	7	j	j	PROPN
ajlm-2916	153	8	,	,	PUNCT
ajlm-2916	153	9	zhang	zhang	PROPN
ajlm-2916	153	10	h.	h.	PROPN
ajlm-2916	153	11	low	low	PROPN
ajlm-2916	153	12	copy	copy	NOUN
ajlm-2916	153	13	numbers	number	NOUN
ajlm-2916	153	14	of	of	ADP
ajlm-2916	153	15	fcgr3a	fcgr3a	PROPN
ajlm-2916	153	16	and	and	CCONJ
ajlm-2916	153	17	fcgr3b	fcgr3b	NOUN
ajlm-2916	153	18	associated	associate	VERB
ajlm-2916	153	19	with	with	ADP
ajlm-2916	153	20	chinese	chinese	ADJ
ajlm-2916	153	21	patients	patient	NOUN
ajlm-2916	153	22	with	with	ADP
ajlm-2916	153	23	sle	sle	PROPN
ajlm-2916	153	24	and	and	CCONJ
ajlm-2916	153	25	aasv	aasv	NOUN
ajlm-2916	153	26	.	.	PUNCT
ajlm-2916	154	1	lupus	lupus	NOUN
ajlm-2916	154	2	.	.	PUNCT
ajlm-2916	155	1	2017;26(13):1383–1389	2017;26(13):1383–1389	NOUN
ajlm-2916	155	2	.	.	PUNCT
ajlm-2916	155	3	https://doi.org/10.1177/0961203317700485	https://doi.org/10.1177/0961203317700485	PROPN
ajlm-2916	155	4	yu	yu	PROPN
ajlm-2916	155	5	b	b	PROPN
ajlm-2916	155	6	,	,	PUNCT
ajlm-2916	155	7	shao	shao	PROPN
ajlm-2916	155	8	y	y	PROPN
ajlm-2916	155	9	,	,	PUNCT
ajlm-2916	155	10	yue	yue	PROPN
ajlm-2916	155	11	x	x	PROPN
ajlm-2916	155	12	,	,	PUNCT
ajlm-2916	155	13	et	et	PROPN
ajlm-2916	155	14	al	al	PROPN
ajlm-2916	155	15	.	.	PROPN
ajlm-2916	155	16	copy	copy	NOUN
ajlm-2916	155	17	number	number	NOUN
ajlm-2916	155	18	variations	variation	NOUN
ajlm-2916	155	19	of	of	ADP
ajlm-2916	155	20	interleukin-12b	interleukin-12b	PROPN
ajlm-2916	155	21	and	and	CCONJ
ajlm-2916	155	22	t	t	PROPN
ajlm-2916	155	23	-	-	PUNCT
ajlm-2916	155	24	bet	bet	NOUN
ajlm-2916	155	25	are	be	AUX
ajlm-2916	155	26	associated	associate	VERB
ajlm-2916	155	27	with	with	ADP
ajlm-2916	155	28	systemic	systemic	ADJ
ajlm-2916	155	29	lupus	lupus	PROPN
ajlm-2916	155	30	erythematosus	erythematosus	PROPN
ajlm-2916	155	31	.	.	PUNCT
ajlm-2916	156	1	rheumatology	rheumatology	NOUN
ajlm-2916	156	2	.	.	PUNCT
ajlm-2916	157	1	2011;50(7):1201–1205	2011;50(7):1201–1205	PROPN
ajlm-2916	157	2	.	.	PUNCT
ajlm-2916	158	1	https://doi.org/10.1093/rheumatology/keq439	https://doi.org/10.1093/rheumatology/keq439	PROPN
ajlm-2916	158	2	meng	meng	PROPN
ajlm-2916	158	3	s	s	PROPN
ajlm-2916	158	4	,	,	PUNCT
ajlm-2916	158	5	fan	fan	PROPN
ajlm-2916	158	6	s	s	PROPN
ajlm-2916	158	7	,	,	PUNCT
ajlm-2916	158	8	li	li	PROPN
ajlm-2916	158	9	y	y	PROPN
ajlm-2916	158	10	,	,	PUNCT
ajlm-2916	158	11	et	et	PROPN
ajlm-2916	158	12	al	al	PROPN
ajlm-2916	158	13	.	.	PROPN
ajlm-2916	158	14	aberrant	aberrant	ADJ
ajlm-2916	158	15	methylation	methylation	NOUN
ajlm-2916	158	16	of	of	ADP
ajlm-2916	158	17	mir-34b	mir-34b	NOUN
ajlm-2916	158	18	and	and	CCONJ
ajlm-2916	158	19	il-12b	il-12b	PROPN
ajlm-2916	158	20	mrna	mrna	PROPN
ajlm-2916	158	21	promoters	promoter	NOUN
ajlm-2916	158	22	contributes	contribute	VERB
ajlm-2916	158	23	to	to	ADP
ajlm-2916	158	24	the	the	DET
ajlm-2916	158	25	reduced	reduced	ADJ
ajlm-2916	158	26	severity	severity	NOUN
ajlm-2916	158	27	of	of	ADP
ajlm-2916	158	28	ankylosing	ankylose	VERB
ajlm-2916	158	29	spondylitis	spondylitis	NOUN
ajlm-2916	158	30	.	.	PUNCT
ajlm-2916	159	1	biochem	biochem	PROPN
ajlm-2916	159	2	genet	genet	PROPN
ajlm-2916	159	3	.	.	PUNCT
ajlm-2916	160	1	2021;59(3):714–730	2021;59(3):714–730	X
ajlm-2916	160	2	.	.	X
ajlm-2916	160	3	https://doi.org/10.1007/s10528-020-10023-w	https://doi.org/10.1007/s10528-020-10023-w	VERB
ajlm-2916	160	4	wang	wang	PROPN
ajlm-2916	160	5	m	m	PROPN
ajlm-2916	160	6	,	,	PUNCT
ajlm-2916	160	7	xu	xu	PROPN
ajlm-2916	160	8	s	s	PROPN
ajlm-2916	160	9	,	,	PUNCT
ajlm-2916	160	10	zhang	zhang	PROPN
ajlm-2916	160	11	x	x	PROPN
ajlm-2916	160	12	,	,	PUNCT
ajlm-2916	161	1	et	et	PROPN
ajlm-2916	161	2	al	al	PROPN
ajlm-2916	161	3	.	.	PROPN
ajlm-2916	161	4	association	association	PROPN
ajlm-2916	161	5	of	of	ADP
ajlm-2916	161	6	tlr7	tlr7	PROPN
ajlm-2916	161	7	gene	gene	NOUN
ajlm-2916	161	8	copy	copy	NOUN
ajlm-2916	161	9	number	number	NOUN
ajlm-2916	161	10	variations	variation	NOUN
ajlm-2916	161	11	with	with	ADP
ajlm-2916	161	12	ankylosing	ankylose	VERB
ajlm-2916	161	13	spondylitis	spondylitis	NOUN
ajlm-2916	161	14	in	in	ADP
ajlm-2916	161	15	a	a	DET
ajlm-2916	161	16	chinese	chinese	ADJ
ajlm-2916	161	17	population	population	NOUN
ajlm-2916	161	18	:	:	PUNCT
ajlm-2916	161	19	a	a	DET
ajlm-2916	161	20	case	case	NOUN
ajlm-2916	161	21	control	control	NOUN
ajlm-2916	161	22	study	study	NOUN
ajlm-2916	161	23	.	.	PUNCT
ajlm-2916	162	1	clin	clin	PROPN
ajlm-2916	162	2	exp	exp	NOUN
ajlm-2916	162	3	rheumatol	rheumatol	NOUN
ajlm-2916	162	4	.	.	PUNCT
ajlm-2916	163	1	2018;36(5):814–819	2018;36(5):814–819	X
ajlm-2916	163	2	.	.	PUNCT
ajlm-2916	164	1	https://hdl.handle.net/102.100.100/560014	https://hdl.handle.net/102.100.100/560014	PROPN
ajlm-2916	164	2	machado	machado	PROPN
ajlm-2916	164	3	pm	pm	PROPN
ajlm-2916	164	4	,	,	PUNCT
ajlm-2916	164	5	landewé	landewé	NOUN
ajlm-2916	164	6	r	r	PROPN
ajlm-2916	164	7	,	,	PUNCT
ajlm-2916	164	8	van	van	PROPN
ajlm-2916	164	9	der	der	PROPN
ajlm-2916	164	10	heijde	heijde	PROPN
ajlm-2916	164	11	d.	d.	PROPN
ajlm-2916	164	12	ankylosing	ankylose	VERB
ajlm-2916	164	13	spondylitis	spondylitis	NOUN
ajlm-2916	164	14	disease	disease	NOUN
ajlm-2916	164	15	activity	activity	NOUN
ajlm-2916	164	16	score	score	NOUN
ajlm-2916	164	17	(	(	PUNCT
ajlm-2916	164	18	asdas	asdas	PROPN
ajlm-2916	164	19	):	):	PUNCT
ajlm-2916	164	20	2018	2018	NUM
ajlm-2916	164	21	update	update	NOUN
ajlm-2916	164	22	of	of	ADP
ajlm-2916	164	23	the	the	DET
ajlm-2916	164	24	nomenclature	nomenclature	NOUN
ajlm-2916	164	25	for	for	ADP
ajlm-2916	164	26	disease	disease	NOUN
ajlm-2916	164	27	activity	activity	NOUN
ajlm-2916	164	28	states	state	NOUN
ajlm-2916	164	29	.	.	PUNCT
ajlm-2916	165	1	ann	ann	PROPN
ajlm-2916	165	2	rheum	rheum	PROPN
ajlm-2916	165	3	dis	dis	PROPN
ajlm-2916	165	4	.	.	PUNCT
ajlm-2916	166	1	2018;77(10):1539–1540	2018;77(10):1539–1540	X
ajlm-2916	166	2	.	.	PUNCT
ajlm-2916	167	1	https://doi.org/10.1136/annrheumdis-2018-213184	https://doi.org/10.1136/annrheumdis-2018-213184	PROPN
ajlm-2916	167	2	moll	moll	PROPN
ajlm-2916	167	3	jm	jm	PROPN
ajlm-2916	167	4	.	.	PROPN
ajlm-2916	168	1	new	new	ADJ
ajlm-2916	168	2	criteria	criterion	NOUN
ajlm-2916	168	3	for	for	ADP
ajlm-2916	168	4	the	the	DET
ajlm-2916	168	5	diagnosis	diagnosis	NOUN
ajlm-2916	168	6	of	of	ADP
ajlm-2916	168	7	ankylosing	ankylose	VERB
ajlm-2916	168	8	spondylitis	spondylitis	NOUN
ajlm-2916	168	9	.	.	PUNCT
ajlm-2916	169	1	scand	scand	PROPN
ajlm-2916	169	2	j	j	PROPN
ajlm-2916	169	3	rheumatol	rheumatol	NOUN
ajlm-2916	169	4	.	.	PUNCT
ajlm-2916	170	1	1987;16(sup65):12–24	1987;16(sup65):12–24	NUM
ajlm-2916	170	2	.	.	PUNCT
ajlm-2916	171	1	https://doi.org/10.3109/03009748709102173	https://doi.org/10.3109/03009748709102173	PROPN
ajlm-2916	171	2	parks	parks	PROPN
ajlm-2916	171	3	vr	vr	PROPN
ajlm-2916	171	4	,	,	PUNCT
ajlm-2916	171	5	torres	torre	VERB
ajlm-2916	171	6	da	da	PROPN
ajlm-2916	171	7	.	.	PROPN
ajlm-2916	171	8	yield	yield	NOUN
ajlm-2916	171	9	gel	gel	NOUN
ajlm-2916	171	10	via	via	ADP
ajlm-2916	171	11	quantitative	quantitative	ADJ
ajlm-2916	171	12	gel	gel	NOUN
ajlm-2916	171	13	electrophoresis	electrophoresis	NOUN
ajlm-2916	171	14	.	.	PUNCT
ajlm-2916	172	1	in	in	ADP
ajlm-2916	172	2	:	:	PUNCT
ajlm-2916	172	3	c.	c.	PROPN
ajlm-2916	172	4	cupples	cupples	PROPN
ajlm-2916	172	5	connon	connon	PROPN
ajlm-2916	172	6	(	(	PUNCT
ajlm-2916	172	7	ed	ed	NOUN
ajlm-2916	172	8	.	.	PUNCT
ajlm-2916	172	9	)	)	PUNCT
ajlm-2916	172	10	.	.	PUNCT
ajlm-2916	173	1	,	,	PUNCT
ajlm-2916	173	2	forensic	forensic	ADJ
ajlm-2916	173	3	dna	dna	NOUN
ajlm-2916	173	4	analysis	analysis	NOUN
ajlm-2916	173	5	:	:	PUNCT
ajlm-2916	173	6	methods	method	NOUN
ajlm-2916	173	7	and	and	CCONJ
ajlm-2916	173	8	protocols	protocol	NOUN
ajlm-2916	173	9	.	.	PUNCT
ajlm-2916	174	1	new	new	PROPN
ajlm-2916	174	2	york	york	PROPN
ajlm-2916	174	3	,	,	PUNCT
ajlm-2916	174	4	ny	ny	PROPN
ajlm-2916	174	5	:	:	PUNCT
ajlm-2916	174	6	springer	springer	NOUN
ajlm-2916	174	7	us	we	PRON
ajlm-2916	174	8	,	,	PUNCT
ajlm-2916	174	9	2023	2023	NUM
ajlm-2916	174	10	;	;	PUNCT
ajlm-2916	174	11	p.	p.	NOUN
ajlm-2916	174	12	129–147	129–147	NUM
ajlm-2916	174	13	.	.	PUNCT
ajlm-2916	175	1	https://doi.org/10.1007/978-1-0716-3295-6_9	https://doi.org/10.1007/978-1-0716-3295-6_9	PROPN
ajlm-2916	175	2	ma	ma	PROPN
ajlm-2916	175	3	l	l	PROPN
ajlm-2916	175	4	,	,	PUNCT
ajlm-2916	175	5	chung	chung	PROPN
ajlm-2916	175	6	wk	wk	PROPN
ajlm-2916	175	7	.	.	PROPN
ajlm-2916	176	1	quantitative	quantitative	ADJ
ajlm-2916	176	2	analysis	analysis	NOUN
ajlm-2916	176	3	of	of	ADP
ajlm-2916	176	4	copy	copy	NOUN
ajlm-2916	176	5	number	number	NOUN
ajlm-2916	176	6	variants	variant	NOUN
ajlm-2916	176	7	based	base	VERB
ajlm-2916	176	8	on	on	ADP
ajlm-2916	176	9	real	real	ADJ
ajlm-2916	176	10	-	-	PUNCT
ajlm-2916	176	11	time	time	NOUN
ajlm-2916	176	12	lightcycler	lightcycler	NOUN
ajlm-2916	176	13	pcr	pcr	NOUN
ajlm-2916	176	14	.	.	PUNCT
ajlm-2916	177	1	curr	curr	PROPN
ajlm-2916	177	2	protoc	protoc	VERB
ajlm-2916	177	3	hum	hum	PROPN
ajlm-2916	177	4	genet	genet	PROPN
ajlm-2916	177	5	.	.	PUNCT
ajlm-2916	178	1	2014;80(1):7–21	2014;80(1):7–21	X
ajlm-2916	178	2	.	.	PUNCT
ajlm-2916	179	1	https://doi.org/10.1002/0471142905.hg0721s80	https://doi.org/10.1002/0471142905.hg0721s80	PROPN
ajlm-2916	179	2	haendiges	haendige	VERB
ajlm-2916	179	3	j	j	PROPN
ajlm-2916	179	4	,	,	PUNCT
ajlm-2916	179	5	timme	timme	PROPN
ajlm-2916	179	6	r	r	NOUN
ajlm-2916	179	7	,	,	PUNCT
ajlm-2916	179	8	ramachandran	ramachandran	PROPN
ajlm-2916	179	9	p	p	NOUN
ajlm-2916	179	10	,	,	PUNCT
ajlm-2916	179	11	balkey	balkey	ADJ
ajlm-2916	179	12	m.	m.	NOUN
ajlm-2916	179	13	dna	dna	PROPN
ajlm-2916	179	14	quantification	quantification	NOUN
ajlm-2916	179	15	using	use	VERB
ajlm-2916	179	16	the	the	DET
ajlm-2916	179	17	qubit	qubit	NOUN
ajlm-2916	179	18	fluorometer	fluorometer	NOUN
ajlm-2916	179	19	v1	v1	PROPN
ajlm-2916	179	20	.	.	PUNCT
ajlm-2916	179	21	2020	2020	NUM
ajlm-2916	180	1	[	[	X
ajlm-2916	180	2	homepage	homepage	NOUN
ajlm-2916	180	3	on	on	ADP
ajlm-2916	180	4	the	the	DET
ajlm-2916	180	5	internet	internet	NOUN
ajlm-2916	180	6	]	]	PUNCT
ajlm-2916	181	1	[	[	X
ajlm-2916	181	2	cited	cite	VERB
ajlm-2916	181	3	2025	2025	NUM
ajlm-2916	181	4	sep	sep	PROPN
ajlm-2916	181	5	19	19	NUM
ajlm-2916	181	6	]	]	PUNCT
ajlm-2916	181	7	.	.	PUNCT
ajlm-2916	182	1	available	available	ADJ
ajlm-2916	182	2	from	from	ADP
ajlm-2916	182	3	:	:	PUNCT
ajlm-2916	182	4	https://www.protocols.io/view/dna-quantification-using-the-qubit-fluorometer-bi8dkhs6dx.doi.org/10.17504/protocols.io.bi8dkhs6	https://www.protocols.io/view/dna-quantification-using-the-qubit-fluorometer-bi8dkhs6dx.doi.org/10.17504/protocols.io.bi8dkhs6	PROPN
ajlm-2916	182	5	kelley	kelley	PROPN
ajlm-2916	182	6	j	j	PROPN
ajlm-2916	182	7	,	,	PUNCT
ajlm-2916	182	8	johnson	johnson	PROPN
ajlm-2916	182	9	mr	mr	PROPN
ajlm-2916	182	10	,	,	PUNCT
ajlm-2916	182	11	alarcón	alarcón	PROPN
ajlm-2916	182	12	gs	gs	PROPN
ajlm-2916	182	13	,	,	PUNCT
ajlm-2916	182	14	kimberly	kimberly	PROPN
ajlm-2916	182	15	rp	rp	PROPN
ajlm-2916	182	16	,	,	PUNCT
ajlm-2916	182	17	edberg	edberg	PROPN
ajlm-2916	182	18	jc	jc	PROPN
ajlm-2916	182	19	.	.	PROPN
ajlm-2916	182	20	variation	variation	NOUN
ajlm-2916	182	21	in	in	ADP
ajlm-2916	182	22	the	the	DET
ajlm-2916	182	23	relative	relative	ADJ
ajlm-2916	182	24	copy	copy	NOUN
ajlm-2916	182	25	number	number	NOUN
ajlm-2916	182	26	of	of	ADP
ajlm-2916	182	27	the	the	DET
ajlm-2916	182	28	tlr7	tlr7	NOUN
ajlm-2916	182	29	gene	gene	NOUN
ajlm-2916	182	30	in	in	ADP
ajlm-2916	182	31	patients	patient	NOUN
ajlm-2916	182	32	with	with	ADP
ajlm-2916	182	33	systemic	systemic	ADJ
ajlm-2916	182	34	lupus	lupus	NOUN
ajlm-2916	182	35	erythematosus	erythematosus	NOUN
ajlm-2916	182	36	and	and	CCONJ
ajlm-2916	182	37	healthy	healthy	ADJ
ajlm-2916	182	38	control	control	NOUN
ajlm-2916	182	39	subjects	subject	NOUN
ajlm-2916	182	40	.	.	PUNCT
ajlm-2916	183	1	arthritis	arthritis	NOUN
ajlm-2916	183	2	rheum	rheum	NOUN
ajlm-2916	183	3	.	.	PUNCT
ajlm-2916	184	1	2007;56(10):3375–3378	2007;56(10):3375–3378	X
ajlm-2916	184	2	.	.	PUNCT
ajlm-2916	185	1	https://doi.org/10.1002/art.22916	https://doi.org/10.1002/art.22916	PROPN
ajlm-2916	185	2	marques	marques	PROPN
ajlm-2916	185	3	rb	rb	PROPN
ajlm-2916	185	4	,	,	PUNCT
ajlm-2916	185	5	thabet	thabet	ADJ
ajlm-2916	185	6	mm	mm	PROPN
ajlm-2916	185	7	,	,	PUNCT
ajlm-2916	185	8	white	white	PROPN
ajlm-2916	185	9	sj	sj	PROPN
ajlm-2916	185	10	,	,	PUNCT
ajlm-2916	185	11	et	et	PROPN
ajlm-2916	185	12	al	al	PROPN
ajlm-2916	185	13	.	.	PUNCT
ajlm-2916	186	1	genetic	genetic	ADJ
ajlm-2916	186	2	variation	variation	NOUN
ajlm-2916	186	3	of	of	ADP
ajlm-2916	186	4	the	the	DET
ajlm-2916	186	5	fc	fc	PROPN
ajlm-2916	186	6	gamma	gamma	PROPN
ajlm-2916	186	7	receptor	receptor	NOUN
ajlm-2916	186	8	3b	3b	NUM
ajlm-2916	186	9	gene	gene	NOUN
ajlm-2916	186	10	and	and	CCONJ
ajlm-2916	186	11	association	association	NOUN
ajlm-2916	186	12	with	with	ADP
ajlm-2916	186	13	rheumatoid	rheumatoid	NOUN
ajlm-2916	186	14	arthritis	arthritis	NOUN
ajlm-2916	186	15	.	.	PUNCT
ajlm-2916	187	1	plos	plos	PROPN
ajlm-2916	187	2	one	one	NUM
ajlm-2916	187	3	.	.	PUNCT
ajlm-2916	188	1	2010;5(10):e13173	2010;5(10):e13173	NUM
ajlm-2916	188	2	.	.	PUNCT
ajlm-2916	189	1	https://doi.org/10.1371/journal.pone.0013173	https://doi.org/10.1371/journal.pone.0013173	PROPN
ajlm-2916	189	2	boon	boon	NOUN
ajlm-2916	189	3	-	-	PUNCT
ajlm-2916	189	4	peng	peng	PROPN
ajlm-2916	189	5	h	h	PROPN
ajlm-2916	189	6	,	,	PUNCT
ajlm-2916	189	7	mat	mat	PROPN
ajlm-2916	189	8	jusoh	jusoh	PROPN
ajlm-2916	189	9	ja	ja	PROPN
ajlm-2916	189	10	,	,	PUNCT
ajlm-2916	189	11	marshall	marshall	PROPN
ajlm-2916	189	12	cr	cr	PROPN
ajlm-2916	189	13	,	,	PUNCT
ajlm-2916	189	14	et	et	PROPN
ajlm-2916	189	15	al	al	PROPN
ajlm-2916	189	16	.	.	PROPN
ajlm-2916	190	1	rare	rare	PROPN
ajlm-2916	190	2	copy	copy	NOUN
ajlm-2916	190	3	number	number	NOUN
ajlm-2916	190	4	variants	variant	NOUN
ajlm-2916	190	5	identified	identify	VERB
ajlm-2916	190	6	suggest	suggest	VERB
ajlm-2916	190	7	the	the	DET
ajlm-2916	190	8	regulating	regulate	VERB
ajlm-2916	190	9	pathways	pathway	NOUN
ajlm-2916	190	10	in	in	ADP
ajlm-2916	190	11	hypertension	hypertension	NOUN
ajlm-2916	190	12	-	-	PUNCT
ajlm-2916	190	13	related	relate	VERB
ajlm-2916	190	14	left	leave	VERB
ajlm-2916	190	15	ventricular	ventricular	ADJ
ajlm-2916	190	16	hypertrophy	hypertrophy	NOUN
ajlm-2916	190	17	.	.	PUNCT
ajlm-2916	191	1	plos	plos	PROPN
ajlm-2916	191	2	one	one	NUM
ajlm-2916	191	3	.	.	PUNCT
ajlm-2916	192	1	2016;11(3):e0148755	2016;11(3):e0148755	NUM
ajlm-2916	192	2	.	.	PUNCT
ajlm-2916	193	1	https://doi.org/10.1371/journal.pone.0148755	https://doi.org/10.1371/journal.pone.0148755	NOUN
ajlm-2916	193	2	dahmani	dahmani	PROPN
ajlm-2916	193	3	ca	can	AUX
ajlm-2916	193	4	,	,	PUNCT
ajlm-2916	193	5	benzaoui	benzaoui	PROPN
ajlm-2916	193	6	a	a	PRON
ajlm-2916	193	7	,	,	PUNCT
ajlm-2916	193	8	amroun	amroun	ADJ
ajlm-2916	193	9	h	h	NOUN
ajlm-2916	193	10	,	,	PUNCT
ajlm-2916	193	11	zemani	zemani	NOUN
ajlm-2916	193	12	-	-	PUNCT
ajlm-2916	193	13	fodil	fodil	NOUN
ajlm-2916	193	14	f	f	NOUN
ajlm-2916	193	15	,	,	PUNCT
ajlm-2916	193	16	petit	petit	NOUN
ajlm-2916	193	17	-	-	PUNCT
ajlm-2916	193	18	teixeira	teixeira	PROPN
ajlm-2916	193	19	e	e	PROPN
ajlm-2916	193	20	,	,	PUNCT
ajlm-2916	193	21	boudjema	boudjema	ADJ
ajlm-2916	193	22	a.	a.	PROPN
ajlm-2916	193	23	association	association	PROPN
ajlm-2916	193	24	study	study	NOUN
ajlm-2916	193	25	of	of	ADP
ajlm-2916	193	26	copy	copy	NOUN
ajlm-2916	193	27	number	number	NOUN
ajlm-2916	193	28	variants	variant	NOUN
ajlm-2916	193	29	in	in	ADP
ajlm-2916	193	30	ccl3l1	ccl3l1	NOUN
ajlm-2916	193	31	,	,	PUNCT
ajlm-2916	193	32	fcgr3a	fcgr3a	ADJ
ajlm-2916	193	33	and	and	CCONJ
ajlm-2916	193	34	fcgr3b	fcgr3b	NOUN
ajlm-2916	193	35	genes	gene	NOUN
ajlm-2916	193	36	with	with	ADP
ajlm-2916	193	37	risk	risk	NOUN
ajlm-2916	193	38	of	of	ADP
ajlm-2916	193	39	ankylosing	ankylose	VERB
ajlm-2916	193	40	spondylitis	spondylitis	NOUN
ajlm-2916	193	41	in	in	ADP
ajlm-2916	193	42	a	a	DET
ajlm-2916	193	43	west	west	ADJ
ajlm-2916	193	44	algerian	algerian	ADJ
ajlm-2916	193	45	population	population	NOUN
ajlm-2916	193	46	.	.	PUNCT
ajlm-2916	194	1	int	int	PROPN
ajlm-2916	194	2	j	j	PROPN
ajlm-2916	194	3	immunogenet	immunogenet	PROPN
ajlm-2916	194	4	.	.	PUNCT
ajlm-2916	195	1	2019;46(6):437–443	2019;46(6):437–443	X
ajlm-2916	195	2	.	.	PUNCT
ajlm-2916	196	1	https://doi.org/10.1111/iji.12454	https://doi.org/10.1111/iji.12454	PROPN
ajlm-2916	196	2	ivanova	ivanova	PROPN
ajlm-2916	196	3	m	m	PROPN
ajlm-2916	196	4	,	,	PUNCT
ajlm-2916	196	5	manolova	manolova	VERB
ajlm-2916	196	6	i	i	PRON
ajlm-2916	196	7	,	,	PUNCT
ajlm-2916	196	8	miteva	miteva	PROPN
ajlm-2916	196	9	l	l	PROPN
ajlm-2916	196	10	,	,	PUNCT
ajlm-2916	196	11	gancheva	gancheva	PROPN
ajlm-2916	196	12	r	r	NOUN
ajlm-2916	196	13	,	,	PUNCT
ajlm-2916	196	14	stoilov	stoilov	NOUN
ajlm-2916	196	15	r	r	NOUN
ajlm-2916	196	16	,	,	PUNCT
ajlm-2916	196	17	stanilova	stanilova	PROPN
ajlm-2916	196	18	s.	s.	PROPN
ajlm-2916	196	19	genetic	genetic	ADJ
ajlm-2916	196	20	variations	variation	NOUN
ajlm-2916	196	21	in	in	ADP
ajlm-2916	196	22	the	the	DET
ajlm-2916	196	23	il-12b	il-12b	NOUN
ajlm-2916	196	24	gene	gene	NOUN
ajlm-2916	196	25	in	in	ADP
ajlm-2916	196	26	association	association	NOUN
ajlm-2916	196	27	with	with	ADP
ajlm-2916	196	28	il-23	il-23	NOUN
ajlm-2916	196	29	and	and	CCONJ
ajlm-2916	196	30	il-12p40	il-12p40	PROPN
ajlm-2916	196	31	serum	serum	NOUN
ajlm-2916	196	32	levels	level	NOUN
ajlm-2916	196	33	in	in	ADP
ajlm-2916	196	34	ankylosing	ankylose	VERB
ajlm-2916	196	35	spondylitis	spondylitis	NOUN
ajlm-2916	196	36	.	.	PUNCT
ajlm-2916	197	1	rheumatol	rheumatol	PROPN
ajlm-2916	197	2	int	int	NOUN
ajlm-2916	197	3	.	.	PUNCT
ajlm-2916	198	1	2019;39(1):111–119	2019;39(1):111–119	X
ajlm-2916	198	2	.	.	PUNCT
ajlm-2916	199	1	https://doi.org/10.1007/s00296-018-4204-0	https://doi.org/10.1007/s00296-018-4204-0	NUM
ajlm-2916	199	2	jin	jin	PROPN
ajlm-2916	199	3	q	q	X
ajlm-2916	199	4	,	,	PUNCT
ajlm-2916	199	5	ren	ren	NOUN
ajlm-2916	199	6	f	f	NOUN
ajlm-2916	199	7	,	,	PUNCT
ajlm-2916	199	8	song	song	PROPN
ajlm-2916	199	9	p.	p.	NOUN
ajlm-2916	199	10	innovate	innovate	VERB
ajlm-2916	199	11	therapeutic	therapeutic	ADJ
ajlm-2916	199	12	targets	target	NOUN
ajlm-2916	199	13	for	for	ADP
ajlm-2916	199	14	autoimmune	autoimmune	ADJ
ajlm-2916	199	15	diseases	disease	NOUN
ajlm-2916	199	16	:	:	PUNCT
ajlm-2916	199	17	insights	insight	NOUN
ajlm-2916	199	18	from	from	ADP
ajlm-2916	199	19	proteome	proteome	ADJ
ajlm-2916	199	20	-	-	PUNCT
ajlm-2916	199	21	wide	wide	ADJ
ajlm-2916	199	22	mendelian	mendelian	ADJ
ajlm-2916	199	23	randomization	randomization	NOUN
ajlm-2916	199	24	and	and	CCONJ
ajlm-2916	199	25	bayesian	bayesian	NOUN
ajlm-2916	199	26	colocalization	colocalization	NOUN
ajlm-2916	199	27	.	.	PUNCT
ajlm-2916	200	1	autoimmunity	autoimmunity	NOUN
ajlm-2916	200	2	.	.	PUNCT
ajlm-2916	201	1	2024;57(1):2330392	2024;57(1):2330392	NUM
ajlm-2916	201	2	.	.	PUNCT
ajlm-2916	202	1	https://doi.org/10.1080/08916934.2024.233039	https://doi.org/10.1080/08916934.2024.233039	PROPN
ajlm-2916	202	2	dai	dai	PROPN
ajlm-2916	202	3	l	l	PROPN
ajlm-2916	202	4	,	,	PUNCT
ajlm-2916	202	5	xia	xia	PROPN
ajlm-2916	202	6	l	l	PROPN
ajlm-2916	202	7	,	,	PUNCT
ajlm-2916	202	8	su	su	PROPN
ajlm-2916	202	9	g	g	PROPN
ajlm-2916	202	10	,	,	PUNCT
ajlm-2916	202	11	gao	gao	PROPN
ajlm-2916	202	12	y	y	PROPN
ajlm-2916	202	13	,	,	PUNCT
ajlm-2916	202	14	jiang	jiang	PROPN
ajlm-2916	203	1	q	q	PROPN
ajlm-2916	203	2	,	,	PUNCT
ajlm-2916	203	3	yang	yang	PROPN
ajlm-2916	203	4	p.	p.	NOUN
ajlm-2916	203	5	identifying	identify	VERB
ajlm-2916	203	6	prioritization	prioritization	NOUN
ajlm-2916	203	7	of	of	ADP
ajlm-2916	203	8	therapeutic	therapeutic	ADJ
ajlm-2916	203	9	targets	target	NOUN
ajlm-2916	203	10	for	for	ADP
ajlm-2916	203	11	ankylosing	ankylose	VERB
ajlm-2916	203	12	spondylitis	spondylitis	NOUN
ajlm-2916	203	13	:	:	PUNCT
ajlm-2916	203	14	a	a	DET
ajlm-2916	203	15	multi	multi	ADJ
ajlm-2916	203	16	-	-	ADJ
ajlm-2916	203	17	omics	omics	ADJ
ajlm-2916	203	18	mendelian	mendelian	ADJ
ajlm-2916	203	19	randomization	randomization	NOUN
ajlm-2916	203	20	study	study	NOUN
ajlm-2916	203	21	.	.	PUNCT
ajlm-2916	204	1	j	j	PROPN
ajlm-2916	204	2	transl	transl	PROPN
ajlm-2916	204	3	med	med	PROPN
ajlm-2916	204	4	.	.	PUNCT
ajlm-2916	205	1	2024;22(1	2024;22(1	NUM
ajlm-2916	205	2	):	):	PUNCT
ajlm-2916	205	3	1115	1115	NUM
ajlm-2916	205	4	.	.	PUNCT
ajlm-2916	206	1	https://doi.org/10.1186/s12967-024-05925-x	https://doi.org/10.1186/s12967-024-05925-x	PROPN